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ABSTRACT 
 
CRAIG R. LEE: Cytochrome P450 Derived Eicosanoids, Endothelial Function and 
Cardiovascular Disease 
(Under the direction of Darryl C. Zeldin, Dhiren Thakker, J. Herbert Patterson, Kari E. North 
Celeste M. Lindley and Kirkwood F. Adams, Jr.) 
 
 
    Endothelial dysfunction plays an integral role in the pathogenesis and progression of 
cardiovascular disease in humans.  The development of endothelial dysfunction has been 
primarily ascribed to functional impairments in nitric oxide biosynthesis.  However, 
arachidonic acid metabolism by the cyclooxygenase and cytochrome P450 epoxygenase 
pathways also appears to regulate endothelial function.  Consequently, genetic variation in 
these pathways may be important modifiers of cardiovascular disease risk in humans.  The 
collective objective of the studies outlined in this doctoral dissertation was to determine if 
genetic variation in these established (NOS3, PTGS1 and PTGS2) and recently characterized 
(EPHX2, CYP2J2 and CYP2C8) pathways are significantly associated with cardiovascular 
disease risk.  First, metabolic studies conducted in vitro demonstrate that certain genetic 
variants in cyclooxygenase-1 possess significantly lower metabolic activity compared to 
wild-type cyclooxygenase-1.  Second, the observed associations between genetic variation in 
PTGS1, PTGS2 and NOS3 and risk of incident coronary heart disease and ischemic stroke 
events further implicate these established pathways in the development of cardiovascular 
disease in humans.  Third, the observed associations between genetic variation in EPHX2, 
CYP2J2 and CYP2C8 and risk of incident coronary heart disease events also demonstrate the 
potential importance of the cytochrome P450 epoxygenase pathway in the pathogenesis of 
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ischemic cardiovascular disease in humans.  Fourth, the development and baseline 
characterization of transgenic mice that exhibit vascular endothelial cell-specific 
overexpression of either human CYP2J2 or CYP2C8 will enable further mechanistic 
characterization of the cytochrome P450 epoxygenase pathway in the regulation of 
endothelial function and the pathogenesis of cardiovascular disease. 
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CHAPTER I 
 
INTRODUCTION 
 
 
Endothelial Function and Cardiovascular Disease 
    Ischemic cardiovascular disease is the leading cause of morbidity and mortality in the U.S. 
(1).  It is estimated that 1.2 million Americans will experience an acute coronary heart 
disease (CHD) event and 0.7 million will experience an acute stroke event this year (1).  
Endothelial dysfunction plays an integral role in the pathogenesis and progression of 
ischemic cardiovascular disease in humans (2).  Inflammation is also a key regulator in the 
pathogenesis of atherosclerotic cardiovascular disease, particularly via its role in the 
development and progression of endothelial dysfunction (2, 3).  Endothelial dysfunction is 
typically manifested by substantially reduced endothelial-dependent vasodilation in the 
coronary, cerebral and peripheral vasculature, and increased expression of various pro-
inflammatory mediators such as vascular adhesion molecules and chemokines (2-5).  Risk 
factors including cigarette smoking (6), hypercholesterolemia (7), and diabetes (8) 
significantly contribute to the development and progression of endothelial dysfunction, 
which is markedly impaired in patients with established atherosclerosis (9) and 
independently associated with an increased risk of myocardial infarction and ischemic stroke 
events (10, 11).  Moreover, pharmacological therapies such as HMG-CoA reductase 
inhibitors (statins) and angiotensin-converting enzyme (ACE) inhibitors significantly
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improve endothelial function and reduce the risk of cardiovascular disease events in patients 
(2).   
 
Nitric Oxide.  The development of endothelial dysfunction has been primarily ascribed to 
functional impairments in nitric oxide biosynthesis and activity.  Nitric oxide is synthesized 
by endothelial nitric oxide synthase (eNOS, NOS3) in the vasculature, where it possesses 
potent vasodilatory (12), anti-inflammatory (13), and anti-remodeling (14) effects.  
Impairment in eNOS-mediated nitric oxide synthesis significantly contributes to endothelial 
dysfunction and promotes the development of atherosclerosis (15, 16).  In particular, 
cigarette smoking elicits many of its deleterious endothelial effects via attenuation of nitric 
oxide synthesis and activity (17, 18).  Although nitric oxide is considered the primary 
endothelial-derived relaxing factor, arachidonic acid metabolism also appears to be important 
in the regulation of endothelial function, as illustrated in Figure 1. 
 
Endothelial Arachidonic Acid Metabolism 
    Arachidonic acid is a polyunsaturated fatty acid present in mammalian cell membranes via 
esterification to membrane glycerophospholipids.  Upon release by activation of cellular 
phospholipases, arachidonic acid is available for enzymatic oxidation by cyclooxygenases 
(COX) (19) and cytochromes P450 (20) into various biologically active mediators important 
in the regulation of endothelial and myocardial function.  Lipoxygenase-mediated 
arachidonic acid metabolism is also an important and well-characterized pathway; however, 
its contribution to endothelial function will not be discussed (21). 
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Cyclooxygenases.  The role of the COX metabolic pathway in cardiovascular physiology 
and disease pathogenesis has been extensively characterized.  Briefly, COX-1 and COX-2 
catalyze the oxidative conversion of arachidonic acid to prostaglandin (PG) H2, which is 
subsequently metabolized by specific prostaglandin synthases to biologically active products 
including prostacyclin (PGI2), thromboxane A2 and PGE2 (19).  Although both COX-1 and 
COX-2 catalyze the same metabolic reaction with similar efficiencies, they are encoded by 
distinct gene products and differ substantially in their regulation and expression (19).  COX-1 
is constitutively expressed and is responsible for the biosynthesis of prostaglandins involved 
in various housekeeping functions, such as the regulation of renal, gastrointestinal, and 
platelet function (19).  COX-2 is induced by multiple biological mediators, and primarily 
catalyzes prostaglandin synthesis in cells involved in both local and systemic inflammatory 
responses (19).  However, the relative contribution of both COX-1 and COX-2-mediated 
prostaglandin biosynthesis appears to be a critical regulator of vascular function in vivo (22).  
For instance, despite their potential anti-inflammatory and atherosclerotic plaque stabilizing 
effects, nonselective COX-1/COX-2 and selective COX-2 antagonists inhibit endothelial 
prostacyclin biosynthesis without influencing platelet thromboxane A2 production and appear 
to increase risk of myocardial infarction, particularly in high risk patients (23, 24).  Although 
preferential inhibition of COX-1 derived thromboxane A2 in platelets via low-dose aspirin 
administration significantly reduces the risk of myocardial infarction, ischemic stroke and 
death in high-risk patients (25), suppression of endothelial COX metabolism appears to 
worsen endothelial function and predispose patients to higher risk of acute cardiovascular 
events. 
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Cytochromes P450.  Multiple cytochromes P450 also metabolize arachidonic acid to various 
eicosanoid products, including four regioisomeric epoxyeicosatrienoic acids (EETs) via 
olefin epoxidation (5,6-EET, 8,9-EET, 11,12-EET and 14,15-EET) (20, 26).  Multiple P450 
isoforms can catalyze the regio- and stereoselective formation of EETs in various species and 
tissues; however, the CYP2J and CYP2C subfamilies constitute the primary P450 
epoxygenases (20).  In humans, CYP2J2 and CYP2C8 are the primary isoforms responsible 
for the formation of EETs in endothelial cells and cardiomyocytes, where they possess potent 
biological effects (20).  Once formed, EETs are rapidly hydrolyzed to their corresponding 
dihydroxyeicosatrienoic acid (DHET) metabolites by soluble epoxide hydrolase (sEH, 
EPHX2) (27-29).  In general, DHETs are much less active than EETs in the cardiovascular 
system (20).  Therefore, it has been proposed that sEH regulates steady-state EET levels in 
vivo, as illustrated in Figure 2. 
 
P450 Epoxygenase Pathway – Biological Relevance 
    Previous work has demonstrated that EETs have substantial vasodilatory (30, 31), anti-
inflammatory (32), fibrinolytic (33), post-ischemic cardioprotective (34, 35), pro-angiogenic 
(36), and vascular smooth muscle cell anti-migratory (37) effects.  The EETs are potent 
vasodilators in the coronary microcirculation in both animals and humans, and are leading 
candidates for endothelial-derived hyperpolarization factor (EDHF) since their vasodilator 
effects are mediated via opening of vascular smooth muscle cell Ca2+-dependent K+ (BKCa) 
channels (30, 31).  These effects are most pronounced in the presence of inhibitors of nitric 
oxide and PGI2 biosynthesis, suggesting that this pathway may serve as an important reserve 
system to these primary endothelial-derived relaxing factors.  In fact, EET-mediated 
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vasodilation may play a substantially larger role in patients with established endothelial 
dysfunction and reduced nitric oxide availability, since nitric oxide is known to inhibit P450 
enzymatic activity (38) and attenuate the release of EDHF (39).  
    In addition, both CYP2J2 overexpression and exogenous administration of EETs have 
potent anti-inflammatory effects in endothelial cells by significantly attenuating cytokine-
induced endothelial cell adhesion molecule expression and leukocyte adhesion to the 
vascular wall via inhibition of inhibitor kappa B-α (IκB-α) phosphorylation and nuclear 
factor kappa B (NF-κB) subunit RelA translocation to the nucleus (32), a well-characterized 
initiating event of pro-inflammatory signaling in the vasculature (5).  Subsequent work has 
further characterized the anti-inflammatory properties of EETs via mechanisms involving 
activation of peroxisome proliferator-activated receptor-α (PPAR-α) (40) and PPAR-γ (41), 
and attenuation of COX-2-mediated PGE2 synthesis (42).  The EETs also play a significant 
role in the regulation of cardiac function following ischemia (34, 35).  Specifically, 
transgenic mice with cardiomyocyte-specific overexpression of CYP2J2 and enhanced 
cardiac EET biosynthesis exhibit significant cardioprotection and improvement in post-
ischemic recovery of left ventricular function via activation of mitochondrial KATP channels 
and p42/p44 mitogen-activated protein kinase (MAPK) signaling (35).  Lastly, P450-derived 
EETs also contribute to the regulation of eNOS and COX-2 expression in the endothelium 
(43, 44), demonstrating the inter-related contribution of each of these pathways in the 
vasculature. 
    Importantly, sEH is integrally involved in regulation of both cellular levels and the 
cardiovascular effects of EETs.  For instance, Ephx2-/- mice have significantly lower blood 
pressure (45) and significantly greater post-ischemic recovery of heart contractile function 
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(46) compared to wild type mice.  Moreover, sEH inhibitors significantly lower blood 
pressure in spontaneously and angiotensin II-induced hypertensive rats (28, 47), inhibit 
vascular smooth muscle cell proliferation (48), and possess potent anti-inflammatory effects 
(41, 49).  Hence, inhibition of sEH may represent a novel therapeutic strategy for the 
prevention and/or treatment of endothelial dysfunction and cardiovascular disease via 
augmentation of the cardiovascular effects of P450-derived EETs. 
    Although both CYP2J and CYP2C isoforms catalyze EET biosynthesis in endothelial 
cells, the source of EETs may be a critical determinant of their biological effects due to 
simultaneous formation of pro-inflammatory reactive oxygen species (ROS).  For instance, 
unlike most other P450s CYP2J2 expression minimized ROS formation in the presence of 
enhanced oxidative stress (50), a characteristic common to patients with endothelial 
dysfunction.  However, it has been reported that even though CYP2C overexpression in 
endothelial cells increased EET synthesis in vitro, no net anti-inflammatory effect was 
observed after cytokine challenge due to a simultaneous increase in ROS formation (51).  
These preliminary studies suggest that the source of EETs may be a critical factor related to 
their biological properties; however, evaluation of the relative differences between CYP2J2 
and CYP2C8-mediated EET biosynthesis and ROS formation in vivo under controlled 
conditions remains to be characterized. 
 
Perspective.  Collectively, the results from various cellular and rodent models have 
demonstrated the importance of P450-mediated EET biosynthesis in cardiovascular 
physiology.  However, the role of CYP2J2 and CYP2C8-derived EETs in the regulation of 
endothelial function, intravascular inflammation and atherosclerotic lesion development in 
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vivo remains poorly understood.  Development of genetically altered mice overexpressing 
human CYP2J2 or CYP2C8 in the vasculature will be necessary to further characterize the in 
vivo role of both CYP2J2 and CYP2C8-derived EETs in these processes, which have proven 
vital to the development and progression of cardiovascular disease in humans. 
 
Genetic Variation in Endothelial Pathways 
    Genetic polymorphisms have become increasingly recognized as important contributors to 
disease risk and variability in response to certain medications in humans (52) (Appendix I).  
Numerous polymorphisms in the genes encoding eNOS (NOS3), COX-1 (PTGS1), COX-2 
(PTGS2), CYP2J2 (CYP2J2), CYP2C8 (CYP2C8) and sEH (EPHX2) have been recently 
discovered.  The NIEHS Environmental Genome Single Nucleotide Polymorphism (egSNP) 
program has resequenced the PTGS1, PTGS2, CYP2J2, CYP2C8 and EPHX2 genes 
(https://dir-apps.niehs.nih.gov/egsnp/home.htm).  Many of the identified variants include 
functionally relevant polymorphisms in either the proximal promoter or exonic regions of the 
gene which encode amino acid changes in the protein (i.e., nonsynonymous).  However, their 
relevance to cardiovascular disease susceptibility remains poorly understood. 
 
NOS3, PTGS1 and PTGS2.  Multiple genetic polymorphisms in NOS3 have been 
discovered, including the T-786C and Glu298Asp variants which have been associated with 
reduced nitric oxide biosynthesis (53, 54).  Numerous clinical studies evaluating potential 
associations between NOS3 polymorphisms and cardiovascular disease risk have reported 
inconsistent results (55).  However, few investigations have evaluated incident clinical 
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events.  Moreover, few have considered the potential influence of cigarette smoking despite 
their potential synergistic contribution to worsening endothelial function in vivo (56, 57).   
    The identification and functional characterization of genetic polymorphisms in PTGS2 
have also been reported (58, 59).  These studies have demonstrated that certain variants 
significantly alter COX-2 expression and/or activity and may be important risk factors for 
disease in humans (58-60).  In particular, the G-765C polymorphism in the proximal 
promoter of PTGS2 disrupts a Sp1 binding site and is associated with significantly lower 
PTGS2 transcription (59).  Moreover, due to its anti-inflammatory effects, the variant -765C 
allele was associated with significantly lower risk of prevalent myocardial infarction or 
ischemic stroke events in a high-risk Italian population (60).  However, associations between 
PTGS2 polymorphisms and risk of incident cardiovascular events have not been investigated.   
    In contrast, characterization of genetic variation in PTGS1 has not been as widely 
investigated.  Polymorphisms in both coding and noncoding regions of human PTGS1 have 
been identified, including nonsynonymous variants encoding amino acid substitutions in the 
COX-1 protein (61, 62).  However, the functional consequences of these variants, in terms of 
their influence on basal COX-1-mediated arachidonic acid metabolism, have not been 
studied.  Moreover, putative associations between PTGS1 polymorphisms and cardiovascular 
disease risk have not been evaluated to date. 
 
CYP2J2, CYP2C8 and EPHX2.  Multiple genetic polymorphisms in CYP2J2 have also been 
recently discovered (63, 64).  The Thr143Ala (CYP2J2*2), Arg158Cys (CYP2J2*3), 
Ile192Asn (CYP2J2*4) and Asn404Tyr (CYP2J2*6) nonsynonymous variants were 
associated with significant reductions in EET biosynthesis in vitro compared to wild-type 
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protein; however, these variants were prevalent at very low frequencies (<2%) in the general 
population (63).  A G-50T (CYP2J2*7) polymorphism in the proximal promoter of CYP2J2 
was also identified; although the minor allele was present at higher frequencies than the 
described nonsynonymous variants (approximately 8% in Caucasians) (63, 64).  Presence of 
this variant resulted in loss of a critical Sp1 transcription factor binding site, and led to 
reduced transcription of CYP2J2 in vitro and EET biosynthesis in vivo (64).  Importantly, the 
-50T variant allele was associated with higher risk of prevalent coronary artery disease in a 
German population (64), suggesting that genetic variation in CYP2J2 may impact the 
development of cardiovascular disease in humans. 
    Numerous genetic polymorphisms in CYP2C8 have also been recently discovered, 
including the nonsynonymous Ile269Phe (CYP2C8*2), Arg139Lys/Lys399Arg (CYP2C8*3) 
and Ile264Met (CYP2C8*4) variants which possess reduced CYP2C8 metabolic activity in 
vitro compared to wild-type protein (65, 66).  The Ile264Met and Arg139Lys/Lys399Arg 
variant alleles are more frequent in Caucasian populations, while the Ile269Phe variant is 
more frequent in African-Americans.  The Ile264Met and Ile269Phe variants have exhibited 
reduced capacity to metabolize the anticancer drug paclitaxel (65, 66).  The 
Arg139Lys/Lys399Arg variant was markedly defective in the metabolism of both 
arachidonic acid and paclitaxel (65).  Moreover, the Arg139Lys/Lys399Arg variant allele 
was associated with higher risk of prevalent myocardial infarction in a Swedish cohort (67). 
    Multiple single nucleotide polymorphisms in EPHX2 have also been discovered (68, 69).  
These include nonsynonymous polymorphisms that demonstrate either increased (Lys55Arg, 
Glu470Gly) or decreased (Arg103Cys, Arg287Gln, 402InsArg) sEH-mediated conversion of 
EETs to DHETs in vitro compared to wild-type protein (68, 69).  An association between the 
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Arg287Gln polymorphism variant allele and increased coronary artery calcification, a 
subclinical measure of atherosclerotic burden, has been reported in African-Americans (70); 
however, since this variant carries reduced sEH activity, the observed association appears in 
contrast to the current hypotheses regarding the protective effects of EETs in the 
cardiovascular system.  Importantly, associations between polymorphisms in CYP2J2, 
CYP2C8 and EPHX2 and the risk of incident clinical events have not been evaluated to date. 
 
Perspective.  Although preliminary associations have been reported between variation in 
these established (NOS3, PTGS2) and recently characterized (CYP2J2, CYP2C8 and EPHX2) 
genes involved in the regulation of endothelial function and cardiovascular disease risk, 
future gene-association studies evaluating risk of incident clinical events such as myocardial 
infarction and ischemic stroke will be necessary to further characterize the role of these 
pathways in cardiovascular disease susceptibility.  Moreover, evaluation of the potential 
influence of environmental factors known to impair endothelial function, such as cigarette 
smoking, on these associations will also be necessary to characterize potential gene-
environment interactions relevant to cardiovascular disease risk.  Lastly, in vitro functional 
characterization of selected variants in PTGS1 will be critical in order to guide the design and 
interpretation of epidemiological studies evaluating associations between PTGS1 variants 
and cardiovascular disease risk. 
 
 
 
 
11
Specific Aims 
I. To determine if nonsynonymous polymorphisms in PTGS1 significantly alter 
cyclooxygenase-1 metabolic activity in vitro. 
Hypothesis.  Certain nonsynonymous variants will be associated with significantly lower 
basal cyclooxygenase-1 metabolic activity in vitro compared to wild-type. 
II. To determine if genetic variation in PTGS1, PTGS2 and/or NOS3 is significantly 
associated with the development of incident coronary heart disease or ischemic 
stroke clinical events in humans. 
Hypothesis A.  Polymorphisms associated with lower cyclooxygenase-1 or 
cyclooxygenase-2 metabolic activity or expression will be associated with significantly 
higher risk of incident coronary heart disease and ischemic stroke events.  These 
associations will be most pronounced in individuals not receiving aspirin therapy. 
Hypothesis B.  Polymorphisms associated with lower nitric oxide synthase metabolic 
activity or expression will be associated with significantly higher risk of incident 
coronary heart disease and ischemic stroke events.  These associations will be most 
pronounced in cigarette smokers. 
III. To determine if genetic variation in CYP2J2, CYP2C8 and/or EPHX2 is significantly 
associated with the development of incident coronary heart disease clinical events in 
humans. 
Hypothesis A.  Polymorphisms associated with higher and lower soluble epoxide 
hydrolase metabolic activity will be associated with significantly higher and lower risk of 
incident coronary heart disease events, respectively. 
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Hypothesis B.  Polymorphisms associated with lower CYP2J2 or CYP2C8 metabolic 
activity or expression will be associated with significantly higher risk of incident 
coronary heart disease events. 
IV. To develop transgenic mice that exhibit vascular endothelial cell-specific 
overexpression of human CYP2J2 or CYP2C8. 
Hypothesis.  Constitutive, vascular endothelial cell-specific overexpression of CYP2J2 
and CYP2C8 can be achieved using the Tie2 promoter and Tie2 full enhancer, resulting 
in increased systemic epoxyeicosatrienoic acid concentrations. 
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Figure 1:  Endothelial pathways of interest. 
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Figure 2:  Regulation of steady-state EET levels by P450 epoxygenases and sEH. 
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Introduction 
    Cyclooxygenases (COX)-1 and -2 catalyze the oxidative conversion of arachidonic acid to 
prostaglandin (PG) H2, which is subsequently metabolized to various biologically active 
metabolites such as prostacyclin and thromboxane A2 (19).  Although both COX-1 and COX-
2 catalyze the same metabolic reaction with similar efficiencies, they are encoded by distinct 
gene products and differ substantially in their regulation and expression (19).   
    The gene encoding human COX-1 (PTGS1) has been mapped to chromosome 9q32-q33.3, 
is approximately 22 kilobases in length, and contains 11 exons (71, 72).  COX-1 is 
constitutively expressed and is responsible for the biosynthesis of PGs involved in various 
housekeeping functions, such as the regulation of renal, gastrointestinal, and platelet function 
(19).  COX-2 is induced by multiple biological mediators, and primarily catalyzes PG 
synthesis in cells involved in both local and systemic inflammatory responses (19).  
Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit COX-mediated PG synthesis and are 
widely used for the prevention and/or treatment of various diseases (73).  As a therapeutic 
class, these agents demonstrate a wide range of relative selectivity for COX-1 and COX-2, 
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and significant inter-individual variability in clinical response exists (73).  Due to the 
inducible nature of COX-2 regulation and its potential role in the pathogenesis of various 
inflammatory disorders, the overwhelming majority of research characterizing the role of 
COXs in human disease to date has focused on COX-2.  However, recent evidence, including 
associations between selective COX-2 inhibitor utilization and myocardial infarction risk, 
suggests the relative contribution of COX-1 and COX-2-mediated PG synthesis is important 
(23, 24).  Consequently, genetic variation in both PTGS1 and PTGS2 may be important 
modifiers of disease risk in humans.   
    The identification and functional characterization of genetic polymorphisms in PTGS2 
have been reported (58, 59).  These studies demonstrate that certain variants significantly 
alter COX-2 expression and/or activity and may be important risk factors for disease in 
humans (58-60).  In contrast, characterization of genetic variation in PTGS1 has not been as 
widely investigated, even though the presence of functionally relevant variants may 
significantly influence PG biosynthesis, disease risk, and NSAID pharmacodynamics in 
humans.  Polymorphisms in both coding and noncoding regions of human PTGS1 have been 
previously identified (61, 62, 74, 75), including by resequencing as part of the SeattleSNPs 
Variation Discovery Resource (http://pga.mbt.washington.edu/).  In particular, 
nonsynonymous variants encoding amino acid substitutions in the COX-1 protein have been 
identified (61, 62, 74, 75).  However, the functional consequences of these variants, in terms 
of their influence on basal COX-1-mediated arachidonic acid metabolism, have not been 
characterized to date.  Human studies have evaluated the potential influence of certain 
variants on NSAID-mediated inhibition of COX metabolism in vivo and ex vivo (62, 76-78); 
however, the functional consequences of most variants on NSAID pharmacodynamics are not 
 
 
 
19
well understood.  The primary objectives of this investigation were to: 1) identify or confirm 
the existence of polymorphisms in PTGS1 by resequencing, 2) characterize the linkage 
disequilibrium (LD) structure in PTGS1, and 3) evaluate the functional consequences of 
selected variants using established in vitro assays. 
 
Methods 
Chemicals.  All chemicals were purchased from Sigma (St. Louis, MO), unless otherwise 
noted. 
 
DNA Samples.  Genomic DNA was extracted from 72 human lymphoblastoid cell lines 
(Coriell Institute, Camden, NJ) obtained from healthy individuals with the following 
ancestries: 24 Africans [16 African-Americans, 8 African Pygmy], 24 Asians [5 Indo-
Pakistani, 5 native Taiwanese, 5 mainland Chinese, 3 Cambodian, 3 Japanese, 3 Melanesian], 
24 European/Caucasians [9 European-Americans, 5 Druze, 5 Adygei, 5 Russian], and an 
additional 20 anonymous healthy U.S. residents (DNA Polymorphism Discovery Resource, 
NIH) (79), as part of the NIEHS Environmental Genome Single Nucleotide Polymorphism 
(egSNP) program (https://dir-apps.niehs.nih.gov/egsnp/home.htm) (58, 63, 69, 80). 
 
Genotyping.  A resequencing strategy was used to identify variants in both coding and 
noncoding regions of PTGS1.  Sequencing spanned all 11 exons, including approximately 75 
base pairs 3’ and 5’ of each intron-exon boundary, and 2.4 kilobases into the 5’ untranslated 
region (5’UTR).  Amplified polymerase chain reaction (PCR) products containing these 
regions were generated using oligonucleotide primers specific to PTGS1.  All sequencing 
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was performed in both directions, as previously described, at the Lawrence Livermore 
National Laboratory (58, 63, 69, 80).  Since all DNA samples came from commercially 
available cell lines, this protocol was considered exempt by the Lawrence Livermore 
National Laboratory Institutional Review Board. 
 
LD Statistics.  Minor allele frequencies and pairwise LD statistics were calculated for each 
polymorphism, and the corresponding LD plots were generated (Haploview 3.2) (81).  All 
analyses were completed independently in the African, Asian, and European/Caucasian 
ethnic groups. 
 
Evaluation of COX-1 Gene and Protein Sequences.  Approximately 1.8 kilobases of the 
human PTGS1 5’UTR sequence was extracted from the University of California Santa Cruz 
Genome Browser (http://genome.ucsc.edu/), and the corresponding human, mouse, rat, dog 
and chimp sequences for this region were aligned to screen for nucleotide conservation 
across species at each of the polymorphic sites.  The sequences surrounding each 
polymorphism were then evaluated for potential location within putative transcription factor 
binding sites using the TRANSFAC database (82). 
    The human, rat, mouse, and sheep COX-1 amino acid sequences were obtained from 
Genbank and aligned using the ClustalW program (83) to determine if the identified 
nonsynonymous polymorphisms occurred in conserved regions of the protein.  A model of 
the human COX-1 protein was constructed based on the ovine COX-1 crystal structure (PDB 
accession 1Q4G) (84), which has 96% sequence identity to human COX-1.  The model was 
also compared with the murine COX-2 crystal structure (PDB accession 1CVU) (85, 86).  
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Additional crystallographic refinement was performed for both structures using the deposited 
diffraction data after analysis by MolProbity (87).  In both cases, the crystallographic R-
factor was reduced by more than 1% in working and test reflection sets.  The procedure for 
modeling human COX-1 from the refined ovine structure consisted primarily of selecting 
preferred rotamers (87).  The high level of sequence conservation and lack of insertions or 
deletions eliminated the need for changes to the C-alpha backbone coordinates.  Substitution 
of side chains using common side-chain rotamers produced an acceptable fit in all cases, so 
no energy minimization was performed.  In order to predict the potential impact of amino 
acid substitutions on the structure and function of the COX-1 protein, the R53H, R78W, 
K185T, G230S, L237M, and V481I variant amino acids were individually built into the wild-
type human COX-1 model.  Since the R8W and P17L polymorphisms occur in the COX-1 
signal peptide and the ovine COX-1 crystal structure starts at amino acid residue 25 (84), the 
impact of these variants were not evaluated in the model. 
 
Plasmid Construction and Site-Directed Mutagenesis.  The full-length COX-1 cDNA was 
subcloned into pcDNA3.1 (Invitrogen, Carlsbad, CA), as previously described (88).  Single 
nucleotide polymorphisms (SNPs) were introduced into the wild-type COX-1 cDNA by site-
directed mutagenesis using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La 
Jolla, CA) per the manufacturer instructions.  The specific primer sequences used to generate 
each of the 8 mutations are provided in Table 1.  Presence of the desired mutation in each 
ampicillin-resistant clone was confirmed by sequencing the entire COX-1 cDNA using the 
BigDye Terminator Reaction Ready Mix (Applied Biosystems, Foster City, CA) and ABI 
Prism 377 DNA sequencer (Applied Biosystems).  Wild-type and variant cDNAs with the 
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desired substitutions and no secondary mutations were then subcloned into the BamHI/NotI 
sites of the pVL1393 Baculovirus Transfer Vector (BD Biosciences, San Diego, CA) via the 
intermediate pCR Blunt II-TOPO vector (Invitrogen).  The orientation and sequence of the 
wild-type and variant cDNAs in pVL1393 were confirmed by direct sequencing. 
  
Expression of Human COX-1 in Sf9 Cells.  Sf9 cells were plated in T-25 tissue culture 
flasks at 2 x 106 cells/flask, cotransfected with 0.5 μg of BaculoGold Bright linearized 
baculovirus DNA (BD Biosciences) and 2 μg of pVL1393 containing the COX-1 inserts, and 
incubated at 27°C for 96 hours.  Recombinant baculovirus was amplified by infecting 50 mL 
of Sf9 cells (70% confluent) in HyQ SFX-Insect cell culture media (Fisher Chemical, 
Fairlawn, NJ) and 5% fetal bovine serum with 1 mL of the transfection supernatant, and 
incubated in spinner flasks for 72 hours at 27°C at 120 rpm.  Cells were harvested and lysed 
by sonication in a 80 mM Tris, 2 mM EDTA buffer (pH=7.2).  Viral amplification was 
qualitatively confirmed by visualizing GFP fluorescence in the lysed cells under ultraviolet 
light.  Uninfected negative control cells demonstrated no fluorescence.  For large scale COX-
1 expression, 1 liter of Sf9 cells (70% confluent) were infected with each amplification 
supernatant and incubated for 72 hours in spinner flasks at 27°C at 120 rpm, as described 
(58, 89, 90).  Cells were centrifuged for 20 minutes at 4°C at 3000 rpm, washed with ice cold 
phosphate buffered saline, and centrifuged again.  Cell pellets were stored at -80°C after 
removal of the supernatant. 
    Cell pellets were thawed on ice and lysed by sonication in a 80 mM Tris, 2 mM EDTA 
buffer (pH=7.2) containing 0.1 M silver diethyldithiocarbamate and protease inhibitors, as 
described (58, 89, 90).  Cell lysates were ultracentrifuged at 40,000 rpm at 4°C for 1 hour, 
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and the microsomal pellets were homogenized in a 200 mM Tris, 0.1 mM EDTA buffer 
(pH=8.0) containing 0.4% CHAPS.  Homogenates were stirred for 1.5 hours at 4°C while 
bringing the final volume to 1% CHAPS (w/v), and ultracentrifuged at 40,000 rpm at 4°C for 
45 minutes.  Supernatants, which contained the solubilized COX-1 enzyme, were stored in 
aliquots at -80°C. 
 
Immunoblotting.  Protein concentrations of the solubilized microsomal fractions were 
quantified using the Bio-Rad protein assay (Bio-Rad, Hercules, CA).  Protein normalized 
samples were added to 4X sample buffer containing β-mercaptoethanol and boiled for 5 
minutes.  Proteins were separated by 10% Novex Tris-glycine polyacrylamide gels 
(Invitrogen) and transferred to nitrocellulose membranes (Invitrogen) in transfer buffer 
containing 20% methanol.  The membranes were blocked in 5% nonfat milk in Tris-buffered 
saline (TBS) for 2 hours, incubated in a 1:250 dilution of COX-1 specific monoclonal 
antibody (Cayman Chemical, Ann Arbor, MI) at 4°C overnight, and then washed in 0.05% 
TBS-Tween 20 four times.  After incubation with a 1:2000 dilution of horseradish peroxidase 
conjugated bovine anti-mouse secondary antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA) and additional washing, COX-1 immunoreactive bands were detected by 
chemiluminescence using the SuperSignal West Pico chemiluminescent substrate (Pierce, 
Rockford, IL).   
    In order to estimate differences in COX-1 expression across each preparation, 
densitometry was completed after multiple immunoblots and mean fold differences in COX-
1 immunoreactivity were calculated for each variant relative to wild-type.  The total amount 
of solubilized microsomal protein used in all subsequent activity studies was normalized to 
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COX-1 immunoreactivity based on these calculations.  Similar protein normalization 
methods have been utilized for the functional characterization of nonsynonymous 
polymorphisms in other genes using a baculovirus/insect cell expression system (58, 69). 
 
COX-1 Enzymatic Assay.  COX-1 enzymatic activity was determined by measuring oxygen 
consumption at 37°C in an oxygraph chamber using an YSI Model 53 oxygen monitor and 
electrode (YSI International, Yellow Springs, OH), as described (58, 89-91).  The reaction 
buffer consisted of 100 mM Tris (pH=8.0) containing 500 µM phenol.  Solubilized 
microsomal protein from the wild-type (3.4 mg of total protein) and 8 variant (total protein 
amounts normalized to COX-1 immunoreactivity) preparations were reconstituted in reaction 
buffer with 10 µM hematin for 1 minute on ice.  Solubilized microsomal protein from 
uninfected Sf9 cells (3.4 mg of total protein) was used as a negative control.  Samples were 
then equilibrated in reaction buffer for 1 minute at 37°C.  Oxygen consumption was 
measured for 120 seconds following the addition of 100 µM arachidonic acid (Cayman 
Chemical), and the rate of oxygen consumption was calculated and expressed as µM 
O2/minute/mg microsomal protein.  Three independent experiments were completed, each in 
triplicate. 
    Inhibitor studies were completed with 0 (vehicle), 0.1, 1, 5, 10, and 25 µM indomethacin 
(Cayman Chemical) in the wild-type, R8W, P17L, G230S, and L237M preparations.  
Solubilized microsomal proteins were reconstituted on ice for 10 minutes with hematin plus 
indomethacin, each completed in triplicate, and oxygen consumption was measured using the 
experimental conditions described above. 
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Statistical Analysis.  The rate of oxygen consumption was expressed relative to wild-type 
and averaged.  Data are presented as mean±standard error of the mean (SEM), and were 
compared across COX-1 preparation by analysis of variance (ANOVA).  A post-hoc 
Dunnett’s test assessed the presence of statistical differences between each mutant relative to 
wild-type.  A P-value <0.05 was considered statistically significant. 
    In order to determine if certain variants significantly influenced indomethacin-mediated 
inhibition of COX-1, IC50 values were estimated.  First, the data for each preparation were 
plotted as percent activity relative to control (vehicle) versus natural log indomethacin 
concentration.  The IC50 value for each was estimated according to the Hill equation by 
nonlinear regression (WinNonlin, Pharsight Corporation), where Emax=1.0, C=natural log 
indomethacin concentration, and the IC50 and γ (an exponential term influencing the 
sigmoidal shape of the curve) values were estimated according to the model’s fit of the data:   
 
 
Triplicate values at each indomethacin concentration were simultaneously modeled for 
estimation of a single IC50 value (±95% confidence intervals) for each preparation.  Inclusion 
of a 1/Y2 weighting factor substantially improved the model’s fit of the data according to the 
Akaike Information Criterion value. 
 
Results 
Identification of PTGS1 Variants.  Sequencing the PTGS1 gene in 72 individuals of known 
ethnicity identified 44 variants (42 SNPs, 1 nucleotide insertion, and 1 nucleotide deletion).  
Evaluation of an additional 20 anonymous individuals of unknown ethnicity identified one 
 
 
 
26
additional SNP.  Of these 45 variants, 14 were located in the 5’UTR, 12 were in exons, and 
19 were in introns.  Seven of the 12 exonic substitutions were nonsynonymous (R8W, R8P, 
P17L, R78W, K185T, L237M, and V481I) and 5 were synonymous.  The R8P and R78W 
variants have not been previously reported.  The R8P variant was identified in a single 
individual of African descent.  The R78W variant was identified in a single individual of 
unknown ethnicity.  The R53H and G230S variants reported in other populations (61, 62) 
were not identified in this resequencing analysis; however, their existence was confirmed at 
frequencies <1% in an independent African-American population (n=367) (see Chapter III).  
The minor allele frequencies of most polymorphisms differed significantly across ethnicity, 
with the Asian sample demonstrating the least genetic variation.  The location and minor 
allele frequencies of all 45 variants are summarized in Table 2.  Given the magnitude of 
genetic diversity and admixture across human populations, and the small number of 
chromosomes screened within each ethnic group, the reported minor allele frequencies 
should be considered an approximation. 
 
LD Structure of the PTGS1 Gene.  The LD structure across PTGS1 is presented for each 
ethnicity (Figure 3).  A substantial degree of LD was observed throughout the 5’UTR.  This 
LD pattern specifically involved seven polymorphisms (T-1749C, G-1598A, A-1202G, A-
1201G, G-1006A, A-918G and A-707G) (Table 2) and was observed in both the 
European/Caucasian (D’=1.0, r2=0.73-1.0) and African (D’=1.0, r2=1.0) samples, suggesting 
these seven polymorphisms are on the same haplotype.  In European/Caucasians, these 
5’UTR polymorphisms were also in significant LD with the P17L variant in exon 2.  
Interestingly, only two of the identified 5’UTR polymorphisms (C-1160G and G-951A) are 
 
 
 
27
located in regions relatively conserved across human, mouse, rat, dog and chimp, suggesting 
that most are in regions that are not selectively constrained.  The completed transcription 
factor binding site search suggests the T-1749C polymorphism could weaken a putative 
AML/RUNX1 binding site by changing the core motif from TGTTGT to TGCTGT, the linked 
A-1202G and A-1201G polymorphisms could destroy a putative NF-Y binding site by 
changing the core NF-Y motif from CCAAT to CCGGT, and the G-951A polymorphism 
could disrupt a putative NF-AT binding site.  In addition, the G-1006A polymorphism could 
create a putative heat shock protein (HSF) binding site. 
 
Structural Analysis of the COX-1 Protein.  Alignment of human, mouse, rat and sheep 
COX-1 amino acid sequences demonstrated that the R78, G230 and L237 amino acids are 
conserved across each of these species (Figure 4).  Interestingly, L237 is also conserved 
across all COX-2 protein sequences.  The R53H, R78W, K185T, G230S, L237M, and V481I 
variants were individually incorporated into the wild-type human COX-1 model (Figure 5).  
Substitution of a serine for glycine at residue 230 (G230S) appears to significantly impact the 
structure of COX-1 (Figure 6).  First, glycine 230 is located on a 310 helical turn, suggesting 
that this tight turn requires a glycine residue.  The equivalent residue in COX-2 is asparagine 
231.  Comparison of the current model to murine COX-2 (PDB accession 1CVU) (85, 86) 
reveals that some of the backbone interactions in COX-2 are less favorable than observed in 
COX-1, but these are offset through favorable interactions by the asparagine 231 side chain 
to the backbone carbonyl of glutamine 208 and the side chain of aspartic acid 229 (Figure 
6C).  In the current human COX-1 model, there is a single sterically-compatible rotamer 
conformation for serine 230 substitution, which can interact favorably with only one 
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hydrogen-bond acceptor (Figure 6B).  The minimum conformational change to avoid a 
negative interaction is the rotation of aspartic acid 228 to a position within hydrogen-bonding 
distance to arginine 332.  However, this position requires a displacement of tryptophan 138' 
which perturbs the dimer interface association, potentially influencing enzyme activity 
(Figure 6D, where ‘prime’ indicates a residue from the dimer associated molecule).  
Moreover, arginine 332 is solvent-accessible at the bottom of a narrow crevasse where 
arachidonic acid could form hydrogen bonds and prevent stabilization of the proposed 
alternate conformation of aspartic acid 228. 
    In the presence of the R53H, R78W, K185T, L237M, or V481I substitutions, common 
rotamer conformations yielded reasonable accommodation of the substituted amino acid; 
however, in certain cases potential minor alterations in structure that could influence enzyme 
activity were noted.  For instance, arginine 53 is in a solvent exposed region where 
substitution with histidine (R53H) has no obvious effects; however, this substitution could 
have a minor influence on glycosylation of asparagine 67 or the adjacent dimerization 
contact, both of which are approximately about 10-11Å away.  The arginine 78 residue is at 
the membrane binding surface and, although conserved, a tryptophan substitution at this 
position (R78W) is also favorable for membrane binding and unlikely to directly influence 
enzyme activity.  The most feasible functional role for arginine at this site would be to assist 
retrieval of arachidonic acid into the active site.  The lysine 185 residue is on a solvent 
exposed loop, distant from any functional site likely to influence catalysis; however, this 
residue is in a positively charged region with several arginines, which could serve some non-
obvious function potentially altered by a threonine substitution (K185T).  The leucine 237 
residue is likely involved in a dimerization interaction, with significant contacts to sugars 
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linked to asparagine 143 of the related monomer.  A methionine substitution (L237M) fits 
reasonably well into this site with favorable hydrophobic interactions, but it is larger and 
more flexible.  This mutation is predicted to have a small effect on the dimerization interface.  
Moreover, oxidation of methionine could conceivably impact the dimerization contact; 
however, it is unclear whether either of these effects could significantly influence enzyme 
activity.  The valine 481 residue is distant from both the catalytic site and dimerization 
surface.  Since an isoleucine substitution (V481I) is conservative, this mutation appears 
unlikely to influence enzyme activity. 
 
Expression of the Wild-type and Variant COX-1 Proteins.  The COX-1 wild-type and 
mutant R8W, P17L, R53H, R78W, K185T, G230S, L237M, and V481I proteins were 
expressed in Sf9 cells using a single promoter baculovirus system.  The R8P variant was not 
expressed since the R8W variant occurred at the same amino acid position and was more 
frequent.  Expression was verified by immunoblotting, with a molecular mass of 
approximately 70-kDa for the wild-type and mutant proteins (Figure 7A).  COX-1 expression 
was not observed in uninfected Sf9 cells.  Consistent with previous studies of COX-1 
expression in Sf9 cells (89, 90), the relative amount of COX-1 in the solubilized microsomal 
fraction to the total amount of protein was fairly low.  However, large scale expression of 
each preparation generated enough COX-1 protein for functional characterization.   
    Densitometry analysis of multiple immunoblots demonstrated variability in the level of 
COX-1 immunoreactivity across preparations, with an approximate range of 0.3-1.4-fold 
differences relative to wild-type.  Immunoblots were repeated with varying amounts of 
solubilized microsomal protein according to these densitometry results in order to normalize 
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each preparation for COX-1 immunoreactivity, as presented in Figure 7A.  Such an approach 
normalized these preparation differences in COX-1 expression and yielded approximately 
0.9-1.1-fold differences in COX-1 immunoreactivity across each preparation relative to wild-
type.  Subsequently, equivalent amounts of immunoreactive COX-1 for each preparation 
were included in the activity studies. 
 
COX-1 Enzymatic Activity.  The mean rate of oxygen consumption calculated for the wild-
type COX-1 preparation was 19.7±2.0 µM O2/minute/mg microsomal protein.  The 
uninfected negative control demonstrated undetectable oxygen consumption, suggesting 
detectable oxygen consumption in the COX-1 preparations was due to recombinant COX-1-
mediated arachidonic acid metabolism.  Pooled analysis of three independent experiments 
demonstrated the R53H (35.0±4.9%), R78W (36.1±3.9%), K185T (59.2±6.4%), G230S 
(56.6±3.5%) and L237M (51.0±2.5%) variants had significantly lower metabolic activity 
relative to wild-type COX-1 (100.0±7.2%) (Figure 7B, P<0.05 of each variant versus wild-
type).  No significant differences in enzymatic activity were detected in the R8W 
(103.8±10.0%), P17L (113.3±7.0%), and V481I (121.3±10.2%) variants compared to wild-
type (Figure 7B).  Similar results were obtained in each of the three independent 
experiments.  Moreover, weight-adjusting the calculated oxygen consumption rates 
according to the mean 0.9-1.1-fold differences in COX-1 immunoreactivity observed across 
each normalized preparation did not significantly alter these results (data not shown). 
 
Inhibition of COX-1 Enzymatic Activity.  The sensitivity of the wild-type and R8W, P17L, 
G230S, and L237M variants to inhibition by indomethacin, a nonselective COX inhibitor 
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with greater potency for COX-1 than COX-2 in recombinant systems, was evaluated.  The 
R8W and P17L variants were selected since they are the most frequent nonsynonymous 
polymorphisms.  The G230S and L237M variants were selected based on the basal metabolic 
activity and modeling results reported above.  The effects of increasing indomethacin 
concentrations on metabolic activity for each preparation relative to vehicle-incubated 
controls are presented (Figures 8A-D).  From these data, IC50 values for each preparation 
were estimated (Table 3).  The P17L and G230S variants demonstrated significantly lower 
IC50 values compared to wild-type, suggesting presence of these mutations significantly 
increase COX-1 sensitivity to inhibition by indomethacin.  This increase in sensitivity is 
evident in Figures 8B and 8C, respectively.  No significant differences in IC50 values were 
observed with the R8W and L237M variants compared to wild-type.  The R8W variant 
appeared more resistant to inhibition at lower indomethacin concentrations relative to wild-
type (Figure 8A); however, this effect was lost at higher indomethacin concentrations and the 
estimated IC50 value was not statistically different from wild-type.  The L237M variants 
appeared more sensitive to inhibition at higher indomethacin concentrations relative to wild-
type (Figure 8D); however, the estimated IC50 value was not statistically different from wild-
type. 
    In order to take into account basal COX-1 activity, the rate of oxygen consumption in each 
preparation was compared after treatment with 25 µM indomethacin relative to wild-type 
after treatment with vehicle control (Figure 8E).  The P17L (13.8±1.7%), G230S (4.1±1.3%), 
and L237M (6.9±2.6%) variants each demonstrated significantly lower metabolic activity 
compared to wild-type (36.7±0.5%) (P<0.05 of each variant versus wild-type).  Significant 
differences were not observed with the R8W variant (29.4±4.1%) compared to wild-type.  
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These findings suggest that combination of indomethacin treatment and the P17L, G230S 
and L237M variants significantly reduce COX-1 metabolic activity compared to 
indomethacin treatment of wild-type COX-1. 
 
Discussion 
    COX-1 and COX-2 derived PGs play a vital role in the regulation of various biological 
processes in humans, such that nonselective and selective NSAIDs are routinely administered 
for the prevention and/or treatment of a variety of clinical conditions (19, 23, 24, 73).  
Genetic variation in PTGS1 and PTGS2 may significantly modify disease risk in humans 
and/or contribute to inter-individual variability in the pharmacodynamic response to 
NSAIDs.  Although the functional relevance of genetic variants in PTGS2 has been evaluated 
(58, 59), functional characterization of human PTGS1 variants has not been as widely 
investigated.  In order to guide the design and interpretation of future genetic epidemiology 
and pharmacogenomic studies, the primary aim of this investigation was to identify or 
confirm the existence of genetic polymorphisms in PTGS1, characterize the LD structure, 
and evaluate the functional consequences of selected variants in vitro. 
    Multiple variants were identified in both coding and noncoding regions of human PTGS1 
by resequencing 92 healthy individuals.  Twenty-four of the 45 variants had been previously 
reported in the published literature (61, 62, 74, 75) and/or publicly available databases 
(http://www.ncbi.nlm.nih.gov/snp), and were present at comparable frequencies within each 
ethnic group.  Interestingly, seven of the 45 variants were nonsynonymous changes (R8W, 
R8P, P17L, R78W, K185T, L237M, and V481I), most of which were present at low (≤6%) 
frequencies in distinct ethnic groups.  The previously reported R53H and G230S variants 
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(61) were not identified in the egSNP population, but their existence was confirmed at low 
frequencies in an independent African-American population (Chapter III).  Multiple 
polymorphisms in the PTGS1 5’UTR were also identified, including seven (T-1749C, G-
1598A, A-1202G, A-1201G, G-1006A, A-918G and A-707G) on the same haplotype in the 
European/Caucasian and African samples.  Moreover, these 5’UTR polymorphisms were 
also in near complete LD with the P17L variant in European/Caucasian, but not African 
individuals.  The presence of LD between the A-707G and P17L polymorphisms in 
Caucasians has been previously reported (62, 74, 76, 92); however, the current analysis is the 
first to suggest that this LD pattern involves six additional polymorphisms further upstream 
in the 5’UTR.  A recent human investigation demonstrated that presence of this variant 
haplotype was not associated with PTGS1 RNA expression in oral mucosa (92).  Preliminary 
sequence analysis in the current investigation suggests that certain 5’UTR variant alleles may 
disrupt putative transcription factor binding sites.  Further functional characterization of these 
promoter polymorphisms via transcriptional activation and DNA binding studies appears 
necessary. 
    Recombinant wild-type COX-1 and the R8W, P17L, R53H, R78W, K185T, G230S, 
L237M, and V481I mutant proteins were expressed and basal COX-1 metabolic activity was 
evaluated in vitro.  As summarized in Table 4, the R53H, R78W, K185T, G230S, and 
L237M variants demonstrated significantly lower metabolic activity (35-60%) relative to 
wild-type COX-1; although, none completely abolished activity, most likely since these 
variants did not occur at or in immediate proximity to residues critical for substrate binding 
and/or enzyme activity such as arginine 120 or tyrosine 385 (93-96).  Protein modeling 
suggests the G230S variant may significantly alter COX-1 protein structure.  These structural 
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observations, in conjunction with the observed functional effects, suggest that the G230S 
variant disrupts the active conformation of COX-1 by shifting the dimer interface via D228 
and W138'.  This conformational change could also influence catalysis more directly through 
an interaction between D228 and R332.  R332 is a member of helix 6 (84), which also 
includes residues contributing to formation of the active site.  A shift in this helix could serve 
as the mechanism underlying the observed effect on catalytic function. 
    Similar reductions in enzyme activity were also observed with the R53H, R78W, K185T, 
and L237M variants; although, their predicted impact on COX-1 structure were not as 
obvious.  The L237 residue is conserved across all known COX-1 and COX-2 species, and 
the L237M variant presumably could influence catalytic activity through its predicted impact 
on dimerization; however, the association between alterations in COX dimerization and 
metabolic activity has not been well characterized.  The mechanism underlying the 
alterations in activity observed with the R53H, R78W, and K185T variants does not appear 
to be explained by the protein modeling results.  However, recent COX-1 structure-function 
studies suggest that several amino acid substitutions with modest influence on arachidonic 
acid binding to the COX-1 active site can alter the catalytic efficiency and metabolite profile 
of COX-1-mediated arachidonic acid metabolism (96, 97).  Perhaps these variants could 
reduce overall metabolic efficiency by altering the interaction between arachidonic acid and 
the active site.  Future studies evaluating the mechanism underlying these functional effects 
appear necessary.  No significant changes in enzymatic activity were detected with the R8W, 
P17L, and V481I variants relative to wild-type.  The R8W and P17L variants occur at amino 
acids lying within the COX-1 signal peptide sequence, which is post-translationally cleaved 
(84, 95), and would be unlikely to significantly impact enzymatic activity.  Protein modeling 
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suggests the V481I variant is also unlikely to significantly alter COX-1 structure or activity.  
Additional low frequency nonsynonymous variants in PTGS1 have also been recently 
discovered (L15-L16del, R108Q, I136V, K341R, R458Q) (61, 75, 78, 98); however, their 
potential influence on COX-1 metabolic activity has not been investigated.  Moreover, the in 
vivo functional consequences of the R53H, R78W, K185T, G230S, L237M and 5’UTR 
variants remain to be evaluated via quantification of systemic (plasma, urine) and local 
(tissue-, cell-specific) PG concentrations, particularly since the relative contribution of COX-
2 to PG biosynthesis may also be altered in individuals with certain PTGS1 polymorphisms.  
In vitro and in vivo functional studies will substantially aid in the interpretation of genetic 
epidemiological studies evaluating associations between PTGS1 polymorphisms and risk of 
diseases known to involve altered COX-derived PG synthesis, such as cardio- and 
cerebrovascular disease, colorectal cancer, and asthma (23, 73).   
    Inhibition studies with indomethacin demonstrated the P17L and G230S variants were 
significantly more sensitive to indomethacin-mediated inhibition of COX-1 activity relative 
to wild-type, as determined by estimation of IC50 values for each preparation.  Since the 
P17L variant resides within the COX-1 signal peptide sequence, the mechanism underlying 
the observed alteration in indomethacin sensitivity is unclear.  The estimated IC50 values for 
the R8W and L237M variants were not significantly different from wild-type; however, 
COX-1 metabolic activity was significantly lower with the L237M variant relative to wild-
type after inhibition with indomethacin since the L237M variant also had significantly lower 
basal activity.  The estimated indomethacin IC50 value for the wild-type preparation in the 
current study (8.37 µM) was higher than those previously reported with purified COX-1 
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preparations (approximately 1 µM) (89, 90).  This is likely due to utilization of crude 
microsomal protein preparations.   
    Interestingly, a recent human study demonstrated that platelets isolated from Caucasian 
individuals heterozygous for the P17L variant allele were significantly more sensitive to 
aspirin-mediated inhibition of PGF2α production compared to wild-type individuals (62).  
The in vitro data with the P17L variant and indomethacin from the current study are 
consistent with these findings (Table 4), even though aspirin and indomethacin inhibit COX-
1 activity via different mechanisms, suggesting individuals carrying this variant may be 
significantly more sensitive to NSAID-mediated inhibition of COX-1 activity and potentially 
more susceptible to adverse events such as gastrointestinal bleeding, renal dysfunction, 
and/or cardiovascular events (73).  Similar associations may also exist with the G230S and 
L237M variants; although, the population impact of the P17L polymorphism may be more 
substantial since it is significantly more frequent in both European/Caucasian and African 
populations.  In contrast, human studies have also suggested that the P17L variant may be 
associated with resistance to aspirin-mediated inhibition of platelet aggregation (76) and 
aspirin-mediated reduction in risk of colorectal polyps (78).  Importantly, these investigations 
were also conducted in Caucasian populations, such that presence of the aforementioned 
PTGS1 5’UTR variant alleles, and not the P17L variant allele, may be driving these observed 
interactions with aspirin therapy.  Presence of the P17L variant has also been associated with 
rofecoxib and celecoxib-mediated inhibition of thromboxane formation in vivo (77).  The 
population evaluated in this investigation consisted of Caucasian, African-American and 
Asian individuals.  Since the ethnicities of those carrying the P17L variant allele were not 
reported, the potential contribution of PTGS1 5’UTR polymorphisms could not be 
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ascertained.  Collectively, the mechanisms underlying these conflicting in vitro and in vivo 
observations remain to be characterized; however, the relative contribution of the P17L and 
5’UTR polymorphisms may be an important determinant of NSAID pharmacodynamics in 
humans.  Additional human pharmacogenomic studies evaluating potential associations 
between PTGS1 polymorphisms and NSAID pharmacodynamics in both Caucasians and 
African-Americans, including risk of adverse events, appear warranted. 
    Certain limitations exist in the current analysis.  First, utilization of a non-mammalian 
expression system could significantly impact the expression and function of a recombinant 
protein, particularly glycosylated proteins such as COX-1.  However, recombinant COX-1 
has been expressed in insect cell systems previously, and has exhibited similar post-
translational processing, glycosylation and activity profiles compared to native COX-1 (89, 
90).  Second, the limitations related to evaluation of metabolic activity at a single substrate 
concentration are recognized.  The observed differences in the rate of oxygen consumption in 
certain mutant preparations compared to wild-type may be a reflection of reduced metabolic 
capacity (decreased Vmax) and/or reduced substrate binding (increased Km).  Evaluation of 
metabolic activity across a range of substrate concentrations will ultimately be necessary to 
more completely characterize the enzyme kinetics of each mutant relative to wild-type.  
However, quantification of oxygen consumption after addition of 100 µM of arachidonic acid 
has been previously utilized to evaluate COX-1 metabolic activity in recombinant systems 
(89, 90).  Moreover, similar conditions have been employed for IC50 determinations of 
multiple COX inhibitors, including indomethacin (89, 90).  Since indomethacin is not 
utilized clinically as widely as aspirin, or for the same indication, the clinical applicability of 
the completed inhibition studies may not extend to all NSAIDs.  However, indomethacin has 
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demonstrated greater potency for inhibition of COX-1 than COX-2 and has been widely 
studied in this recombinant in vitro system under these experimental conditions (89, 90).  
Consequently, indomethacin was a more appropriate inhibitor for the initial characterization 
of selected COX-1 variants. 
    In summary, the R53H, R78W, K185T, G230S, and L237M variants in PTGS1 
demonstrated significantly lower basal metabolic activity in vitro relative to wild-type COX-
1, suggesting individuals carrying these variant alleles may have significantly altered PG 
biosynthesis in vivo.  In addition, the P17L and G230S variants were significantly more 
sensitive to indomethacin-mediated inhibition of COX-1 activity relative to wild-type, 
suggesting individuals carrying these variant alleles may be more susceptible to NSAID-
associated adverse events.  Future studies confirming the in vivo relevance of these variants, 
including their influence on disease susceptibility and NSAID pharmacodynamics, are 
warranted. 
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Table 1.  Primers used for the site-directed mutagenesis of human COX-1. 
 
Mutation   Sequences of Forward (F) and Reverse (R) Primers* 
Arg8Trp (R8W)  (F)  5’–CCATGAGCCGGAGTCTCTTGCTCTGGTTCTTGCTGTTCCTGCTCC–3’ 
    (R)  5’–GGAGCAGGAACAGCAAGAACCAGAGCAAGAGACTCCGGCTCATGG–3’ 
Pro17Leu (P17L)  (F)  5’–GCTGTTCCTGCTCCTGCTCCTGCCGCTCCCCGTCCTGCTCG–3’ 
    (R)  5’–CGAGCAGGACGGGGAGCGGCAGGAGCAGGAGCAGGAACAGC–3’ 
Arg53His (R53H)  (F)  5’–CCGCTTCGGCCTTGACCACTACCAGTGTGACTGC–3’ 
    (R)  5’–GCAGTCACACTGGTAGTGGTCAAGGCCGAAGCGG–3’ 
Arg78Trp (R78W)  (F)  5’–GCCTGTGGACCTGGCTCTGGAATTCACTGCGGCCC–3’ 
    (R)  5’–GGGCCGCAGTGAATTCCAGAGCCAGGTCCACAGGC–3’ 
Lys185Thr (K185T)  (F)  5’–GCTTCCTGCTCAGGAGGACGTTCATACCTGACCCCC–3’ 
    (R)  5’–GGGGGTCAGGTATGAACGTCCTCCTGAGCAGGAAGC–3’ 
Gly230Ser (G230S)  (F)  5’–GGGCCATGGGGTAGACCTCAGCCACATTTATGGAGAC–3’ 
    (R)  5’–GTCTCCATAAATGTGGCTGAGGTCTACCCCATGGCCC–3’ 
Leu237Met (L237M)  (F)  5’–CGGCCACATTTATGGAGACAATATGGAGCGTCAGTATCAACTGCGGC–3’ 
    (R)  5’–GCCGCAGTTGATACTGACGCTCCATATTGTCTCCATAAATGTGGCCG–3’ 
Val481Ile (V481I)  (F)  5’–CCTCCTTCCAGGAGCTCATAGGAGAGAAGGAGATGGC–3’ 
    (R)  5’–GCCATCTCCTTCTCTCCTATGAGCTCCTGGAAGGAGG–3’ 
*Primers were PAGE-purified (Invitrogen).  Bold/underlined bases indicate the mutated nucleotides.  The R8P mutant was not expressed. 
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Table 2.  PTGS1 variants identified from the NIEHS egSNP sequencing project.* 
     Estimated Minor Allele Frequency‡  
Polymorphism Nucleotide† Location Amino Acid   Caucasian   African Asian All 
       (n=24)  (n=24)  (n=24) (n=72 or 92§) 
(1)    C>G -1862  5’UTR  -  0  0.02  0  0.01§ 
(2)    T>C║ -1749  5’UTR  -  0.06  0.04  0  0.07§ 
(3)    T>G -1702 5’UTR - 0 0 0.02 0.01§ 
(4)    G>A║ -1598 5’UTR - 0.06 0.04 0 0.07§ 
(5)    T>C -1541 5’UTR - 0.19 0.33 0.46 0.39§ 
(6)    A>G║ -1202 5’UTR - 0.06 0.04 0.02 0.07§ 
(7)    A>G║ -1201 5’UTR - 0.06 0.04 0.02 0.07§ 
(8)    C>G -1160 5’UTR - 0.02 0.04 0 0.02§ 
(9)    G>A║ -1006 5’UTR - 0.08 0.04 0 0.08§ 
(10)  G>A -951 5’UTR - 0 0.02 0 0.01 
(11)  A>G║ -918 5’UTR - 0.08 0.04 0 0.04 
(12)  Insertion AA -748 5’UTR - 0 0.08 0 0.03 
(13)  A>G║ -707 5’UTR - 0.08 0.04 0 0.04 
(14)  T>C -640 5’UTR - 0 0.02 0 0.01 
(15)  C>T 250 Exon 2 R8W 0.04 0 0.06 0.05§ 
(16)  G>C 251 Exon 2 R8P 0 0.02 0 0.01§ 
(17)  C>T# 278 Exon 2 P17L 0.06 0.06 0 0.06§ 
(18)  G>C 6817 Intron 2 - 0.02 0 0 0.01 
(19)  C>T 6843 Intron 2 - 0 0.02 0 0.01 
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Table 2 (con’t). 
                 Estimated Minor Allele Frequency‡  
Polymorphism Nucleotide† Location Amino Acid  Caucasian African Asian All 
    (n=24) (n=24) (n=24) (n=72 or 92§) 
(20)  G>A (rs3842788) 6975 Exon 3 Q41Q 0.02 0.23 0.02 0.09 
(NI)*G>A (rs3842789) 7010 Exon 3 R53H 0 0 0 0 
(21)  C>T (rs10306139) 7056 Exon 3 C68C 0 0.02 0 0.01 
(22)  G>A (rs876567) 7095 Intron 3 - 0.04 0.02 0 0.02 
(23)  G>C (rs2282169) 7465 Intron 3 - 0.13 0.35 0.06 0.22§ 
(24)  C>T 7501 Exon 4 R78W 0 0 0 0.01§ 
(25)  C>G (rs10306148) 10153 Intron 5 - 0.08 0.42 0.04 0.24 
(26)  T>C 10203 Intron 5 - 0.02 0 0 0.01 
(27)  A>G 10354 Intron 5 - 0 0.02 0 0.01 
(28)  A>C (rs3842792) 10476 Exon 6 K185T 0 0.04 0 0.01 
(29)  C>A (rs5788) 10561 Exon 6 G213G 0.04 0.46 0.04 0.21 
(30)  G>A (rs3842794) 10651 Intron 6 - 0 0.02 0 0.01 
(NI)*G>A 10721 Exon 7 G230S 0 0 0 0 
(31)  C>A (rs5789) 10742 Exon 7 L237M 0.04 0 0 0.01 
(32)  G>A 10805 Intron 7 - 0 0.02 0 0.01 
(33)  Deletion A (rs3215925) 10809 Intron 7 - 0.13 0.40 0.04 0.26 
(34)  C>G 12754 Intron 8 - 0.02 0 0 0.01§ 
(35)  G>A 12867 Intron 8 - 0 0.06 0 0.02§ 
(36)  G>A (rs10306153) 12880 Intron 8 - 0 0.31 0 0.09§ 
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Table 2 (con’t). 
                 Estimated Minor Allele Frequency‡  
Polymorphism Nucleotide† Location Amino Acid  Caucasian African Asian All 
    (n=24) (n=24) (n=24) (n=72 or 92§) 
(37)  T>C 12921 Intron 8 - 0 0.04 0 0.01§ 
(38)  A>G 13020 Intron 8 - 0 0.02 0 0.02§ 
(39)  T>C (rs4836885) 13138 Intron 8 - 0.04 0.41 0.02 0.23§ 
(40) G>A (rs10306230) 13148 Intron 8 - 0.02 0.02 0.02 0.02§ 
(41) G>A (rs5794) 19389 Exon 10 V481I 0.04 0 0 0.01§ 
(42) A>T 21195 Intron 10 - 0 0.04 0 0.01§ 
(43) T>C (rs3842801) 21205 Intron 10 - 0 0.17 0 0.07§ 
(44) G>A (rs3842802) 21286 Exon 11 A499A 0 0.06 0 0.02§ 
(45) T>C (rs3842803) 21301 Exon 11 P504P 0 0.23 0 0.08§ 
5’UTR = 5’ untranslated region 
*The R53H and G230S nonsynonymous variants were not identified (NI) in the egSNP population. 
†Nucleotide position relative to the transcriptional start site (Genbank accession number AF440204). 
‡Number of individuals. 
§Indicates sequencing data that was obtained in an additional 20 anonymous individuals of unknown ethnicity (n=92 total). 
║These polymorphisms are in complete or near complete linkage disequilibrium with one another in both the African (D’=1.0, r2=1.0) and 
Caucasian (D’=1.0, r2=0.73-1.0) populations.  See Figure 3.  
#The P17L polymorphism is in complete or near complete linkage disequilibrium with the 5’UTRe polymorphisms in the Caucasian population 
only (D’=1.0, r2=0.73-1.0).  See Figure 3.
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Table 3.  Estimated IC50 values for indomethacin with wild-type COX-1 and the R8W, 
P17L, G230S, and L237M variants. 
 
COX-1 Variant Estimated IC50 (μM) 
 (95% confidence interval) 
Wild-type 8.37 (5.00–14.0) 
R8W 15.3 (11.1–21.0) 
P17L 2.80 (1.72–4.56)* 
G230S 1.36 (0.54–3.42)* 
L237M 3.55 (1.73–7.29) 
*P-value <0.05 versus wild-type. 
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Table 4.  Functional relevance of nonsynonymous polymorphisms in PTGS1.* 
 
PTGS1 Amino Acid Modeling In Vitro In Vitro Ex Vivo 
Variant Conserved Predicted Metabolic Sensitivity to Sensitivity 
 Across Functional Activity† Indomethacin† to Aspirin‡ 
 Species† Impact† 
R8W No No ↔ ↔ ↔ 
P17L No No ↔ ↑ ↑ or ↓ 
R53H No ? / Yes (minor) ↓ ? ? 
R78W Yes ? / No ↓ ? ? 
K185T No ? / No ↓ ? ? 
G230S Yes Yes (major) ↓ ↑ ? 
L237M Yes Yes (minor) ↓ ↔ / ↑ ? 
V481I No No ↔ ? ? 
*Functional effects indicated as increased (↑), decreased (↓), unchanged (↔), or unknown (?) compared to wild-type. 
†Based on the analyses and in vitro functional studies completed in the current investigation. 
‡Based on the previously published studies by Halushka et al. (62) and Maree et al. (76) in humans.  Conflicting results have been reported with 
the P17L variant, which was in complete linkage disequilibrium with the A-707G polymorphism in both populations.
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Figure Legends 
Figure 3.  Pairwise estimates of LD between each PTGS1 polymorphism are plotted for the 
(A) African, (B) European/Caucasian, and (C) Asian ethnic groups using Haploview 3.2.  
Each polymorphism is numbered according to its position in the PTGS1 gene as presented in 
Table 2.  Black squares indicate complete LD (r2=1.0), white squares indicate zero LD 
(r2=0.0), and increasing intensity of gray indicates increasing degrees of LD. 
 
Figure 4.  Alignment of the human (Genbank accession number P23219), mouse 
(AAH05573), rat (NP_058739), and sheep (P05979) COX-1 amino acid sequences using the 
ClustalW program.  Amino acid locations of the eight evaluated nonsynonymous variants are 
highlighted. 
 
Figure 5.  Overview of the COX-1 dimer and the R53H, R78W, K185T, G230S, L237M, 
and V481I variants, with (A) a top view of the dimer complex, and (B) a side view of one 
monomer facing the dimerization surface.  Mutations are illustrated with space-filling atoms.  
The heme group is shown in maroon, and arachidonic acid is shown in yellow.  Sugars are 
shown in cyan, with two sugars per glycosylation site. 
 
Figure 6.  Structural characterization of the G230S variant.  (A) The vicinity of G230 in the 
model of wild-type COX-1.  The position of D228 is stabilized by a hydrogen-bond to the 
backbone nitrogen of G230.  (B) The G230S substitution allows for only one rotamer 
position without significant structural changes.  (C) The corresponding site in human COX-2 
has an N231 in a similar position to the modeled S230 substitution; however, N231 also 
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provides several interactions that help stabilize the observed conformation.  (D) In COX-1, 
S230 destabilizes the observed conformation, which could be avoided by a rotation of D228 
towards R332, which also requires a shift in the dimer interaction with W138'. 
 
Figure 7.  (A) Representative immunoblot of solubilized microsomes containing 
recombinant wild-type and eight variant COX-1 proteins.  The amount of solubilized 
microsomal protein loaded per lane for each preparation was normalized to COX-1 
immunoreactivity based on previous immunoblots.  The wild-type lane contains 34 μg of 
microsomal protein.  Lane 1 contains COX-1 ovine protein standard (Cayman Chemical, 1 
μg) as a positive control.  Lane 11 contains solubilized microsomes made from uninfected 
Sf9 cells (34 μg) as a negative control.  (B) Mean±SEM rate of oxygen consumption for each 
of the 8 variant COX-1 preparations relative to wild-type.  Solubilized microsomal protein 
from uninfected Sf9 cells were used as a negative control.  The data presented are pooled 
from three independent experiments, each completed in triplicate.  The rate of oxygen 
consumption was significantly associated with the COX-1 microsomal preparation 
(ANOVA: P<0.001, r2=0.78).  *P<0.05 versus wild-type by a post-hoc Dunnett’s test. 
 
Figure 8.  Inhibition of COX-1-mediated arachidonic acid metabolism by increasing 
concentrations of indomethacin in the (A) R8W, (B) P17L, (C) G230S, and (D) L237M 
variants compared to wild-type.  Values represent the mean±SEM rate of oxygen 
consumption calculated at each indomethacin concentration (0.1, 1, 5, 10, and 25 µM) 
relative to the rate of oxygen consumption detected with vehicle control for each preparation.  
Each data point includes three independent measurements.  (E)  Mean±SEM rate of oxygen 
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consumption for the wild-type and R8W, P17L, G230S, and L237M variants after incubation 
with 25 µM indomethacin relative to the rate of oxygen consumption detected after 
incubation with vehicle control in the wild-type preparation.  Each data point includes three 
independent measurements.  The rate of oxygen consumption after incubation with 25 µM 
indomethacin was significantly associated with the COX-1 preparation (ANOVA: P<0.001, 
r2=0.93).  *P<0.05 versus wild-type by a post-hoc Dunnett’s test. 
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Figure 3.  PTGS1 linkage disequilibrium plots. 
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Figure 4.  COX-1 amino acid sequence alignment. 
 
        R8W      P17L                                  R53H 
PTGS1_human_WT       MSR-SLLLRFLLFLLLLPPL--PVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCD 57 
PTGS1_mouse          MSRRSLSLWFPLLLLLLLPPTPSVLLADPGVPSPVNPCCYYPCQNQGVCVRFGLDNYQCD 60 
PTGS1_rat            MSRRSLSLQFPLLLLLLLLPPPPVLLTDAGVPSPVIPCCYYPCQNQGVCVRFGLDHYQCD 60 
PTGS1_sheep          MSRQSISLRFPLLLLLLSPS--PVFSADPGAPAPVNPCCYYPCQHQGICVRFGLDRYQCD 58 
 
      R78W 
PTGS1_human_WT       CTRTGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLT 117 
PTGS1_mouse          CTRTGYSGPNCTIPEIWTWLRNSLRPSPSFTHFLLTHGYWLWEFVNATFIREVLMRLVLT 120 
PTGS1_rat            CTRTGYSGPNCTIPEIWTWLRSSLRPSPSFTHFLLTHGYWIWEFVNATFIREVLMGWVLT 120 
PTGS1_sheep          CTRTGYSGPNCTIPEIWTWLRTTLRPSPSFIHFMLTHGRWLWDFVNATFIRDTLMRLVLT 118 
                      
PTGS1_human_WT       VRSNLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLA 177 
PTGS1_mouse          VRSNLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDVQLLA 180 
PTGS1_rat            VRSNLIPSPPTYNTAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDIHLLA 180 
PTGS1_sheep          VRSNLIPSPPTYNIAHDYISWESFSNVSYYTRILPSVPRDCPTPMGTKGKKQLPDAEFLS 178 
 
                          K185T       G230S  L237M 
PTGS1_human_WT       RRFLLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNL 237 
PTGS1_mouse          QQLLLRREFIPAPQGTNILFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNL 240 
PTGS1_rat            QRLLLRREFIPAPQGTNVLFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDSL 240 
PTGS1_sheep          RRFLLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNL 238 
                      
PTGS1_human_WT       ERQYQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGL 297 
PTGS1_mouse          ERQYHLRLFKDGKLKYQVLDGEVYPPSVEQASVLMRYPPGVPPERQMAVGQEVFGLLPGL 300 
PTGS1_rat            ERQYHLRLFKDGKLKYQVLDGELYPPSVEQASVKMRYPPGVPPEKQMAVAQEVFGLLPGL 300 
PTGS1_sheep          ERQYQLRLFKDGKLKYQMLNGEVYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGL 298 
                      
PTGS1_human_WT       MLYATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQ 357 
PTGS1_mouse          MLFSTIWLREHNRVCDLLKEEHPTWDDEQLFQTTRLILIGETIKIVIEEYVQHLSGYFLQ 360 
PTGS1_rat            MLFSTIWLREHNRVCDLLKEEHPTWDDEQLFQTTRLILRGETIEIIIEEYVQHLSGYFLQ 360 
PTGS1_sheep          MLYATIWLREHNRVCDLLKAEHPTWGDEQLFQTARLILIGETIKIVIEEYVQQLSGYFLQ 358 
                      
PTGS1_human_WT       LKFDPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYG 417 
PTGS1_mouse          LKFDPELLFRAQFQYRNRIAMEFNHLYHWHPLMPNSFQVGSQEYSYEQFLFNTSMLVDYG 420 
PTGS1_rat            LKFDPELLFRAQFQYRNRIAMEFNHLYHWHPFMPDSFQVGSQEYSYEQFLFNTSMLVDYG 420 
PTGS1_sheep          LKFDPELLFGAQFQYRNRIAMEFNQLYHWHPLMPDSFRVGPQDYSYEQFLFNTSMLVDYG 418 
              
PTGS1_human_WT       VEALVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSF 477 
PTGS1_mouse          VEALVDAFSRQRAGRIGGGRNFDYHVLHVAVDVIKESREMRLQPFNEYRKRFGLKPYTSF 480 
PTGS1_rat            VEALVDAFSRQRAGRIGGGRNFDYHVLHVAEDVIKESREMRLQSFNEYRKRFGLKPYTSF 480 
PTGS1_sheep          VEALVDAFSRQPAGRIGGGRNIDHHILHVAVDVIKESRVLRLQPFNEYRKRFGMKPYTSF 478 
         
         V481I              
PTGS1_human_WT       QELVGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNP 537 
PTGS1_mouse          QELTGEKEMAAELEELYGDIDALEFYPGLLLEKCQPNSIFGESMIEMGAPFSLKGLLGNP 540 
PTGS1_rat            QEFTGEKEMAAELEELYGDIDALEFYPGLMLEKCQPNSLFGESMIEMGAPFSLKGLLGNP 540 
PTGS1_sheep          QELTGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEMGAPFSLKGLLGNP 538 
                      
PTGS1_human_WT       ICSPEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL 599 
PTGS1_mouse          ICSPEYWKPSTFGGDVGFNLVNTASLKKLVCLNTKTCPYVSFRVPDYPGDDGSVLVRRSTEL 602 
PTGS1_rat            ICSPEYWKPSTFGGDVGFNIVNTASLKKLVCLNTKTCPYVSFRVPDYPGDDGSVFVRPSTEL 602 
PTGS1_sheep          ICSPEYWKASTFGGEVGFNLVKTATLKKLVCLNTKTCPYVSFHVPDPRQEDRPGVERPPTEL 600 
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Figure 5.  COX-1 protein model. 
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Figure 6.  Structural characterization of the G230S variant. 
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Figure 7.  Expression and functional characterization of COX-1 polymorphisms. 
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Figure 8.  COX-1 polymorphisms and indomethacin inhibition. 
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CHAPTER III 
 
CYCLOOXYGENASE POLYMORPHISMS AND RISK OF CARDIOVASCULAR 
EVENTS: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY 
 
 
Introduction 
    Ischemic cardiovascular disease is a major public health problem.  It is estimated that 1.2 
million Americans will experience an acute coronary heart disease (CHD) event and 0.7 
million will experience an acute stroke event this year (1).  Cyclooxygenase (COX)-1 and 
COX-2 derived prostaglandins are critical regulators of vascular, myocardial and platelet 
function, and alterations in their expression and/or activity can significantly modify risk of 
cardiovascular disease events in humans (22-25, 99, 100).  Although both COX-1 and COX-
2 catalyze the same metabolic reaction with similar efficiencies, they are encoded by distinct 
gene products and differ substantially in their regulation and expression (19).  Recent 
evidence demonstrating associations between selective COX-2 inhibitor utilization and 
elevated risk of myocardial infarction (23, 24), coupled with the well-known protective 
effects of low-dose aspirin (25), suggests the relative contribution of COX-1 and COX-2-
mediated prostaglandin synthesis is an integral mediator of cardiovascular homeostasis.  
Consequently, genetic variation in both COX-1 (PTGS1) and COX-2 (PTGS2) may be 
important modifiers of cardiovascular disease risk. 
    Numerous genetic polymorphisms in coding and noncoding regions of PTGS1 and PTGS2 
have been identified (58, 59, 61, 62).  For instance, the G-765C polymorphism in the 
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proximal promoter of PTGS2 disrupts a Sp1 binding site and is associated with significantly 
lower PTGS2 transcription (59).  Moreover, due to its anti-inflammatory effects, the variant -
765C allele was associated with significantly lower risk of prevalent myocardial infarction or 
ischemic stroke events in a high-risk Italian population (60).  However, associations between 
PTGS2 polymorphisms and incident events have not been investigated.  Certain 
nonsynonymous polymorphisms in PTGS1, such as the G230S variant, have significantly 
lower COX-1 metabolic activity in vitro (101) (Chapter II); however, potential associations 
between PTGS1 polymorphisms and cardiovascular disease risk have not been evaluated to 
date.  The primary aim of this investigation was to determine if genetic variation in PTGS1 
and PTGS2 was associated with risk of incident CHD or ischemic stroke events in 
individuals enrolled in the biethnic Atherosclerosis Risk in Communities (ARIC) study.  An 
important secondary aim was to determine if this risk was modified by aspirin utilization. 
 
Methods 
Study Population.  Participants were selected from the ARIC study, a longitudinal, 
population-based cohort study of 15,792 men and women aged 45 to 64 years from four U.S. 
communities (Forsyth County, NC; Jackson, MS; Minneapolis, MN; and Washington 
County, MD) enrolled between 1987 and 1989 (102).  Since enrollment, participants have 
been followed prospectively via annual phone interviews, clinic examinations approximately 
every three years through 1998, and ongoing abstraction of hospital and death certificate 
records.  The study protocol was approved by the Institutional Review Board of each center, 
and consent was obtained from each participant. 
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Ascertainment of Incident CHD and Stroke Cases.  All incident cases that occurred 
between baseline and December 31, 1998 were evaluated (median follow-up 9.1 years), 
excluding participants with a history of a physician-diagnosed CHD or stroke event at 
baseline (n=1434), whose self-reported race was neither Caucasian nor African-American 
(n=48), and African-Americans enrolled in the Minneapolis, MN and Washington County, 
MD study centers (n=55).  Incident CHD (n=1085) was defined as 1) definite or probable 
myocardial infarction (n=520), 2) electrocardiographic evidence of silent myocardial 
infarction (n=112), 3) definite CHD death (n=110), or 4) coronary revascularization 
procedure (n=343).  Incident stroke was defined as a definite or probable ischemic stroke 
(n=300).  Of note, n=68 individuals experienced an incident CHD and ischemic stroke event 
on separate occasions. 
    The ascertainment of cases and criteria for classification have been previously described 
(103, 104).  All potential events were systematically reviewed and adjudicated by the ARIC 
Morbidity and Mortality Classification Committee (102-104).  Hospitalized myocardial 
infarction was classified as definite or probable based on chest pain symptoms, cardiac 
enzyme levels, and electrocardiographic changes.  Definite CHD death was classified based 
on chest pain symptoms, underlying cause of death, hospitalization records, and medical 
history.  Coronary revascularization procedures included coronary artery bypass grafting and 
percutaneous coronary intervention.  Using the National Survey of Stroke criteria (105), a 
stroke event was classified as definite or probable if there was 1) rapid onset of neurological 
symptoms that lasted >24 hours or led to death within 24 hours, 2) no evidence of pathology 
that could have mimicked stroke, and 3) one major (e.g., aphasia or hemiparesis) or two 
minor (e.g., diplopia or dysarthria) neurological deficits.  Qualifying cases were further 
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classified as ischemic (thrombotic brain infarction, cardioembolic stroke) or hemorrhagic 
(subarachnoid hemorrhage, intracerebral hemorrhage) on the basis of neuroimaging studies 
and autopsy, when available (104). 
 
Baseline Measurements.  Detailed demographic, clinical, and biochemical data were 
obtained from each subject at baseline.  Race was self-reported.  Prevalent CHD and stroke 
were defined as history of a physician-diagnosed event.  Hypertension was defined as 
systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or current 
antihypertensive medication use.  Diabetes was defined as fasting blood glucose ≥126 
mg/dL, nonfasting blood glucose ≥200 mg/dL, physician diagnosis, or pharmacologic 
treatment.  Detailed information on cigarette smoking was obtained through an interview-
administered questionnaire.  Aspirin utilization (yes/no), including aspirin-containing 
products, was assessed through a detailed medication history, as described (106).  Dose and 
duration of use were not determined. 
 
Cohort Random Sample.  A random sample of all ARIC participants without history of 
CHD or stroke at baseline was assembled to serve as the reference group for the case-cohort 
comparisons (n=1065; 85 and 29 of which are also incident CHD and stroke cases, 
respectively).  Sampling of the cohort was stratified on age (≥55 or <55 years), gender, and 
race (Caucasian or African-American).  Sampling proportions varied across each stratum.   
 
Genotyping.  Genomic DNA from all incident CHD and ischemic stroke cases and the 
cohort random sample was genotyped for the G-1006A, R8W, P17L, R53H, G230S and 
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L237M polymorphisms in PTGS1 and the V511A polymorphism in PTGS2 using multiplex 
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry 
methods (Sequenom Inc., San Diego, CA), as described (107) (Appendix II).  Since MALDI-
TOF methods were unsuccessful, the G-765C polymorphism in PTGS2 was genotyped using 
the BeadArray system (Illumina, Inc., San Diego, CA), as described (108) (Appendix III).  
Blind replicates were included for quality control.  Missing genotypes were present in <5% 
of individuals.   
    These polymorphisms were identified from a resequencing effort as part of the NIEHS 
Environmental Genome Single Nucleotide Polymorphism program (https://dir-
apps.niehs.nih.gov/egsnp/home.htm) and/or the published literature (Table 5) (58, 59, 61, 62, 
101) (Chapter II).  The G-1006A polymorphism is one of seven polymorphisms in the 5’ 
untranslated region (UTR) of PTGS1 present in significant linkage disequilibrium (LD), and 
on the same haplotype, in both European/Caucasian and African individuals (101) (Chapter 
II).  The G-1006A polymorphism was selected to capture variation at each of these loci since 
the functional relevance of each variant remains to be characterized.  The other selected 
polymorphisms represent either functionally relevant variants (PTGS1: R53H, G230S, 
L237M; PTGS2: G-765C) or the most frequent nonsynonymous variants (PTGS1: R8W, 
P17L; PTGS2: V511A) identified to date in each gene (58, 59, 101) (Chapter II).  
 
Data Analysis.  Inverse sampling fractions from each stratum were used as weights in 
variance estimation of adjusted covariate means and proportions by linear and logistic 
regression, respectively.  Cohort random sample allele frequencies were evaluated for 
deviation from Hardy-Weinberg equilibrium, and pairwise LD statistics were calculated 
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(Haploview 3.2) (81).  Hazard rate ratios (HRR) and 95% confidence intervals (CI) for the 
development of incident CHD or ischemic stroke in relation to genotype were calculated by 
weighted proportional hazards regression, using Barlow’s method to account for the stratified 
random sampling and case-cohort design (109).  Model 1 included baseline age, gender, and 
study center as covariates.  Model 2 also included significant clinical covariates, which were 
current smoking status, diabetes, hypertension, high density lipoprotein cholesterol, total 
cholesterol, and body mass index at baseline for the CHD endpoint, and current smoking 
status, diabetes, and hypertension for the stroke endpoint.  Assuming an autosomal dominant 
mode of inheritance, individuals with one or two variant alleles were combined for 
comparison to wild-type individuals.  All analyses were completed separately in Caucasians 
and African-Americans.  Assuming a case-control design, type I error α=0.05 and 20% 
variant genotype frequency, there was approximately 99% and 94% power for the CHD 
endpoint and 94% and 83% power for the stroke endpoint to detect an odds ratio of 2.0 in 
Caucasians and African-Americans, respectively. 
    Interaction testing was completed on a multiplicative scale between baseline aspirin 
utilization (yes/no) and both G-1006A (PTGS1) and G-765C (PTGS2) genotype for both 
endpoints in Caucasians, using a Wald chi-square test for significance of the estimated β-
coefficient for the interaction term (110).  Gene-aspirin interaction testing was not completed 
in African-Americans due to low aspirin utilization and sample size limitations.  Because 
interaction hypothesis testing on a multiplicative scale is underpowered, the critical value for 
statistical significance was set to α=0.15, two-sided (111).  Stratified weighted proportional 
hazards regression was also completed to further explore potential interactions. 
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    To minimize the impact of the multiple statistical tests conducted in this analysis, the false 
discovery rate (FDR) q-value was estimated for each comparison, separately for each 
endpoint, which is defined as the proportion of statistical tests deemed significant that are 
actually false-positives (QVALUE) (112).  In order to calculate conservative q-value 
estimates, statistical tests from the unadjusted, model 1 and model 2 association analyses for 
each PTGS1 and PTGS2 polymorphism were considered, even though each model assessed 
the same independent variable.  Additional q-value estimates were also calculated for the 
gene-aspirin interaction analysis.  Only q-values for significant findings are presented. 
 
Results 
Study Population.  Significant baseline differences in various risk factors were observed 
between CHD and stroke cases and non-cases included in the cohort random sample (Table 
6).  Incident CHD and stroke cases were significantly older and more likely to be male, 
smokers, diabetic, hypertensive and have abnormal fasting lipid panels compared to non-
cases.  Stroke cases were also more likely to be African-American and less likely to report 
aspirin use at baseline.  Aspirin utilization at baseline was significantly lower in African-
Americans compared to Caucasians in the cohort random sample (11.3% versus 29.9%, 
P<0.001), CHD cases (13.8% versus 30.2%, P<0.001) and ischemic stroke cases (13.3% 
versus 23.6%, P=0.021), respectively. 
 
PTGS1/PTGS2 Genotype.  The location and observed race-specific allele frequencies of the 
6 PTGS1 and 2 PTGS2 polymorphisms evaluated are listed in Table 5.  The G-1006A and 
P17L polymorphisms in PTGS1 were in almost complete LD in Caucasians (D’=0.99, 
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r2=0.96), but not African-Americans (D’=0.46, r2=0.16).  No evidence of LD was observed 
between the other variants in either ethnic group (r2<0.01).  The allelic distribution of the 
PTGS1 P17L polymorphism deviated significantly from Hardy-Weinberg equilibrium in 
Caucasians (P=0.002); however, all other polymorphisms were in Hardy-Weinberg 
equilibrium in both Caucasians and African-Americans (P>0.05).  
 
PTGS1 Polymorphisms.  In Caucasians, the variant -1006A allele was significantly more 
common among ischemic stroke cases compared to cohort random sample non-cases (18.2% 
versus 10.6%, respectively, P=0.027) (Table 7).  Presence of at least one variant -1006A 
allele was associated with significantly higher risk of incident ischemic stroke events relative 
to -1006G homozygotes after adjusting for age, gender and study center (model 1, HRR 1.78, 
95% CI 1.08-2.92, P=0.024, q=0.080) (Table 8).  A similar association was observed after 
also adjusting for cigarette smoking, diabetes and hypertension status (model 2, HRR 1.70, 
95% CI 0.99-2.93, P=0.056, q=0.120); however, this did not attain statistical significance.  
This relationship was not modified by gender (P=0.252).  No evidence of a significant 
association between the variant -1006A allele and risk of ischemic stroke in African-
Americans, or risk of CHD in either Caucasians or African-Americans, was observed (Tables 
7-10).  Similar associations with each endpoint were also observed with common 
reconstructed haplotypes tagged by the variant -1006A allele (data not shown). 
    In African-Americans, the rare G230S variant allele appeared to be more common in 
ischemic stroke cases compared to non-cases (2.6% versus 1.2%, respectively) (Table 7).  
Moreover, presence of the G230S variant allele was associated with significantly higher risk 
of incident ischemic stroke events after covariate adjustment (model 2, HRR 14.8, 95% CI 
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1.94-112.4, P=0.009, q=0.085) (Table 8).  A similar, but less pronounced association was 
also observed between this rare variant and risk of incident CHD events (model 2, HRR 7.42, 
95% CI 1.21-45.7, P=0.031, q=0.465) (Table 10).  One individual carrying the G230S variant 
allele experienced both an incident ischemic stroke and CHD event on separate occasions.  
When considering the composite endpoint, presence of the G230S variant allele was also 
associated with significantly higher risk of an incident ischemic stroke or CHD event after 
covariate adjustment (model 2, HRR 8.37, 95% CI 1.53-45.8, P=0.014).  No associations 
between the R8W, P17L, R53H or L237M variant alleles and risk of either endpoint were 
observed (Tables 7-10). 
 
PTGS2 Polymorphisms.  In African-Americans, the variant -765C allele was significantly 
more common among ischemic stroke cases compared to cohort random sample non-cases 
(61.4% versus 49.4%, respectively, P=0.032) (Table 11).  Presence of at least one variant -
765C allele was associated with significantly higher risk of incident ischemic stroke events 
relative to -765G homozygotes after covariate adjustment (model 2, HRR 1.76, 95% CI 1.05-
2.94, P=0.031, q=0.146) (Table 12).  This relationship was not modified by gender 
(P=0.645).  The -765C allele was not significantly associated with risk of ischemic stroke in 
Caucasians, or risk of CHD in either Caucasians or African-Americans (Tables 11 and 12).  
No association between the V511A variant allele and risk of either endpoint was observed in 
African-Americans (Tables 11 and 12). 
 
Aspirin Utilization.  In Caucasians, aspirin utilization at baseline appeared to modify the 
relationship between the G-765C polymorphism in PTGS2 and risk of incident CHD events 
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(P for interaction=0.065, q=0.102) (Table 13).  When stratified by aspirin use at baseline, the 
variant -765C allele demonstrated a non-significant association with higher risk of CHD in 
aspirin non-users (model 2, HRR 1.37, 95% CI 0.98-1.92, P=0.064) and lower risk of CHD 
in those receiving aspirin therapy (model 2, HRR 0.60, 95% CI 0.36-1.02, P=0.058); 
however, these stratified associations did not attain statistical significance.  Aspirin 
utilization did not modify the relationship between the G-765C polymorphism and risk of 
ischemic stroke (P for interaction=0.630), or the relationship between the G-1006A 
polymorphism in PTGS1 and risk of either ischemic stroke (P for interaction=0.228) or CHD 
(P for interaction=0.933).   
 
Discussion 
    The current analysis demonstrated that genetic variation in PTGS1 and PTGS2 was 
associated with risk of incident ischemic cardiovascular disease events in Caucasians and 
African-Americans enrolled in the ARIC study.  Specifically, the variant -1006A allele in 
PTGS1 and -765C allele in PTGS2 were associated with higher risk of ischemic stroke events 
in Caucasians and African-Americans, respectively.  Moreover, the rare G230S variant allele 
in PTGS1 was associated with significantly higher risk of both ischemic stroke and CHD 
events in African-Americans.  Although the G-765C polymorphism in PTGS2 was not 
significantly associated with CHD incidence, aspirin utilization appeared to modify this 
relationship in Caucasians.  The variant -765C allele appeared to be associated with higher 
risk of CHD in aspirin non-users and lower risk in those receiving aspirin therapy. 
    Cyclooxygenase derived prostaglandins are important regulators of vascular, myocardial 
and platelet function in vivo, and the relative contribution of COX-1 and COX-2-mediated 
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prostaglandin biosynthesis appears to be a critical determinant of cardio- and cerebrovascular 
disease risk (22-25).  For instance, the balance between prostacyclin and thromboxane A2 
significantly modifies atherosclerotic lesion development (100).  Moreover, preferentially 
inhibiting COX-1 derived thromboxane A2 in platelets via low-dose aspirin administration 
significantly reduces the risk of myocardial infarction, ischemic stroke and death in high-risk 
patients (25).  In contrast, despite their potential anti-inflammatory and atherosclerotic plaque 
stabilizing effects, selective COX-2 antagonists inhibit endothelial prostacyclin biosynthesis 
without influencing platelet thromboxane A2 production and increase risk of myocardial 
infarction events, particularly in higher risk patients (23, 24).  COX-1 and COX-2 derived 
prostaglandins are also important mediators of cerebrovascular function.  Selective inhibition 
of COX-1 significantly reduces cerebral blood flow and vasodilatory responses, and COX-1-/- 
mice have significantly larger cerebral infarct volumes compared to wild-type mice after 
middle cerebral artery (MCA) occlusion (113, 114).  Moreover, cerebral COX-1 gene 
transfer prior to MCA occlusion significantly reduces cerebral infarct volume in rats via 
increased prostacyclin production (115).  Selective inhibition of COX-2 also abolishes 
cerebral vasodilatory responses to bradykinin (116).  However, COX-2-/- mice have 
significantly smaller infarct volumes compared to wild-type mice after MCA occlusion 
(117), and transgenic mice with neuronal overexpression of COX-2 have larger infarct 
volumes, implicating the post-ischemic inflammatory effects of increased COX-2 expression 
and PGE2 production in brain injury (118).  Collectively, preclinical and clinical 
investigations have demonstrated the importance of COX-1 and COX-2-mediated 
prostaglandin biosynthesis in the pathogenesis of ischemic stroke and CHD.  Consequently, 
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genetic variation in PTGS1 and PTGS2 may be important modifiers of ischemic stroke and 
CHD susceptibility in humans. 
    The rare G230S variant allele in PTGS1, which is monomorphic in Caucasians, was 
associated with significantly higher risk of ischemic stroke events in African-Americans.  
The G230S variant has been previously shown to have significantly lower COX-1 metabolic 
activity in vitro compared to wild-type enzyme (101) (Chapter II).  Moreover, molecular 
modeling suggests this variant may indirectly disrupt the active conformation of COX-1, 
leading to the observed reductions in metabolic activity (101) (Chapter II).  Association 
between the G230S variant and risk of ischemic stroke incidence is consistent with the 
described preclinical data demonstrating the protective role of COX-1 in cerebrovascular 
function (113-115).  A significant association was also observed between the G230S variant 
allele and higher risk of CHD events; although, this association was less pronounced and 
carried a substantial FDR estimate (q=0.465).  Due to the rare frequency of the G230S 
variant allele, the observed associations with both endpoints carried wide confidence 
intervals and should be interpreted with caution.  In Caucasians, the variant -1006A allele in 
PTGS1 was associated with greater risk of incident ischemic stroke.  This polymorphism is 
one of seven variants within the PTGS1 5’UTR present in substantial LD (101) (Chapter II); 
however, the functional relevance of the variant haplotype and each individual variant has 
not been characterized to date.  Consequently, the G-1006A polymorphism may not be the 
functionally relevant locus driving the observed association with ischemic stroke risk.  Future 
studies evaluating the functional effects of these variants are necessary. 
    A significant association was also observed between the variant -765C allele in PTGS2 
and higher risk of ischemic stroke incidence in African-Americans.  No significant 
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association was observed in Caucasians.  This variant has previously been shown to disrupt a 
Sp1 binding site in the PTGS2 proximal promoter, reduce COX-2 transcription and 
expression, and carry significant anti-inflammatory effects (59, 60).  Moreover, presence of 
this variant has been associated with lower risk of prevalent myocardial infarction or 
ischemic stroke in a high-risk Italian population (60), contrasting epidemiological and 
clinical trial evidence demonstrating associations between selective COX-2 inhibitor use and 
increased risk of cardiovascular events (23, 24).  The current analysis suggests that the -765C 
allele is associated with higher risk of ischemic stroke events in African-Americans.  
Importantly, post-event complications and outcomes were not evaluated, even though 
preclinical evidence suggests that lower COX-2 expression reduces the extent of ischemic 
brain injury after a cerebral infarct (117).  Future studies evaluating the influence of the G-
765C polymorphism on prognosis after ischemic stroke events appear necessary.  
    A significant association between the -765C allele and risk of incident CHD events was 
not observed.  However, aspirin utilization appeared to modify this relationship in 
Caucasians, such that the -765C allele appeared to be associated with higher risk of CHD in 
aspirin non-users and lower risk in those receiving aspirin therapy.  This observation is 
consistent with the hypothesis that concomitant aspirin utilization may mitigate the 
cardiovascular hazard associated with selective COX-2 inhibition via restoration of 
prostacyclin-thromboxane A2 balance, which is altered in favor of thromboxane A2 with 
COX-2 inhibition (24).  However, this hypothesis has not been rigorously validated in 
prospective clinical trials.  Nonetheless, presence of this potential interaction with aspirin 
utilization could help explain, at least in part, the aforementioned association between the -
765C allele and lower cardiovascular risk observed by Cipollone et al. (60).  Since this 
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analysis of prevalent outcomes targeted a population at high-risk of cardiovascular events, 
67% were receiving aspirin therapy (60).  Although the variant -765C allele was not 
associated with overall risk of incident CHD events in Caucasians in the current analysis, -
765C allele carriers receiving aspirin at baseline tended to be at lower risk of CHD while 
those not receiving aspirin tended to be at higher risk.  Perhaps aspirin use in -765C allele 
carriers restores prostacyclin-thromboxane A2 balance, allows the plaque stabilizing effects 
related to suppression of COX-2 mediated PGE2 synthesis and matrix metalloproteinase 
activity to predominate (60), and results in lower risk of CHD events.  Thus, aspirin use may 
not just attenuate risk associated with the variant -765C allele, the combination may provide 
synergistic benefit in the prevention of CHD events.  Moreover, perhaps presence of the -
765C allele without concomitant aspirin therapy leads to altered prostacyclin-thromboxane 
A2 balance and greater risk of CHD events, similar to what has been observed with the 
selective COX-2 inhibitors.  However, due to the power limitations in the current interaction 
analysis, these findings must be interpreted with caution and confirmed in larger populations. 
    Although the current study evaluated rigorously ascertained incident events, mechanisms 
underlying the observed associations were not elucidated.  The limitations related to the 
evaluation of aspirin utilization at baseline in an observational study are also recognized.  
Patients were not randomized at baseline, and aspirin therapy was likely initiated in those at 
highest risk of cardiovascular events.  Although potential confounders related to 
cardiovascular disease risk were adjusted for in the current regression analysis, additional 
confounding factors such as misclassification bias, changes in aspirin utilization throughout 
follow-up, duration of therapy and dose could have influenced these observations.  Thus, the 
reported gene-aspirin interaction findings should be considered exploratory and hypothesis-
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generating.  Future studies evaluating the mechanisms underlying this potential interaction 
are necessary.  Moreover, it may be difficult to gauge the statistical significance of the 
polymorphism-disease association findings considering the number of comparisons 
completed in the current analysis.  Consequently, the FDR was assessed across all completed 
tests in the association analysis.  Since all q-values related to the association between the G-
1006A (Caucasians), G230S (African-Americans) and G-765C (African-Americans) 
polymorphisms and ischemic stroke risk were conservatively estimated to be <0.15, there is a 
high level of confidence in these findings; however, validation in an independent population 
is necessary.   
    In summary, the current analysis suggests that genetic variation in PTGS1 and PTGS2 may 
be important risk factors for the development of ischemic stroke events.  Moreover, aspirin 
utilization may modify the association between the G-765C polymorphism in PTGS2 and 
risk of CHD events in Caucasians.  Future studies in multiple populations will be required to 
validate these findings, in addition to molecular, biochemical and physiological studies to 
elucidate the mechanisms underlying the observed associations. 
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Table 5.  Selected PTGS1 and PTGS2 polymorphisms for genotyping. 
 
        CRS Minor Allele Frequency  
Polymorphism Nucleotide* Location Amino Acid Caucasian African-American  Function† 
    (N=698) (N=367)  
PTGS1 
G>A  -1006 5’ UTR - 0.059 0.116 Unknown 
C>T (rs1236913) 250 Exon 2 R8W 0.070 0.012 Normal 
C>T (rs3842787) 278 Exon 2 P17L 0.061 0.145 Normal 
G>A (rs3842789) 7010 Exon 3 R53H 0 0.002 Dec. activity 
G>A 10721 Exon 7 G230S 0 0.005 Dec. activity 
C>A (rs5789) 10742 Exon 7 L237M 0.033 0.005 Dec. activity 
PTGS2 
G>C (rs20417) -765 Promoter - 0.164 0.301 Dec. transcription 
T>C (rs5273) 5792 Exon 10 V511A 0 0.045 Normal 
CRS=cohort random sample, UTR=untranslated region 
*Nucleotide position relative to gene transcriptional start site (Genbank accession numbers: PTGS1 AF440204; PTGS2 AY229989). 
†Based on previous functional studies (58, 59, 101) (Chapter II).
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Table 6.  ARIC baseline characteristics by incident case status. 
Characteristic* CRS CHD Cases† Stroke Cases‡ 
N 1065 1085 300 
Gender (% male) 41.4% 67.4% 53.0%  
Race (% Caucasian) 72.8% 76.6% 55.0% 
Age (years) 53.8 ± 0.10 55.8 ± 0.17 56.7 ± 0.32 
Current smoker (% yes) 24.8% 36.1% 36.8% 
Pack-years >20 (% yes) 29.0% 48.6% 41.4% 
Diabetes (%) 11.1% 25.1% 34.6% 
Hypertension (%) 29.8% 49.4% 66.0% 
SBP (mmHg) 120.4 ± 0.58 128.3 ± 0.63 134.8 ± 1.30 
DBP (mmHg) 73.3 ± 0.37 76.2 ± 0.38 79.4 ± 0.81 
BMI (kg/m2) 27.7 ± 0.20 28.3 ± 0.15 29.0 ± 0.31 
HDL cholesterol (mg/dL) 53.3 ± 0.61 43.4 ± 0.39 48.4 ± 0.90 
LDL cholesterol (mg/dL) 133.7 ± 1.31 151.5 ± 1.26 144.7 ± 2.55 
Total cholesterol (mg/dL) 211.7 ± 1.32 226.2 ± 1.34 222.4 ± 2.90 
Triglycerides (mg/dL) 125.2 ± 2.39 165.2 ± 3.52 153.0 ± 6.33 
Aspirin (% yes) 24.8% 26.4% 19.0% 
*Characteristics weighted according to the sampling fraction.  Data presented as mean±standard error 
of the mean.  CRS=cohort random sample, SBP=systolic blood pressure, DBP=diastolic blood 
pressure, BMI=body mass index, HDL=high density lipoprotein, LDL=low density lipoprotein. 
†P<0.05 for comparison of CHD cases to 980 non-cases in the CRS for all characteristics, except 
aspirin use. 
‡P<0.05 for comparison of stroke cases to 1036 non-cases in the CRS for all characteristics. 
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Table 7.  PTGS1 polymorphism frequency by incident ischemic stroke case status. 
 
 Caucasian   African-American 
Genotype* Non-cases Stroke cases P-value Non-cases Stroke cases P-value 
G-1006A      
G/G  583 (89.4%) 121 (81.8%)   246 (76.9%) 84 (73.0%) 
G/A + A/A  71 (10.6%) 27 (18.2%) P=0.027  70 (23.1%) 31 (27.0%) P=0.436 
R8W       
C/C    571 (86.7%) 131 (87.9%)    308 (97.1%) 112 (97.4%) 
C/T + T/T  85 (13.3%) 18 (12.1%) P=0.694 8 (2.9%) 3 (2.6%) P=N/A 
P17L     
C/C    564 (89.3%) 123 (84.3%)    229 (72.1%) 81 (71.7%) 
C/T + T/T  69 (10.7%) 23 (15.7%) P=0.125 90 (27.9%) 32 (28.3%) P=0.758 
G230S     
G/G     654 (100%) 149 (100%)    311 (98.8%) 112 (97.4%) 
G/A + A/A   0 (0%)  0 (0%)  P=N/A  3 (1.2%) 3 (2.6%) P=N/A 
L237M     
C/C    604 (93.6%) 143 (94.7%)    312 (99.2%) 114 (99.1%) 
C/A + A/A  43 (6.4%) 8 (5.3%)  P=0.613 3 (0.8%) 1 (0.9%) P=N/A 
*Genotype data presented as absolute (percent) genotype frequency.  Frequencies are weighted according to the sampling fraction.  The R53H 
variant allele in PTGS1 (rs3842789) was identified in only one African-American non-case. 
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Table 8.  Hazard rate ratio between PTGS1 polymorphisms and risk of incident ischemic stroke events. 
 Caucasian         African-American 
Polymorphism HRR  95% CI P-value HRR  95% CI P-value 
G-1006A  G/A + A/A versus G/G  G/A + A/A versus G/G 
Model 1*  1.78 1.08 – 2.92 P=0.024 1.46 0.88 – 2.40 P=0.137 
Model 2†  1.70 0.99 – 2.93 P=0.056 1.16 0.64 – 2.10 P=0.616 
R8W   C/T + T/T versus C/C  C/T + T/T versus C/C 
Model 1*  0.80 0.46 – 1.38 P=0.418 0.97 0.25 – 3.74 P=0.965 
Model 2†  0.72 0.40 – 1.30 P=0.278 2.21 0.44 – 11.2 P=0.339 
P17L   C/T + T/T versus C/C  C/T + T/T versus C/C 
Model 1*  1.48 0.88 – 2.50 P=0.143 1.10 0.68 – 1.78 P=0.701 
Model 2†  1.36 0.77 – 2.40 P=0.296 1.04 0.60 – 1.80 P=0.882 
G230S     G/A + A/A versus G/G  G/A + A/A versus G/G 
Model 1*  N/A   4.46 0.72 – 27.7 P=0.109 
Model 2†  N/A   14.8 1.94 – 112.4 P=0.009 
L237M   C/A + A/A versus C/C  C/A + A/A versus C/C 
Model 1*  0.77 0.34 – 1.74 P=0.534 1.26 0.12 – 13.7 P=0.850 
Model 2†  0.96 0.43 – 2.18 P=0.925 0.58 0.05 – 6.66 P=0.661 
HRR=hazard rate ratio, CI=confidence interval, N/A=modeling not completed since 0% frequency in case and/or non-case group.   
*Adjusted for age, gender, and study center. 
†Adjusted for age, gender, study center, current smoker, diabetes, and hypertension. 
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Table 9.  PTGS1 polymorphism frequency by incident CHD case status. 
 
 Caucasian   African-American 
Genotype* Non-cases CHD cases P-value Non-cases CHD cases P-value 
G-1006A       
G/G  542 (89.2%) 666 (86.6%)   234 (75.9%) 168 (76.4%) 
G/A + A/A  68 (10.8%) 103 (13.4%) P=0.164  72 (24.1%) 52 (23.6%) P=0.906 
R8W        
C/C  533 (86.7%) 669 (86.6%)  298 (97.0%) 218 (98.2%) 
C/T + T/T  79 (13.3%) 104 (13.5%) P=0.952 8 (3.0%) 4 (1.8%) P=N/A 
P17L     
C/C  524 (89.1%) 671 (87.9%)  219 (71.5%) 159 (72.0%) 
C/T + T/T  66 (10.9%) 92 (12.1%) P=0.534 90 (28.5%) 62 (28.0%) P=0.913 
G230S      
G/G    610 (100%) 773 (100%)    301 (98.8%) 215 (98.2%) 
G/A + A/A   0 (0%)  0 (0%)  P=N/A  3 (1.2%) 4 (1.8%) P=N/A 
L237M     
C/C  563 (93.7%) 733 (94.0%)  301 (99.2%) 220 (99.6%) 
C/A + A/A  39 (6.3%) 47 (6.0%)  P=0.851 3 (0.8%) 1 (0.4%) P=0.659 
*Genotype data presented as absolute (percent) genotype frequency.  Frequencies are weighted according to the sampling fraction. The R53H 
variant allele in PTGS1 (rs3842789) was identified in only one African-American non-case. 
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Table 10.  Hazard rate ratio between PTGS1 polymorphisms and risk of incident CHD events. 
 Caucasian         African-American 
Polymorphism HRR  95% CI P-value HRR  95% CI P-value 
G-1006A  G/A + A/A versus G/G  G/A + A/A versus G/G 
Model 1*  1.13 0.80 – 1.60 P=0.487 1.15 0.76 – 1.75 P=0.509 
Model 2†  1.28 0.87 – 1.89 P=0.206 1.25 0.77 – 2.04 P=0.367 
R8W   C/T + T/T versus C/C  C/T + T/T versus C/C 
Model 1*  1.04 0.75 – 1.44 P=0.824 0.69 0.20 – 2.34 P=0.548 
Model 2†  1.00 0.69 – 1.44 P=0.991 0.91 0.20 – 4.03 P=0.899 
P17L   C/T + T/T versus C/C  C/T + T/T versus C/C 
Model 1*  1.01 0.71 – 1.46 P=0.940 1.05 0.71 – 1.54 P=0.823 
Model 2†  1.11 0.74 – 1.65 P=0.620 1.25 0.80 – 1.94 P=0.330 
G230S     G/A + A/A versus G/G  G/A + A/A versus G/G 
Model 1*  N/A   3.47 0.60 – 19.9 P=0.163 
Model 2†  N/A   7.42 1.21 – 45.7 P=0.031 
L237M   C/A + A/A versus C/C  C/A + A/A versus C/C 
Model 1*  0.94 0.58 – 1.51 P=0.794 0.60 0.06 – 6.36 P=0.674 
Model 2†  0.92 0.55 – 1.53 P=0.749 0.33 0.03 – 4.45 P=0.407 
HRR=hazard rate ratio, CI=confidence interval, N/A=modeling not completed since 0% frequency in case and/or non-case group.   
*Adjusted for age, gender, and study center. 
†Adjusted for age, gender, study center, current smoker, diabetes, hypertension, HDL cholesterol, total cholesterol, and body mass index. 
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Table 11.  PTGS2 polymorphism frequency by incident ischemic stroke or CHD case status. 
 
 Caucasian   African-American 
Genotype* Non-cases Incident cases P-value Non-cases Incident cases P-value 
Stroke 
G-765C     
G/G     457 (70.7%) 111 (74.5%)    154 (50.6%) 44 (38.6%) 
G/C + C/C   195 (29.3%) 38 (25.5%)  P=0.353  149 (49.4%) 70 (61.4%) P=0.032 
V511A     
T/T    635 (100%) 149 (100%)    290 (91.6%) 104 (92.0%) 
T/C + C/C  0 (0%) 0 (0%) P=N/A 28 (8.4%) 9 (8.0%) P=0.877 
CHD 
G-765C    
G/G    425 (71.0%) 546 (70.4%)    147 (49.7%) 113 (50.5%) 
G/C + C/C   182 (29.0%) 230 (29.6%)  P=0.808  144 (50.3%) 111 (49.6%) P=0.873 
V511A    
T/T  775 (100%)  591 (100%)  280 (91.9%) 202 (90.2%) 
T/C + C/C  0 (0%) 0 (0%) P=N/A 27 (8.1%) 22 (9.8%) P=0.514 
*Genotype data presented as absolute (percent) genotype frequency. Frequencies are weighted according to the sampling fraction. 
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Table 12.  Hazard rate ratio between PTGS2 polymorphisms and risk of incident ischemic stroke or CHD events. 
 Caucasian         African-American 
Polymorphism HRR  95% CI P-value HRR  95% CI P-value 
Stroke 
G-765C   G/C + C/C versus G/G  G/C + C/C versus G/G 
Model 1*  0.78 0.51 – 1.18 P=0.236 1.54 0.98 – 2.41 P=0.059 
Model 2†  0.79 0.50 – 1.25 P=0.314 1.76 1.05 – 2.94 P=0.031 
V511A   T/C + C/C versus T/T  T/C + C/C versus T/T 
Model 1*  N/A   0.87 0.39 – 1.95 P=0.734 
Model 2†  N/A   0.84 0.36 – 2.00 P=0.701 
CHD 
G-765C   G/C + C/C versus G/G  G/C + C/C versus G/G 
Model 1*  1.01 0.79 – 1.29 P=0.929 1.00 0.70 – 1.41 P=0.991 
Model 2†  1.08 0.83 – 1.42 P=0.567 1.03 0.69 – 1.52 P=0.894 
V511A   T/C + C/C versus T/T  T/C + C/C versus T/T 
Model 1*  N/A   1.09 0.60 – 1.98 P=0.786 
Model 2†  N/A   1.03 0.53 – 2.00 P=0.932 
HRR=hazard rate ratio, CI=confidence interval, N/A=modeling not completed since 0% frequency in case and/or non-case group.   
*Adjusted for age, gender, and study center. 
†Adjusted for age, gender, study center, current smoker, diabetes, and hypertension. 
‡Adjusted for age, gender, study center, current smoker, diabetes, hypertension, high density lipoprotein cholesterol, total cholesterol, and body 
mass index. 
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Table 13.  G-765C polymorphism in PTGS2, baseline aspirin utilization, and risk of incident CHD events in Caucasians. 
 
 Non-cases CHD cases P-value HRR* 95% CI P-value 
 G/C + C/C G/C + C/C  G/C + C/C vs. G/G 
All patients 182 (29.0%) 230 (29.6%) P=0.808 1.08 0.83–1.42 P=0.567 
No aspirin 122 (28.0%) 171 (31.7%) P=0.231 1.37 0.98–1.92 P=0.064 
Aspirin 60 (31.5%) 59 (25.0%) P=0.165 0.60 0.36–1.02 P=0.058 
Interaction†    0.57 0.31–1.04 P=0.065 
HRR=hazard rate ratio, CI=confidence interval. 
*Adjusted for age, gender, study center, current smoker, diabetes, hypertension, high density lipoprotein cholesterol, total cholesterol, and body 
mass index. 
†Multiplicative G-765C by aspirin utilization interaction term. 
 
 
 
  
CHAPTER IV 
 
NOS3 POLYMORPHISMS, CIGARETTE SMOKING, AND CARDIOVASCULAR 
DISEASE RISK: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) 
STUDY 
 
Lee CR, North KE, Bray MS, Avery CL, Mosher MJ, Couper DJ, Coresh J, Folsom AR,  
Boerwinkle E, Heiss G, Zeldin DC. Genetic variation in endothelial nitric oxide synthase (NOS3), 
cigarette smoking, and cardiovascular disease risk: the Atherosclerosis Risk in Communities (ARIC) 
study. Pharmacogenet Genomics 2006; (in press). 
 
 
Introduction 
    Ischemic cardiovascular disease is a major public health problem.  It is estimated that 1.2 
million Americans will experience an acute coronary heart disease (CHD) event and 0.7 
million will experience an acute stroke event this year (1).  Endothelial dysfunction is 
integrally involved in the pathogenesis of ischemic cardiovascular disease, and has been 
associated with an increased risk of myocardial infarction and stroke (10, 11). 
    Nitric oxide is synthesized by endothelial nitric oxide synthase (eNOS, NOS3) in the 
vasculature, where it possesses potent vasodilatory (12) and anti-inflammatory (13) effects.  
Impairment in eNOS-mediated nitric oxide biosynthesis contributes to endothelial 
dysfunction and promotes the development of atherosclerosis (15, 16).  Cigarette smoking 
also contributes to endothelial dysfunction and atherosclerosis (6), eliciting many of its 
deleterious endothelial effects via attenuation of nitric oxide biosynthesis and activity (17, 
18). 
    Multiple genetic polymorphisms in NOS3 have been discovered, including the T-786C and 
Glu298Asp (E298D) variants which have been associated with reduced nitric oxide 
  
 
 
79
biosynthesis (53, 54).  Numerous clinical studies evaluating potential associations between 
NOS3 polymorphisms and cardiovascular disease risk have reported inconsistent results (55); 
however, few have specifically evaluated the contribution of cigarette smoking, even though 
smoking may modify the influence of these polymorphisms on endothelial function (56, 57, 
119, 120).  The primary aim of this investigation was to determine if exposure to cigarette 
smoke significantly modified the association between presence of the T-786C or E298D 
polymorphisms in NOS3 and risk of incident CHD or ischemic stroke events in individuals 
enrolled in the biethnic Atherosclerosis Risk in Communities (ARIC) study. 
 
Methods 
Study Population.  Participants were selected from the ARIC study, a longitudinal, 
population-based cohort study of 15,792 men and women aged 45 to 64 years from four U.S. 
communities (Forsyth County, NC; Jackson, MS; Minneapolis, MN; and Washington 
County, MD) enrolled between 1987 and 1989 (102).  Since enrollment, participants have 
been followed prospectively via annual phone interviews, clinic examinations approximately 
every three years through 1998, and ongoing abstraction of hospital and death certificate 
records.  The study protocol was approved by the Institutional Review Board of each center, 
and consent was obtained from each participant. 
 
Ascertainment of Incident CHD and Stroke Cases.  All incident cases that occurred 
between baseline and December 31, 1998 were evaluated (median follow-up 9.1 years), 
excluding participants with history of CHD or stroke at baseline.  Incident CHD (n=1085) 
was defined as 1) definite or probable myocardial infarction (n=520), 2) electrocardiographic 
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evidence of silent myocardial infarction (n=112), 3) definite CHD death (n=110), or 4) 
coronary revascularization procedure (n=343).  Incident stroke was defined as a definite or 
probable ischemic stroke (n=300). 
    The ascertainment of cases and criteria for classification have been previously described 
(103, 104).  All potential events were systematically reviewed and adjudicated by the ARIC 
Morbidity and Mortality Classification Committee (102-104).  Hospitalized myocardial 
infarction was classified as definite or probable based on chest pain symptoms, cardiac 
enzyme levels, and electrocardiographic changes.  Definite CHD death was classified based 
on chest pain symptoms, underlying cause of death, hospitalization records, and medical 
history.  Coronary revascularization procedures included coronary artery bypass grafting and 
percutaneous coronary intervention.  Using the National Survey of Stroke criteria (105), a 
stroke event was classified as definite or probable if there was 1) rapid onset of neurological 
symptoms that lasted >24 hours or led to death within 24 hours, 2) no evidence of pathology 
that could have mimicked stroke, and 3) one major (e.g., aphasia or hemiparesis) or two 
minor (e.g., diplopia or dysarthria) neurological deficits.  Qualifying cases were further 
classified as ischemic (thrombotic brain infarction, cardioembolic stroke) or hemorrhagic 
(subarachnoid hemorrhage, intracerebral hemorrhage) on the basis of neuroimaging studies 
and autopsy, when available (104). 
 
Baseline Measurements.  Detailed demographic, clinical, and biochemical data were 
obtained from each participant at baseline.  Race was self-reported.  Prevalent CHD and 
stroke were defined as history of a physician-diagnosed event.  Hypertension was defined as 
systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or current 
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antihypertensive medication use.  Diabetes was defined as fasting blood glucose ≥126 
mg/dL, nonfasting blood glucose ≥200 mg/dL, physician diagnosis, or pharmacologic 
treatment.  Detailed information on cigarette smoking was obtained through an interview-
administered questionnaire, and was defined by current smoking status (yes/no) and pack-
year smoking history (≥20 or <20 pack-years). 
 
Cohort Random Sample.  A random sample of all ARIC participants without history of 
CHD or stroke at baseline was assembled to serve as the reference group for the case-cohort 
comparisons [n=1065; 85 (57 Caucasians, 28 African-Americans) and 29 (12 Caucasians, 17 
African-Americans)] of which are also incident CHD and stroke cases, respectively).  
Sampling of the cohort was stratified on age (≥55 or <55 years), gender, and race (Caucasian 
or African-American).  Sampling proportions varied across each stratum.   
 
Genotyping.  Genomic DNA from all incident CHD and ischemic stroke cases and the 
cohort random sample was genotyped for the T>C polymorphism at nucleotide position -786 
in the proximal promoter (T-786C) and the G>T polymorphism at nucleotide position 5246 
in exon 7 (E298D) of NOS3, using multiplex matrix-assisted laser desorption/ionization time-
of-flight (MALDI-TOF) mass spectrometry methods, as described (107) (Appendix II).  
Briefly, targeted sequences were amplified via polymerase chain reaction using specific 
forward (T-786C: 5’-ACGTTGGATGACTGTAGTTTCCCTAGTCCC-3’; E298D: 5'-
ACGTTGGATGACCTCAAGGACCAGCTCGG-3') and reverse (T-786C: 5’-
ACGTTGGATGAGGTCAGCAGAGAGACTAGG-3’; E298D: 5'-
ACGTTGGATGAAACGGTCGCTTCGACGTGC-3’) primers for each polymorphism, 
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followed by extension reactions utilizing specific oligonucleotide primers that annealed 
immediately upstream of each polymorphic site and extended the amplification product by a 
single base pair in the forward direction (T-786C: 5’-CATCAAGCTCTTCCCTGGC-3’; 
E298D: 5’-GCTGCAGGCCCCAGATGA-3’).  The mass of the extension reaction products 
was determined and translated into genotype using the MassARRAY RT software 
(Sequenom Inc., San Diego, CA).  Blind replicates were included for quality control.  
Missing genotypes were present in <5% of individuals. 
 
Data Analysis.  Inverse sampling fractions from each stratum were used as weights in 
variance estimation of adjusted covariate means and proportions by linear and logistic 
regression, respectively.  Cohort random sample allele frequencies were evaluated for 
deviation from Hardy-Weinberg equilibrium, and pairwise linkage disequilibrium statistics 
were calculated (Haploview 3.2) (81).  Hazard rate ratios (HRR) and 95% confidence 
intervals (CI) for the development of incident CHD or ischemic stroke in relation to genotype 
were calculated by weighted proportional hazards regression, using Barlow’s method to 
account for the stratified random sampling and case-cohort design (109).  Model 1 included 
age, gender, and study center as covariates.  Model 2 also included significant clinical 
covariates, which were current smoking status, diabetes, hypertension, high density 
lipoprotein cholesterol, total cholesterol, and body mass index for the CHD endpoint, and 
current smoking status, diabetes, and hypertension for the stroke endpoint.  Assuming an 
autosomal dominant mode of inheritance, individuals with one or two variant alleles were 
combined for comparison to wild-type individuals.  All analyses were completed separately 
in Caucasians and African-Americans.  Assuming a case-control design and type I error 
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α=0.05, there was approximately 99% and 90% power for the CHD endpoint and 90% and 
80% power for the stroke endpoint to detect an odds ratio of 2.0 in Caucasians and African-
Americans, respectively. 
    Haplotypes and their frequencies were estimated using the phase reconstruction method 
(PHASE 2.1), which assigned the most probable haplotype pair to each individual (121), and 
compared across case status by chi-square.  Associations between haplotype (0,1) and risk of 
CHD or stroke were evaluated using Barlow’s method (109), by simultaneously modeling 
each haplotype relative to the most common haplotype using the model 2 covariate 
adjustment strategy. 
    Gene-environment interaction testing was completed on a multiplicative scale between 
genotype and current smoking status (yes/no) or pack-year smoking history (≥20 or <20 
pack-years) at baseline using a Wald chi-square test for significance of the estimated β-
coefficient for the interaction term (110).  Haplotype-smoking interaction testing was also 
completed in Caucasians for the reconstructed haplotype containing both the variant T-786C 
and E298D alleles; however, this was not completed in African-Americans due to sample 
size limitations.  Because interaction hypothesis testing on a multiplicative scale is 
underpowered, the critical value for statistical significance was set to α=0.15, two-sided 
(111).  To minimize the impact of the multiple statistical tests conducted in the current 
analysis, the false discovery rate (FDR) q-value was estimated for each interaction test 
separately for the CHD and stroke endpoints (QVALUE).  The FDR q-value is defined as the 
proportion of statistical tests deemed significant that are actually false-positives (112).  
Stratified weighted proportional hazards regression was also completed according to baseline 
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current smoking status or pack-year smoking history using the model 2 covariate adjustment 
strategy (minus current smoking status) to further explore potential interactions.   
 
Results 
Study Population.  Significant baseline differences in various risk factors were observed 
between CHD and stroke cases and non-cases included in the cohort random sample (Table 
6).  Incident CHD and stroke cases were significantly older and more likely to be male, 
smokers, diabetic, hypertensive and have abnormal fasting lipid panels compared to non-
cases.  Stroke cases were also more likely to be African-American.  In the cohort random 
sample, 71.5% of current smokers at baseline also had a ≥20 pack-year history. 
 
NOS3 Genotype.  In the cohort random sample, the T-786C (0.371 versus 0.151) and E298D 
(0.330 versus 0.112) minor allele frequencies were significantly different in Caucasians and 
African-Americans, respectively (P<0.001).  Minimal evidence of pairwise linkage 
disequilibrium was observed between these polymorphisms in both Caucasians (D’=0.47, 
r2=0.19) and African-Americans (D’=0.41, r2=0.12).  The allelic distribution of each 
polymorphism was in Hardy-Weinberg equilibrium (P>0.05). 
 
E298D Polymorphism.  The E298D variant allele was not significantly associated with 
CHD or ischemic stroke incidence in either Caucasians or African-Americans (Tables 14 and 
15), nor were these relationships modified by gender.  However, in Caucasians the 
relationship between E298D genotype and CHD risk was significantly modified by baseline 
current smoking status (interaction P=0.013, q=0.078) and tended to be modified by pack-
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year smoking history (interaction P=0.126, q=0.247), with the highest risk of CHD observed 
in smokers carrying the E298D variant allele (Table 16).  In the stratified analysis, current 
smokers with the E298D variant allele were at significantly greater risk of CHD compared to 
smokers with two wild-type alleles (HRR 1.84, 95% CI 1.10-3.09, P=0.021); however, no 
association between the E298D variant allele and CHD risk was observed in nonsmokers 
(HRR 0.81, 95% CI 0.59-1.10, P=0.168).  Current smoking status (interaction P=0.762) and 
pack-year history (interaction P=0.641) did not modify the relationship between E298D 
genotype and CHD risk in African-Americans (Table 16).  Moreover, neither cigarette 
smoking exposure estimate modified the relationship between E298D genotype and risk of 
ischemic stroke. 
 
T-786C Polymorphism.  In Caucasians, the variant -786C allele tended to be more common 
in CHD cases compared to non-cases (62.7% versus 57.7%, P=0.079) (Table 14), and was 
associated with a trend toward greater CHD risk relative to T-786 homozygotes (HRR 1.24, 
95% CI 0.96-1.62, P=0.106) (Table 15); although, this did not attain statistical significance.  
Pack-year smoking history appeared to modify this association, such that in the stratified 
analysis ≥20 pack-year smokers carrying the variant -786C allele were at significantly greater 
risk of CHD relative to ≥20 pack-year smokers with two -786T alleles (HRR 1.52, 95% CI 
1.01-2.27, P=0.042).  No association was observed between the variant -786C allele and 
CHD risk in <20 pack-year smokers (HRR 1.06, 95% CI 0.75-1.51, P=0.731).  In African-
Americans, no association between the variant -786C allele and risk of CHD was observed 
(P=0.421) (Table 15); however, this relationship tended to be modified by current smoking 
status (interaction P=0.142, q=0.444) (Table 17). 
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    In African-Americans, the variant -786C allele tended to be more common in incident 
stroke cases compared to non-cases (39.5% versus 30.3%, P=0.099) (Table 14), and was 
associated with a trend toward greater risk of stroke relative to -786T homozygotes (HRR 
1.63, 95% CI 0.93-2.88, P=0.090) (Table 15); although, this did not attain statistical 
significance.  This relationship was not modified by gender.  However, cigarette smoking 
exposure significantly modified this association (interaction P=0.037, q=0.148), such that the 
greatest risk of ischemic stroke was observed in ≥20 pack-year smokers carrying the variant -
786C allele (Table 17).  In ≥20 pack-year smokers, stratified analysis demonstrated the -
786C allele was more common in stroke cases compared to non-cases (41.9% versus 23.4%, 
P=0.083), and was associated with significantly higher risk of stroke relative to ≥20 pack-
year smokers with two -786T alleles (HRR 4.23, 95% CI 1.34-13.4, P=0.014).  No 
relationship between the variant -786C allele and risk of stroke was observed in <20 pack-
year smokers (HRR 1.08, 95% CI 0.56-2.10, P=0.813).  A similar association was also 
observed in current smokers carrying the variant -786C allele (HRR 2.65, 95% CI 0.99-7.1, 
P=0.052), but not nonsmokers (HRR 1.16, 95% CI 0.55-2.46, P=0.694).  In Caucasians, the 
variant -786C allele was not significantly associated with risk of ischemic stroke (P=0.665) 
(Table 15), nor was this relationship modified by current smoking status (interaction 
P=0.892) or pack-year history (interaction P=0.488) (Table 17). 
 
NOS3 Haplotypes.  Four potential haplotypes were reconstructed, and in Caucasians only 
haplotype CG (uniquely tagged by the variant -786C allele) was significantly more frequent 
in CHD cases compared to non-cases (16.1% versus 13.1%, P=0.034) (Table 18) and was 
associated with a trend toward greater CHD risk relative to the most common haplotype TG 
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(HRR 1.34, 95% CI 0.97-1.85, P=0.072); although, this did not attain statistical significance.  
No significant differences in haplotype copy frequency were observed across CHD case 
status in African-Americans, or across stroke case status in Caucasians and African-
Americans (Table 18).   
    Haplotype CT (uniquely tagged by both the variant T-786C and E298D alleles) was not 
significantly associated with risk of CHD relative to haplotype TG (HRR 1.16, 95% CI 0.88-
1.53, P=0.296).  Although no statistically significant interaction between haplotype CT and 
either current smoking status (interaction P=0.179) or pack-year history (interaction 
P=0.206) was observed, smokers carrying at least one copy of haplotype CT appeared to 
demonstrate higher risk of CHD compared to nonsmokers without this haplotype (Table 19).  
In the stratified analysis, ≥20 pack-year smokers carrying haplotype CT were at significantly 
higher risk of developing CHD relative to ≥20 pack-year smokers with two haplotype TG 
copies (HRR 1.55, 95% CI 1.02-2.36, P=0.041).  However, no association between 
haplotype CT and CHD risk was observed in <20 pack-year smokers (HRR 0.91, 95% CI 
0.62-1.33, P=0.469).  A similar but nonsignificant association was also observed in current 
smokers carrying haplotype CT (HRR 1.73, 95% CI 0.99-3.02, P=0.054), but not 
nonsmokers (HRR 1.01, 95% CI 0.72-1.42, P=0.937).   
    Haplotype CT was not significantly associated with risk of ischemic stroke relative to 
haplotype TG (HRR 1.03, 95% CI 0.67-1.58, P=0.642).  Moreover, no significant interaction 
between haplotype CT and either current cigarette smoking status (interaction P=0.309) or 
pack-year history (interaction P=0.610) was observed (Table 19).  In the stratified analysis, 
statistically significant associations were not observed between haplotype CT and risk of 
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ischemic stroke in either current smokers (HRR 2.09, 95% CI 0.76-5.77, P=0.156) or 
nonsmokers (HRR 0.85, 95% CI 0.52-1.41, P=0.536) relative to haplotype TG. 
 
Discussion 
    The current analysis demonstrated no statistically significant associations between the T-
786C or E298D polymorphisms and risk of either incident CHD or ischemic stroke in 
Caucasians and African-Americans enrolled in the ARIC study; although, a trend towards 
higher risk was observed with the variant -786C allele for CHD in Caucasians and stroke in 
African-Americans.  Importantly, a potential interaction between genetic variation in NOS3, 
cigarette smoking history, and risk of incident CHD and ischemic stroke events was 
identified in these individuals.  Specifically, the T-786C and E298D polymorphism variant 
alleles appeared to be associated with significantly higher risk of developing CHD or 
ischemic stroke in current cigarette smokers and/or those with a ≥20 pack-year history at 
baseline, whereas these variant alleles were not significantly associated with disease risk in 
the absence of the smoking exposure.  This interaction was particularly evident with E298D 
genotype and CHD risk in Caucasians, and T-786C genotype and ischemic stroke risk in 
African-Americans. 
    The role of endothelial dysfunction in the pathogenesis of cardiovascular disease has 
become increasingly appreciated.  Endothelial dysfunction is typically manifested by 
impairment in endothelial-dependent vasodilation, and is associated with increased risk of 
myocardial infarction and stroke (10, 11).  The vasodilatory, anti-inflammatory, and anti-
proliferative properties of nitric oxide are vital mediators of this process, such that 
impairment in nitric oxide biosynthesis and/or activity elicits a substantial worsening of 
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endothelial function and promotes the development of atherosclerosis (12, 13, 15, 16).  
Cigarette smoking also contributes significantly to endothelial dysfunction and 
atherosclerosis (6), in part through its reduction of eNOS-mediated nitric oxide biosynthesis 
via enhanced oxidative stress and eNOS uncoupling (17, 18).   
    Numerous investigations have evaluated associations between NOS3 polymorphisms and 
cardiovascular disease.  Most have focused on the T-786C and E298D polymorphisms due to 
associations between the variant alleles and reduced nitric oxide biosynthesis (53, 54); 
however, results have been inconsistent (55).  Importantly, few investigations have evaluated 
incident clinical events.  Moreover, few have considered the potential influence of cigarette 
smoking despite their potential synergistic contribution to worsening endothelial function.  
For instance, the variant -786C allele has been significantly associated with risk of coronary 
spasm (120) and decreased cerebral blood flow (56) in smokers, but not nonsmokers.  The 
E298D variant allele has also been associated with significantly lower endothelial-dependent 
vasodilation in smokers, with no significant effect in nonsmokers (57).  Interestingly, the 
E298D variant allele did not influence endothelial-dependent vasodilation in healthy 
volunteers despite being associated with reduced systemic nitric oxide levels (122).  These 
data suggest that presence of established underlying endothelial dysfunction, as observed in 
cigarette smokers, may be necessary for these polymorphisms to significantly attenuate 
endothelial function and predispose patients to increased cardiovascular risk.  Findings from 
the current analysis demonstrating a potential interaction between the T-786C and E298D 
polymorphisms, cigarette smoking, and risk of CHD and stroke events are consistent with 
this hypothesis. 
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    It was observed that associations between the T-786C and E298D polymorphisms and 
CHD incidence may be significantly modified by exposure to cigarette smoke, such that 
smokers carrying these variant alleles were at significantly higher risk of developing CHD 
compared to nonsmokers without these variants.  Smokers carrying the reconstructed 
haplotype containing both variant alleles also appeared to be at greater risk of CHD.  
Moreover, pack-year history significantly modified the association between the -786C allele 
and ischemic stroke risk in African-Americans.  Collectively, these data suggest the potential 
existence of a complex interplay between NOS3 polymorphisms, cigarette smoking exposure, 
endothelial function, and cardiovascular disease risk.   
    Although the current study evaluated rigorously ascertained incident events, mechanisms 
underlying the observed statistical interactions were not elucidated.  It also cannot be ruled 
out that the T-786C and E298D polymorphisms are simply markers in linkage disequilibrium 
with the true causative loci.  However, it was confirmed that these polymorphisms are not in 
significant linkage disequilibrium with each other (55).  A previous epidemiological study 
reported a significant interaction between the NOS3 27-base pair repeat polymorphism in 
intron 4, smoking history, and risk of angiographically documented CHD (123).  Although 
this polymorphism was not evaluated in the current analysis, previous studies have 
demonstrated that it is not in significant linkage disequilibrium with either the E298D or T-
786C polymorphisms (55).  The current analysis also identified a potential haplotype-
smoking interaction.  Since haplotypes are inferred, some uncertainty exists in the haplotype 
assigned to each individual.  However, only two polymorphisms were included in haplotype 
reconstruction, posterior haplotype probabilities exceeded 0.83 in all individuals 
(approximately 75% had a probability of 1.0), and similar haplotype distributions were 
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observed using the expectation-maximization algorithm (81).  Unfortunately, validation of 
reported smoking status via biomarkers of tobacco exposure, such as urinary cotinine, was 
not completed in the ARIC study; however, misclassification of smoking status was expected 
to be minor and more likely to involve a smoker who failed to report cigarette consumption 
in small amounts.  Moreover, previous ARIC analyses evaluating smoking and risk of 
cardiovascular disease outcomes have been consistent with other populations (124).  Thus, it 
is unlikely that misclassification bias, if present, would have a detectable impact on these 
estimates. 
    It may be difficult to gauge the statistical significance of these findings considering the 
number of comparisons completed in the current analysis.  Moreover, some of the reported 
HRR’s were imprecise due to small sample sizes and limited power, particularly in the 
African-American and stroke subsets.  However, even though statistical significance was not 
demonstrated with every comparison, evaluation of two functionally relevant polymorphisms 
(T-786C and E298D), two measures of cigarette smoking exposure (current smoking status 
and pack-year history), and two incident cardiovascular disease endpoints (CHD and 
ischemic stroke) in Caucasian and African-American individuals enrolled in the rigorously 
characterized ARIC study cohort provided a conservative mechanism to characterize this 
potential gene-environment interaction at the population level.  Overall, the internal 
consistency of these results argue in favor of their validity, albeit at the cost of an increased 
number of statistical comparisons.  In order to minimize the impact of the multiple tests 
completed, the FDR of the interaction test results were also assessed.  The estimated q-values 
for the interactions observed with E298D genotype and CHD risk in Caucasians (q=0.078) 
and T-786C genotype and ischemic stroke risk in African-Americans (q=0.148) enhance 
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confidence in the conclusions drawn from these findings.  Moreover, previous studies have 
demonstrated that the T-786C and E298D polymorphisms are particularly associated with 
endothelial dysfunction in cigarette smokers (56, 57, 120), suggesting that existence of a 
causal interaction between genetic variation in NOS3 and smoking in the pathogenesis of 
CHD and stroke is biologically plausible.  However, the observation of significant gene-
smoking interactions in the absence of significant genotype-disease associations independent 
of the interaction (i.e., main effects) suggests these findings should be interpreted with 
caution.  Future studies in different populations will undoubtedly be required to validate 
these findings and improve the current understanding of the complex relationship between 
NOS3, cigarette smoking, and ischemic cardiovascular disease. 
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Table 14.  T-786C and E298D genotype frequency by incident CHD or stroke case status. 
 
 Caucasian   African-American 
Genotype* Non-cases Incident cases P-value Non-cases Incident cases P-value 
CHD 
E298D 
G/G  279 (47.2%) 365 (46.7%)    242 (77.3%) 182 (80.2%) 
G/T + T/T  336 (52.8%) 416 (53.3%)  P=0.862  70 (22.7%) 45 (19.8%) P=0.437 
T-786C 
T/T  248 (42.3%) 276 (37.4%)    212 (68.4%) 155 (74.9%) 
T/C + C/C  362 (57.7%) 463 (62.7%)  P=0.079  91 (31.6%) 52 (25.1%) P=0.126 
Stroke 
E298D 
G/G 296 (47.0%) 70 (46.7%)  255 (78.5%) 86 (74.1%) 
G/T + T/T 364 (53.0%) 80 (53.3%) P=0.939 68 (21.5%) 30 (25.9%) P=0.362 
T-786C 
T/T 268 (42.5%) 56 (39.2%)  223 (69.7%) 66 (60.6%) 
T/C + C/C 386 (57.5%) 87 (60.8%) P=0.466 90 (30.3%) 43 (39.5%) P=0.099 
*Genotype data presented as absolute (percent) genotype frequency, and weighted according to sampling fraction. 
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Table 15.  Hazard rate ratio between T-786C and E298D polymorphisms and risk of incident CHD or stroke. 
 
 Caucasian         African-American 
Polymorphism HRR  95% CI P-value HRR  95% CI P-value 
CHD 
E298D  G/T + T/T versus G/G  G/T + T/T versus G/G 
Model 1* 0.94 0.75–1.17 P=0.586 0.87 0.57–1.34 P=0.526 
Model 2† 1.03 0.80–1.33 P=0.819 0.66 0.40–1.09 P=0.105 
T-786C  T/C + C/C versus T/T  T/C + C/C versus T/T 
Model 1* 1.13 0.90–1.42 P=0.210 0.80 0.52–1.20 P=0.279 
Model 2† 1.24 0.96–1.62 P=0.106 0.83 0.53–1.31 P=0.421 
Stroke 
E298D  G/T + T/T versus G/G  G/T + T/T versus G/G 
Model 1* 0.94 0.65–1.36 P=0.742 1.50 0.89–2.53 P=0.133 
Model 2‡ 0.97 0.65–1.44 P=0.884 1.35 0.76–2.41 P=0.311 
T-786C  T/C + C/C versus T/T  T/C + C/C versus T/T 
Model 1* 1.06 0.72–1.55 P=0.783 1.70 1.05–2.75 P=0.032 
Model 2‡ 1.09 0.73–1.64 P=0.665 1.63 0.93–2.88 P=0.090 
*Adjusted for age, gender, and study center. 
†Adjusted for age, gender, study center, current smoker, diabetes, hypertension, HDL cholesterol, total cholesterol, and body mass index. 
‡Adjusted for age, gender, study center, current smoker, diabetes, and hypertension. 
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Table 16.  E298D genotype by smoking interaction and risk of incident CHD and stroke.*† 
 Caucasian   African-American 
Smoking Exposure E298D Genotype  Interaction‡ E298D Genotype Interaction‡ 
CHD§ G/G G/T + T/T  G/G G/T + T/T  
Current smoker n=365/279 n=416/335  n=182/241 n=44/70 
No 1 (referent) 0.83 (0.61–1.13) 2.10 (1.17–3.76) 1 (referent) 0.63 (0.34–1.16) 1.17 (0.43–3.18) 
Yes 1.19 (0.77–1.83) 2.07 (1.39–3.07) P=0.013 1.90 (1.17–3.10) 1.40 (0.62–3.18) P=0.762 
Pack-years 
<20 years 1 (referent) 0.84 (0.61–1.17) 1.50 (0.89–2.53) 1 (referent) 0.61 (0.35–1.06) 1.30 (0.43–3.90) 
≥20 years 1.23 (0.83–1.83) 1.56 (1.08–2.24) P=0.126 1.19 (0.73–1.93) 0.94 (0.35–2.50) P=0.641 
Stroke║ G/G G/T + T/T  G/G G/T + T/T  
Current smoker  n=70/296 n=80/363  n=85/254 n=30/68 
No  1 (referent) 0.81 (0.51–1.30) 1.70 (0.71–4.06) 1 (referent) 1.26 (0.57–2.77) 1.24 (0.37–4.19) 
Yes  1.58 (0.83–3.00) 2.18 (1.19–3.99) P=0.234 2.00 (1.08–3.69) 3.12 (1.22–7.99) P=0.726 
Pack-years 
<20 years  1 (referent) 0.80 (0.46–1.38) 1.48 (0.66–3.31) 1 (referent) 1.36 (0.67–2.74) 1.00 (0.25–4.01) 
≥20 years  1.49 (0.81–2.75) 1.77 (0.98–3.21) P=0.337 1.39 (0.70–2.75) 1.88 (0.53–6.62) P=0.999 
*Number of cases/non-cases in each genotype cell. 
†Data presented as HRR (95% CI). 
‡Multiplicative E298D by smoking interaction term HRR (95% CI), and P-value. 
§Adjusted for age, gender, study center, diabetes, hypertension, HDL cholesterol, total cholesterol, and body mass index. 
║Adjusted for age, gender, study center, diabetes, hypertension. 
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Table 17.  T-786C genotype by smoking interaction and risk of incident CHD and stroke.*† 
 Caucasian   African-American 
Smoking Exposure T-786C Genotype  Interaction‡ T-786C Genotype Interaction‡ 
CHD§ T/T T/C + C/C  T/T T/C + C/C 
Current smoker n=276/247 n=463/362  n=154/212 n=52/90 
No 1 (referent) 1.33 (0.97–1.81) 0.83 (0.46–1.49) 1 (referent) 0.60 (0.34–1.07) 2.04 (0.79–5.31) 
Yes 1.92 (1.21–3.05) 2.11 (1.41–3.17) P=0.527 1.68 (1.00–2.83) 2.08 (0.95–4.54) P=0.142 
Pack-years 
<20 years 1 (referent) 1.08 (0.77–1.50) 1.44 (0.85–2.44) 1 (referent) 0.66 (0.39–1.11) 1.88 (0.68–5.15) 
≥20 years 1.22 (0.79–1.88) 1.89 (1.32–2.70) P=0.179 1.07 (0.63–1.82) 1.32 (0.58–3.00) P=0.222 
Stroke║ T/T T/C + C/C  T/T T/C + C/C  
Current smoker  n=56/267 n=87/386  n=65/223 n=43/89 
No  1 (referent) 1.09 (0.66–1.79) 0.94 (0.39–2.28) 1 (referent) 1.34 (0.66–2.72) 1.49 (0.45–4.96) 
Yes  2.17 (1.06–4.43) 2.22 (1.20–4.11) P=0.892 1.86 (0.94–3.68) 3.72 (1.39–9.99) P=0.515 
Pack-years 
<20 years  1 (referent) 0.94 (0.54–1.65) 1.33 (0.59–3.02) 1 (referent) 1.06 (0.55–2.06) 3.73 (1.08–12.9) 
≥20 years  1.56 (0.80–3.04) 1.97 (1.09–3.57) P=0.488 1.02 (0.49–2.13) 4.03 (1.54–10.6) P=0.037 
*Number of cases/non-cases in each genotype cell. 
†Data presented as HRR (95% CI). 
‡Multiplicative T-786C by smoking interaction term HRR (95% CI), and P-value. 
§Adjusted for age, gender, study center, diabetes, hypertension, HDL cholesterol, total cholesterol, and body mass index. 
║Adjusted for age, gender, study center, diabetes, hypertension. 
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Table 18.  NOS3 haplotype frequency by incident CHD or stroke case status. 
 
 CHD   Stroke 
Haplotype* Non-case† Incident case† P-value‡  Non-case† Incident case† P-value‡ 
Caucasian§  n=606 n=735  n=650 n=142 
TG 54.4% 53.0% P=0.494 54.2% 53.9% P=0.935 
CT 23.0% 23.0% P=0.987 23.0% 22.5% P=0.870 
CG  13.1% 16.1% P=0.034 13.2% 14.8% P=0.496 
TT  9.6% 8.0% P=0.160 9.7% 8.8% P=0.648 
African-American§  n=303 n=207  n=313 n=109 
TG 78.8% 79.2% P=0.876 79.3% 72.9% P=0.069 
CT 6.5% 3.9% P=0.076 6.0% 7.3% P=0.519 
CG  9.9% 10.1% P=0.891 9.8% 13.8% P=0.145 
TT  4.9% 6.8% P=0.230 4.8% 6.0% P=0.536 
*Haplotype frequencies weighted according to cohort random sample strata.  Tagging polymorphisms are in bold. 
†Estimated copy frequency of each haplotype. 
‡Chi-square P-value for the distribution of each haplotype by CHD or stroke case status. 
§Haplotype includes the T-786C and E298D polymorphisms, respectively. 
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Table 19.  NOS3 haplotype by smoking interaction and risk of incident CHD and stroke 
in Caucasians.*† 
 
Smoking Exposure Haplotype  Interaction‡ 
CHD§ Non-CT CT 
Current smoker n=430/350 n=305/256 
No 1 (referent) 1.00 (0.74–1.35) 1.50 (0.83–2.70) 
Yes 1.46 (1.00–2.13) 2.18 (1.40–3.38) P=0.179 
Pack-years 
<20 years 1 (referent) 0.95 (0.68–1.33) 1.39 (0.84–2.30) 
≥20 years   1.32 (0.93–1.87) 1.74 (1.21–2.51) P=0.206 
Stroke║ Non-CT CT  
Current smoker  n=84/374 n=58/276 
No  1 (referent) 0.87 (0.53–1.45) 1.59 (0.65–3.86) 
Yes  1.67 (0.92–3.04) 2.32 (1.18–4.51) P=0.309 
Pack-years 
<20 years  1 (referent) 0.92 (0.52–1.63) 1.24 (0.54–2.80) 
≥20 years  1.70 (0.98–2.94) 1.93 (0.99–3.74) P=0.610 
*Number of cases/non-cases in each haplotype cell. 
†Data presented as HRR (95% CI). 
‡Multiplicative haplotype by smoking interaction term HRR (95% CI), and P-value. 
§Adjusted for age, gender, study center, diabetes, hypertension, HDL cholesterol, total cholesterol, 
and body mass index. 
║Adjusted for age, gender, study center, diabetes, hypertension. 
 
 
  
PART II 
 
P450 EPOXYGENASE PATHWAY AND CARDIOVASCULAR DISEASE RISK 
 
 
  
CHAPTER V 
 
GENETIC VARIATION IN SOLUBLE EPOXIDE HYDROLASE (EPHX2) AND 
RISK OF CORONARY HEART DISEASE: THE ATHEROSCLEROSIS RISK IN 
COMMUNITIES (ARIC) STUDY 
 
Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ,  
Heiss G, Zeldin DC. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary 
heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet. 
2006;15:1640-1649. 
 
 
Introduction 
    Coronary heart disease (CHD) is a major cause of morbidity and mortality, with 1.2 
million Americans estimated to experience an acute coronary event this year (1).  Endothelial 
dysfunction is integrally involved in its pathogenesis (2), and is independently associated 
with increased risk of acute cardiovascular events (10).  Various risk factors including 
cigarette smoking contribute to this process, which is typically manifested by impairment in 
nitric oxide synthesis and activity (6).  However, dysfunction in other endothelial pathways 
may also be important. 
    Arachidonic acid is metabolized to epoxyeicosatrienoic acids (EETs) in endothelial cells 
by various cytochromes P450 (20).  The EETs possess potent vasodilatory (30, 31), anti-
inflammatory (32), and fibrinolytic (33) effects, and are considered one of the primary 
endothelial-derived hyperpolarizing factors (30, 31).  The EETs are inactivated by soluble 
epoxide hydrolase (EPHX2) via hydrolysis to dihydroxyeicosatrienoic acids (DHETs) (28, 
125).  Multiple polymorphisms in EPHX2 have been recently discovered, including variants 
with higher (K55R) and lower (R287Q) epoxide hydrolase activity (68, 69).  An
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association between EPHX2 polymorphisms and subclinical atherosclerosis has been 
previously reported (70); however, associations with risk of clinical events such as 
myocardial infarction have not been evaluated. 
    The primary aim was to determine if genetic variation in EPHX2 was associated with risk 
of incident CHD events in individuals enrolled in the biethnic Atherosclerosis Risk in 
Communities (ARIC) study.  A secondary aim was to determine if this risk was modified by 
environmental factors known to impair endothelial function such as cigarette smoking.  
 
Methods 
Study Population.  Participants were selected from the ARIC study, a longitudinal, 
population-based cohort study of 15,792 men and women aged 45 to 64 years from four U.S. 
communities (Forsyth County, NC; Jackson, MS; Minneapolis, MN; and Washington 
County, MD) enrolled between 1987 and 1989 (102).  Since enrollment, participants have 
been followed prospectively via annual phone interviews, clinic examinations approximately 
every three years through 1998, and ongoing abstraction of hospital and death certificate 
records.  The study protocol was approved by the Institutional Review Board of each center, 
and consent was obtained from each participant. 
 
Ascertainment of Incident CHD Cases.  All incident cases that occurred between baseline 
and December 31, 1998 were evaluated (median follow-up 9.1 years), excluding subjects 
with a history of CHD or stroke at baseline.  Incident CHD (n=1085) was defined as 1) 
definite or probable myocardial infarction (n=520), 2) electrocardiographic evidence of silent 
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myocardial infarction (n=112), 3) definite CHD death (n=110), or 4) coronary 
revascularization procedure (n=343). 
    The ascertainment of cases and criteria for classification have been previously described 
(103).  All potential events were systematically reviewed and adjudicated by the ARIC 
Morbidity and Mortality Classification Committee (102, 103).  Hospitalized myocardial 
infarction was classified as definite or probable based on chest pain symptoms, cardiac 
enzyme levels, and electrocardiographic changes.  Definite CHD death was classified based 
on chest pain symptoms, underlying cause of death, hospitalization records, and medical 
history.  Coronary revascularization procedures included coronary artery bypass grafting and 
percutaneous coronary interventions. 
 
Baseline Measurements.  Detailed demographic, clinical, and biochemical data were 
obtained from each subject at baseline.  Race was self-reported.  Prevalent CHD and stroke 
were defined as history of a physician-diagnosed event.  Hypertension was defined as 
systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or current 
antihypertensive medication use.  Diabetes was defined as fasting blood glucose ≥126 
mg/dL, nonfasting blood glucose ≥200 mg/dL, physician diagnosis, or pharmacologic 
treatment.  Detailed information on cigarette smoking was obtained through an interview-
administered questionnaire. 
 
Cohort Random Sample.  A random sample of all ARIC participants without history of 
CHD or stroke at baseline was assembled to serve as the reference group for the case-cohort 
comparisons (n=1065, 85 of which are also incident CHD cases).  Sampling of the cohort 
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was stratified on age (<55 or ≥55 years), gender, and race (Caucasian or African-American).  
Sampling proportions varied across each stratum.  The term non-case refers to individuals 
within the cohort random sample who did not develop incident CHD during follow-up 
(n=980). 
 
Genotyping.  Genomic DNA from all incident CHD cases and the cohort random sample 
was genotyped for ten polymorphisms in coding and noncoding regions of EPHX2 (Figure 
9), using multiplex matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) 
mass spectrometry (Sequenom, Inc., San Diego, CA) (107) (Appendix II) or Taqman® 
(Applied Biosystems, Foster City, CA) (126) (Appendix IV) methods, as described.  Blind 
replicates were included for quality control.  Missing genotypes were present in <5% of 
individuals.  These polymorphisms were identified from a resequencing effort as part of the 
NIEHS Environmental Genome Single Nucleotide Polymorphism program (https://dir-
apps.niehs.nih.gov/egsnp/home.htm) (69), and specifically selected based on their known 
functional relevance in vitro (68, 69) and/or haplotype tagging properties.  Briefly, pairwise 
linkage disequilibrium statistics were calculated and haplotypes were reconstructed 
separately in European/Caucasians (n=24) and Africans (n=24) using all polymorphisms 
along EPHX2 identified by resequencing (Haploview 3.2) (69, 81).  Polymorphisms tagging 
haplotypes with >5% frequency in either population were selected for genotyping (127). 
 
Biomarker Analysis.  Plasma from the most recent clinic visit was obtained from 56 
participants selected based on their K55R genotype [A/A (n=19), A/G (n=19), G/G (n=18)] 
and matched for age, gender and race.  Plasma samples were extracted and 
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epoxyoctadecenoic acid (EpOME) to dihydroxyoctadecenoic acid (DHOME) concentrations 
were quantified using a validated HPLC/MS/MS method, as described (128).  Previous 
studies with Ephx2-/- mice suggest that plasma EpOME:DHOME ratios are sensitive and 
specific biomarkers of soluble epoxide hydrolase activity, with lower EpOME:DHOME 
values indicative of higher apparent soluble epoxide hydrolase activity (46). 
 
Data Analysis.  All incident CHD cases and individuals from the cohort random sample 
were included in the current analysis (n=2065).  Inverse sampling fractions from each 
stratum were used as weights in variance estimation of adjusted covariate means and 
proportions by linear and logistic regression, respectively, in non-cases included in the cohort 
random sample.  Hazard rate ratios (HRR) and 95% confidence intervals (CI) for the 
development of incident CHD in relation to EPHX2 genotype were calculated by weighted 
proportional hazards regression, using Barlow’s method to account for the stratified random 
sampling and case-cohort design (109).  Model 1 was unadjusted and included only 
genotype.  Model 2 included age, gender, and study center as covariates.  Model 3 also 
included current smoking status, diabetes, hypertension, high density lipoprotein cholesterol, 
total cholesterol, and body mass index.  Assuming an autosomal dominant mode of 
inheritance, individuals with one or two variant alleles were combined for comparison to 
wild-type individuals.  All analyses were completed separately in Caucasians and African-
Americans.  Assuming a case-control design and type I error α=0.05, there was 
approximately 99% and 80% power to detect an odds ratio of 2.0 and 70% and 30% power to 
detect an odds ratio of 1.5 in Caucasians and African-Americans, respectively, for 
polymorphisms with a 10% variant genotype frequency. 
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    Gene-environment interaction testing was completed on a multiplicative scale between 
genotype and baseline current smoking status (yes/no) using a Wald chi-square test for 
significance of the estimated β-coefficient for the interaction term (110).  Because interaction 
hypothesis testing on a multiplicative scale is underpowered, the critical value for statistical 
significance was set to α=0.15, two-sided (111).  Stratified weighted proportional hazards 
regression was also completed according to baseline current smoking status using the model 
3 covariate adjustment strategy (minus current smoking status) to further explore potential 
interactions. 
    Cohort random sample allele frequencies were evaluated for deviation from Hardy-
Weinberg equilibrium, and pairwise linkage disequilibrium statistics were calculated 
(Haploview 3.2) (81).  Haplotypes and their frequencies were estimated using the phase 
reconstruction method (PHASE 2.1), which assigned the most probable haplotype pair to 
each individual (121, 129).  Only polymorphisms with >5% frequency were considered for 
haplotype reconstruction, which included polymorphisms 1, 5, 6, 7, and 10 in Caucasians and 
1, 2, 4, 5, 6, and 10 in African-Americans (Figure 9).  Haplotype frequencies were compared 
across case status by chi-square, and only haplotypes with >5% frequency were considered.  
Frequency comparisons were repeated using the expectation-maximization algorithm 
(Haploview 3.2) (81), which accounted for the uncertainty in haplotype reconstruction by 
weight-adjusting each inferred haplotype according to its estimated posterior haplotype 
probability.  Associations between haplotype (0,1,2) and risk of incident CHD were also 
evaluated by modeling each haplotype relative all other haplotypes using Barlow’s method 
(109).  The association analysis was repeated after excluding individuals with posterior 
haplotype probabilities <0.75. 
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    To minimize the impact of the multiple statistical tests conducted in the current analysis, 
the false discovery rate (FDR) q-value was estimated for each comparison, which is defined 
as the proportion of statistical tests deemed significant that are actually false-positives 
(QVALUE) (112).  In order to calculate conservative q-value estimates, statistical tests from 
the model 1, 2, and 3 association analysis of each nonsynonymous polymorphism and 
reconstructed haplotype were considered as independent even though each model assessed 
the same independent variable. 
    Plasma EpOME:DHOME ratios were compared across K55R genotype by analysis of 
variance, and post-hoc comparisons between genotypes were completed using the Tukey-
Kramer test.  All data are presented as mean ± standard error of the mean. 
 
Results 
Study Population.  Significant baseline differences in various risk factors were observed 
between incident CHD cases and non-cases included in the cohort random sample (Table 6).  
Cases were significantly older and more likely to be male, cigarette smokers, diabetic, 
hypertensive and have abnormal fasting lipid panels compared to non-cases. 
 
EPHX2 Genotype.  The observed race-specific allele frequencies of the 10 polymorphisms 
evaluated are presented in Figure 9.  The distribution of each was in Hardy-Weinberg 
equilibrium in both Caucasians and African-Americans (P>0.05).  Minimal evidence of 
pairwise linkage disequilibrium was observed between polymorphisms within each race; 
however, polymorphism 10 demonstrated some degree of association with polymorphisms 1 
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(D’=0.97, r2=0.28), 5 (D’=0.96, r2=0.22), and 6 (D’=0.93, r2=0.28) in Caucasians and 5 
(D’=1.0, r2=0.20) in African-Americans. 
 
K55R Biomarker Analysis.  Participants with one (A/G) or two (G/G) copies of the K55R 
polymorphism variant allele demonstrated significantly lower plasma 12,13-
EpOME:DHOME ratios compared to wild-type (A/A) individuals (A/A: 0.40±0.03 versus 
A/G: 0.31±0.04 versus G/G: 0.28±0.03; P=0.030), indicative of higher apparent soluble 
epoxide hydrolase activity in vivo.  Significant differences in plasma 9,10-EpOME:DHOME 
ratios were not observed (A/A: 0.34±0.03 versus A/G: 0.28±0.03 versus G/G: 0.26±0.03; 
P=0.155). 
    In the race-stratified analysis, Caucasians with one or two copies of the K55R variant allele 
demonstrated significantly lower plasma 9,10-EpOME:DHOME (A/A: 0.42±0.04 versus A/G: 
0.28±0.04 versus G/G: 0.24±0.04; P=0.014) and 12,13-EpOME:DHOME ratios (A/A: 
0.42±0.04 versus A/G: 0.31±0.04 versus G/G: 0.25±0.04; P=0.011) compared to wild-type 
individuals (Figure 10A).  Significant differences across genotype were not observed in 
African-Americans for either the 9,10-EpOME:DHOME (A/A: 0.28±0.04 versus A/G: 
0.27±0.05 versus G/G: 0.29±0.05; P=0.983) or 12,13-EpOME:DHOME ratio (A/A: 
0.38±0.05 versus A/G: 0.31±0.06 versus G/G: 0.31±0.06; P=0.602) (Figure 10B).  
Irrespective of genotype, differences in 9,10-EpOME:DHOME (P=0.395) and 12,13-
EpOME:DHOME ratios (P=0.897) were not observed across race. 
 
Genotype Association Analysis.  The K55R polymorphism variant allele was significantly 
more common among Caucasian CHD cases compared to cohort random sample non-cases 
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(20.8% versus 15.3%, respectively, P=0.012) (Table 20).  This difference in genotype 
frequency was observed in both heterozygous A/G (19.8% versus 14.9%) and homozygous 
G/G (1.0% versus 0.4%) individuals.  Significant differences were not observed in African-
Americans (P=0.344) (Table 20). 
    Presence of the K55R variant allele was associated with significantly higher risk of 
incident CHD in Caucasians (model 3, HRR 1.45, 95% CI 1.05 to 2.01, P=0.026, q=0.083) 
(Table 21).  Individuals with the heterozygous A/G (model 3, HRR 1.40, 95% CI 1.00 to 
1.95, P=0.047) and homozygous G/G (model 3, HRR 3.47, 95% CI 1.05 to 11.5, P=0.041) 
genotypes were at a significantly greater risk for developing CHD relative to wild-type A/A 
individuals.  This association was not modified by gender (P for interaction=0.432). 
    No significant differences in the genotype frequency of other nonsynonymous 
polymorphisms were observed across case status in either race (Table 20).  Moreover, 
presence of the R103C, R287Q, 402InsR, or E470G polymorphism variant alleles were not 
significantly associated with risk of CHD (Table 21).  A significant difference in baseline 
diabetes diagnosis was observed between Caucasians in the cohort random sample with (G/A 
or A/A) and without (G/G) the R287Q polymorphism variant allele (1.6% versus 10.2%, 
respectively, P<0.001).  The R287Q variant allele was more common in diabetic CHD cases 
compared to non-cases (20.1% versus 3.6%, respectively, P<0.001); however, differences in 
genotype frequency were not observed in nondiabetics (20.9% versus 20.9%, respectively, 
P=0.987).  Inclusion of the R287Q*diabetes interaction term in model 3 substantially 
attenuated the observed trend between presence of the R287Q variant allele and risk of 
incident CHD in Caucasians (HRR 1.06, 95% CI 0.76 to 1.48, P=0.710).  Moreover, 
stratified analysis demonstrated no association between the R287Q variant allele and risk of 
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CHD in nondiabetic individuals (model 3 minus diabetes, HRR 1.05, 95% CI 0.73 to 1.50, 
P=0.799). 
 
K55R Genotype and Smoking.  The interaction between the K55R variant allele, cigarette 
smoking status at baseline and risk of CHD in Caucasians did not attain statistical 
significance (Table 22).  When stratified by current smoking status at baseline, the K55R 
variant allele was significantly more common among Caucasian cases who smoked 
compared to non-cases (25.6% versus 13.6%, respectively, P=0.006).  Significant differences 
were not observed in non-smokers (18.5% versus 15.8%, respectively, P=0.291).  Caucasian 
smokers carrying the K55R variant allele were at higher risk of CHD compared to smokers 
without the polymorphism (model 3 minus current smoking, HRR 2.06, 95% CI 0.99 to 4.27, 
P=0.053).  No significant association was observed in non-smokers (model 3 minus current 
smoking, HRR 1.26, 95% CI 0.87 to 1.82, P=0.217).  Smoking status did not modify risk 
associated with the K55R variant allele in African-Americans (P for interaction=0.709). 
 
Haplotype Association Analysis.  Haplotype reconstruction including polymorphisms 1, 5, 
6, 7, and 10 in Caucasians and 1, 2, 4, 5, 6, and 10 in African-Americans identified six 
common haplotypes in Caucasians and seven in African-Americans, which accounted for 
97.2% and 92.3% of all chromosomes, respectively.  A significant difference in the overall 
haplotype distribution was observed in Caucasians with and without CHD (P=0.021) (Table 
23); however, no significant difference was observed in African-Americans (P=0.315) (Table 
24).  
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    In Caucasians, haplotype AGGDA (all wild-type alleles) was significantly less frequent 
(23.6% versus 27.6%, P=0.034), and haplotype GGGDG (tagged by the K55R and A53415G 
3’UTR variant alleles) was significantly more frequent (10.7% versus 7.6%, P=0.010) in 
CHD cases compared to non-cases, respectively (Table 23).  Similar differences in haplotype 
AGGDA and GGGDG frequency across case status were also observed using the expectation-
maximization algorithm (P=0.010 and P=0.052, respectively).  Moreover, presence of 
haplotype AGGDA was associated with significantly lower risk of CHD after covariate 
adjustment (model 3, HRR 0.78, 95% CI 0.63 to 0.97, P=0.028, q=0.083), while presence of 
haplotype GGGDG was associated with significantly higher CHD risk (model 3, HRR 1.45, 
95% CI 1.04 to 2.02, P=0.030, q=0.083) (Table 23).  Significant associations were also 
observed after excluding the 0.8% of individuals with a posterior haplotype probability <0.75 
from the analysis (P=0.025 and P=0.027, respectively). 
    In African-Americans, haplotype ACGGGA (all wild-type alleles) was significantly more 
frequent (17.3% versus 12.2%, P=0.026) in CHD cases compared to non-cases, respectively 
(Table 24).  A similar difference was also observed using the expectation-maximization 
algorithm (P=0.060).  Presence of haplotype ACGGGA was associated with higher risk of 
CHD after covariate adjustment (model 3, HRR 1.47, 95% CI 1.01 to 2.13, P=0.042, 
q=0.280) (Table 24); however, this association was substantially weakened after exclusion of 
the 6.7% of individuals with a posterior haplotype frequency <0.75 (model 3, HRR 1.37, 
95% CI 0.92 to 2.05, P=0.119), and should be interpreted with caution. 
 
 
 
  
 
 
111
Discussion 
    The current analysis identified a statistically significant association between genetic 
variation in soluble epoxide hydrolase and risk of incident CHD in Caucasians enrolled in the 
ARIC study, implicating EPHX2 as a potential cardiovascular disease-susceptibility gene.  
Specifically, presence of the K55R polymorphism variant allele was associated with 
significantly higher risk of developing CHD in Caucasians.  Consistent with previous in vitro 
findings (69), higher apparent soluble epoxide hydrolase activity was observed in vivo in 
Caucasians carrying the K55R variant allele.  Variation in EPHX2 at the haplotype level was 
also associated with risk of CHD in Caucasians, suggesting multiple variants within or near 
EPHX2 may contribute to disease risk. 
    The role of endothelial dysfunction in the pathogenesis of atherosclerotic cardiovascular 
disease has become increasingly appreciated.  Endothelial dysfunction is typically manifested 
by impairment in endothelial-dependent vasodilation (2), and is associated with increased 
risk of acute cardiovascular events (10).  The vasodilatory and anti-inflammatory properties 
of EETs are important mediators of this process (20, 130).  Recent data have demonstrated 
higher CHD risk in individuals carrying the G-50T polymorphism variant allele in CYP2J2, 
which exhibits lower promoter activity and EET biosynthesis (64).  Soluble epoxide 
hydrolase rapidly hydrolyzes EETs to DHETs, and is integrally involved in regulation of 
their cellular levels and vascular effects (28, 125, 131).  EPHX2-/- mice have significantly 
lower systolic blood pressures compared to wild-type mice (45).  Soluble epoxide hydrolase 
inhibitors significantly reduce blood pressure in spontaneously and angiotensin II-induced 
hypertensive rats (28, 47, 132), inhibit vascular smooth muscle cell proliferation (48), 
possess potent anti-inflammatory effects (49), and represent a therapeutic strategy of 
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potential clinical utility for the treatment of cardiovascular disease.  Moreover, a significant 
association between genetic variation in EPHX2 and risk of ischemic stroke events was 
recently reported (133). 
    Resequencing efforts have identified nonsynonymous polymorphisms in EPHX2 with 
higher (K55R, C154Y, E470G) and lower (R287Q, 402InsR) epoxide hydrolase activity in 
vitro relative to wild-type enzyme (68, 69).  Higher apparent epoxide hydrolase activity was 
observed in vivo, as measured by EpOME:DHOME ratios, in Caucasians carrying at least 
one K55R variant allele; however, altered EpOME:DHOME ratios were not observed across 
K55R genotype in African-American individuals.  Undetectable plasma EET concentrations 
precluded calculation of EET:DHET ratios.  Based on the role of EPHX2 in endothelial 
function, it was hypothesized that higher epoxide hydrolase activity would be associated with 
higher risk of acute coronary events.  A significant association between the K55R variant 
allele and higher risk of incident CHD in Caucasians is consistent with this hypothesis.   
    Cigarette smoking substantially impairs endothelial-dependent vasodilation in humans (6, 
134), in part via inhibition of nitric oxide synthesis and activity (17), and modifies the 
association between endothelial nitric oxide synthase polymorphisms, endothelial function, 
and cardiovascular disease risk (57, 123, 135) (Chapter IV).  Perhaps presence of established 
underlying endothelial dysfunction, as observed in cigarette smokers, may be necessary for 
these genetic variants to significantly influence endothelial function and cardiovascular 
disease risk.  Interestingly, exposure to cigarette smoke also significantly increases vascular 
EPHX2 expression in mice (136), suggesting upregulated EET hydrolysis may contribute to 
the deleterious effects of cigarette smoking in the endothelium.  Cigarette smoking history 
did not appear to influence plasma EpOME:DHOME ratios in the current biomarker study 
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(data not shown); however, this analysis was not designed or powered to specifically 
characterize such comparisons.  Although preliminary, these findings suggest that the risk of 
CHD associated with the K55R variant allele may be highest in cigarette smokers.  Future 
studies in larger populations will be required to characterize this potential gene-environment 
interaction and the mechanistic contribution of EPHX2 to the vascular effects of cigarette 
smoking. 
    Using haplotype tagging polymorphisms identified from a previous resequencing effort, 
the haplotype analysis suggests that variation along the EPHX2 gene is also an important 
determinant of CHD risk in Caucasians.  Distribution of reconstructed haplotypes differed 
significantly across individuals with and without incident CHD, and haplotypes GGGDG and 
AGGDA were associated with significantly higher and lower CHD risk, respectively.  The 
GGGDG haplotype was tagged by the K55R variant allele, which was associated with 
significantly higher in vivo soluble epoxide hydrolase activity and CHD risk in the genotype 
analysis.  The R287Q and 402InsR variant alleles, which have been associated with lower 
soluble epoxide hydrolase activity in vitro (68, 69), were not located on either the GGGDG 
or AGGDA haplotypes.  Since haplotypes are inferred, some uncertainty exists in the 
haplotype assigned to each individual.  This was mitigated by minimizing the number of 
polymorphisms included in haplotype reconstruction (137).  Moreover, similar results were 
observed using the expectation-maximization algorithm, which accounted for posterior 
haplotype probabilities in the frequency comparisons across case status (81), and after 
excluding individuals with posterior haplotype probabilities <0.75. 
    The lack of an association between CHD and the K55R polymorphism in African-
Americans could be due to lower statistical power in this subset.  However, there was no 
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apparent influence of K55R genotype on in vivo soluble epoxide hydrolase activity in 
African-Americans, whereas significant genotype-dependent differences were observed in 
Caucasians.  Perhaps certain genetic and/or environmental factors not accounted for in the 
current analysis could have contributed to these racial differences in soluble epoxide 
hydrolase activity and CHD risk.  Future studies evaluating the vascular effects of EPHX2 in 
Caucasians and African-Americans appear warranted, particularly since racial differences in 
endothelial-targeted therapies have been reported in other cardiovascular disease populations 
(138). 
    An association between the R287Q variant allele and increased coronary artery 
calcification, a non-invasive measure of atherosclerotic burden, was recently reported in 
African-Americans (70).  The mechanism underlying this association remains unclear since 
this variant has demonstrated lower soluble epoxide hydrolase activity in vitro (68, 69).  A 
significant association between this variant and risk of CHD clinical events was not observed 
in the current analysis.  Although a nonsignificant trend toward higher risk was observed in 
Caucasians (model 3 only), this relationship was modified by baseline diabetes diagnosis.  
No association with CHD risk was observed in nondiabetics, while the apparent trend in 
diabetics was driven by a lower R287Q minor allele frequency in diabetic non-cases (0.017) 
than expected based on previously reported frequencies (approximately 0.10) (69, 70). 
    Although the current study evaluated rigorously ascertained incident events, mechanisms 
underlying the observed associations between genetic variation in EPHX2 and CHD risk 
were not elucidated.  Moreover, the K55R polymorphism could simply be a marker in linkage 
disequilibrium with the true causative locus.  However, the current analysis accounted for 
multiple EPHX2 polymorphisms and also demonstrated significant associations between 
  
 
 
115
haplotype and CHD risk in Caucasians.  Although polymorphisms in this candidate gene with 
known functional relevance in vitro and/or haplotype tagging properties were specifically 
selected, and a hypothesis-driven approach in the analysis was utilized, it may be difficult to 
gauge the statistical significance of these findings considering the number of comparisons 
completed.  However, concerns surrounding false negative findings (i.e., missing true 
associations) are at least as important.  In order to minimize the impact of the multiple tests 
completed in the current analysis the FDR was assessed across all completed tests in the 
genotype and haplotype association analysis, recognizing that such an approach is likely an 
over-correction since certain genotype and haplotype associations are not completely 
independent and the same independent variables were evaluated by each of the three models 
utilized in the analysis.  Since all q-values in Caucasians were conservatively estimated to be 
0.083 or less, there is a high level of confidence in the reported findings; although, validation 
in an independent population is necessary. 
    In conclusion, these findings suggest that genetic variation in EPHX2, particularly 
presence of the K55R polymorphism variant allele, may be an important risk factor for the 
development of CHD clinical events in Caucasians.  Association studies in different 
populations will undoubtedly be required to validate these findings, in addition to molecular 
and physiological studies evaluating the mechanistic relationship between soluble epoxide 
hydrolase, endothelial function, and cardiovascular disease risk. 
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Table 20.  Nonsynonymous EPHX2 polymorphism frequency by CHD case status. 
 
Caucasian    African-American 
Genotype* Non-cases CHD cases P-value Genotype* Non-cases CHD cases P-value 
K55R     K55R   
A/A 461 (84.7%) 608 (79.2%)  A/A   179 (57.6%) 138 (61.9%) 
A/G + G/G 87 (15.3%) 160 (20.8%) P=0.012 A/G + G/G  127 (42.4%) 85 (38.1%) P=0.344 
A allele  92.1% 89.1%  A allele  76.4% 78.9% 
G allele 7.8% 10.9% P=0.009 G allele  23.6% 21.1% P=0.351 
R103C      R103C  
C/C 565 (98.7%) 773 (100%)  C/C   247 (80.7%) 180 (81.1%) 
C/T + T/T 8 (1.3%) 0 (0%) P=N/A C/T + T/T  60 (19.3%) 42 (18.9%) P=0.915 
C allele 99.4% 100%  C allele  90.0% 90.1% 
T allele 0.6% 0%  P=N/A T allele  10.0% 9.9% P=0.968 
R287Q      R287Q  
G/G 496 (80.6%) 616 (79.2%)  G/G   258 (82.9%) 190 (86.0%) 
G/A + A/A 118 (19.4%) 162 (20.8%) P=0.525 G/A + A/A  49 (17.1%) 31 (14.0%) P=0.361 
G allele 89.9% 89.0%  G allele  91.3% 92.3%  
A allele 10.1% 11.0% P=0.485 A allele  8.7% 7.7% P=0.569 
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Table 20 (con’t). 
 
Caucasian    African-American 
Genotype* Non-cases CHD cases P-value Genotype* Non-cases CHD cases P-value 
402InsR†      402InsR† 
D/D 527 (87.6%) 687 (88.1%)  D/D   301 (99.2%) 219 (98.2%) 
D/I + I/I 76 (12.4%) 93 (11.9%) P=0.792 D/I + I/I  3 (0.8%) 4 (1.8%) P=N/A 
D allele 93.5% 93.8%  D allele  99.6% 99.1% 
I allele 6.5% 6.2% P=0.694 I allele  0.4% 0.9% P=N/A 
E470G      E470G 
A/A 557 (100%) 774 (100%)  A/A   300 (97.8%) 222 (97.8%) 
A/G + G/G 0 (0%) 0 (0%) P=N/A A/G + G/G  5 (2.2%) 5 (2.2%) P=0.974 
A allele 100% 100%  A allele 98.9% 98.9% 
G allele 0%  0% P=N/A G allele 1.1% 1.1% P=0.975 
*Data presented as absolute (percent) genotype frequency and allele frequency.  Frequencies are weighted according to the sampling fraction.  
Data for polymorphism 3 (C154Y) and 8 (V422A) are not included due to minor allele frequencies ≤0.1% in both races. 
†For 402InsR (polymorphism 7), the deletion allele is designated by D, and the CGT insertion allele by I. 
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Table 21.  Hazard rate ratio between nonsynonymous polymorphisms in EPHX2 and risk of incident CHD. 
 
 Caucasian         African-American 
Polymorphism HRR  95% CI P-value HRR  95% CI P-value 
K55R  A/G + G/G versus A/A  A/G + G/G versus A/A 
Model 1* 1.43  1.07 – 1.90 P=0.015 0.87 0.60 – 1.27 P=0.474 
Model 2† 1.36 1.01 – 1.83 P=0.045 0.87 0.61 – 1.25 P=0.466 
Model 3‡ 1.45 1.05 – 2.01 P=0.026 0.76 0.50 – 1.16 P=0.208 
R103C     C/T + T/T versus C/C 
Model 1* N/A   0.87 0.55 – 1.35 P=0.528 
Model 2† N/A   0.95 0.61 – 1.47 P=0.801 
Model 3‡ N/A   0.94 0.58 – 1.51 P=0.787 
R287Q  G/A + A/A versus G/G  G/A + A/A versus G/G 
Model 1* 1.03  0.78 – 1.36 P=0.827 0.87 0.52 – 1.44 P=0.560 
Model 2† 1.17 0.88 – 1.54 P=0.284 0.90 0.55 – 1.49 P=0.685 
Model 3‡ 1.34 0.96 – 1.87 P=0.082 1.13 0.64 – 2.01 P=0.676 
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Table 21 (con’t). 
 
 Caucasian         African-American 
Polymorphism HRR  95% CI P-value HRR  95% CI P-value 
402InsR§  D/I + I/I versus D/D  D/I + I/I versus D/D 
Model 1* 0.96  0.69 – 1.34 P=0.819 1.64 0.47 – 5.86 P=0.603 
Model 2† 1.00 0.72 – 1.39 P=0.998 1.40 0.39 – 4.97 P=0.603 
Model 3‡ 1.00 0.70 – 1.45 P=0.990 1.26 0.43 – 3.71 P=0.675 
E470G     A/G + G/G versus A/A 
Model 1* N/A   1.33 0.35 – 5.02 P=0.679 
Model 2† N/A   1.71 0.50 – 5.85 P=0.396 
Model 3‡ N/A   1.87 0.52 – 6.75 P=0.338 
HRR = hazard rate ratio, CI = confidence interval, N/A = modeling not completed since SNP frequency = 0% in incident coronary heart disease 
case and/or non-case group.  Data for polymorphism 3 (C154Y) and 8 (V422A) are not included due to minor allele frequencies ≤0.1% in both 
races. 
*Unadjusted. 
†Adjusted for age, gender, and study center.  
‡Adjusted for age, gender, study center, current smoker, diabetes, hypertension, high density lipoprotein cholesterol, total cholesterol, and body 
mass index.  
§For 402InsR (polymorphism 7), the deletion allele is designated by D, and the CGT insertion allele by I. 
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Table 22.  K55R by smoking interaction and risk of incident CHD in Caucasians. 
 
Smoking Exposure      Susceptibility Genotype (K55R) 
  A/A A/G + G/G 
Non-current smokers 
Model 2*  1 (referent) 1.16 (0.81 – 1.64) 
Model 3†  1 (referent) 1.26 (0.87 – 1.80) 
Current Smokers 
Model 2*  1.57 (1.17 – 2.11) 2.84 (1.62 – 4.99) 
Model 3†  1.57 (1.14 – 2.16) 2.93 (1.54 – 5.55) 
Data presented as Hazard Rate Ratio (95% confidence interval). 
*Adjusted for age, gender, and study center (interaction term: HRR 1.57, 95% CI 0.78-3.13, 
P=0.205). 
†Adjusted for age, gender, study center, diabetes, hypertension, high density lipoprotein cholesterol, 
total cholesterol, and body mass index (interaction term: HRR 1.49, 95% CI 0.69-3.18, P=0.308). 
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Table 23.  EPHX2 haplotypes and risk of incident CHD in Caucasians. 
 
 Distribution Analysis  Association Analysis 
Haplotype*,†,‡ Non-cases CHD cases P-value§ HRR║ 95% CI P-value 
 n=510 n=748    
AAGDA 41.5% 43.8%  1.02 0.84 – 1.24 P=0.842 
AGGDA 27.6% 23.6%  0.78 0.63 – 0.97 P=0.026 
AGADG  9.9% 10.7%  1.39 0.97 – 1.99 P=0.073 
GGGDG 7.6% 10.7%  1.45 1.04 – 2.02 P=0.030 
AGGIA 6.5% 6.2%  0.98 0.67 – 1.42 P=0.908 
AGGDG 6.9% 5.1% P=0.021 0.84 0.58 – 1.22 P=0.367 
HRR = hazard rate ratio, CI = confidence interval 
*Bold nucleotides represent haplotype tagging polymorphisms. 
†Estimated copy frequency of each haplotype weighted according to the sampling fraction. 
‡Haplotype includes polymorphisms 1, 5, 6, 7, and 10 respectively.  For polymorphism 7 (402InsR), the deletion allele is designated by D, and the 
CGT insertion allele by I. 
§Chi-square P-value for the overall distribution of haplotypes by coronary heart disease case status. 
║Adjusted for age, gender, study center, current smoker, diabetes, hypertension, high density lipoprotein cholesterol, total cholesterol, and body 
mass index.  
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Table 24.  EPHX2 haplotypes and risk of incident CHD in African-Americans. 
 
 Distribution Analysis  Association Analysis 
Haplotype*,†,‡ Non-cases CHD cases P-value§ HRR║ 95% CI P-value║ 
 n=305 n=220 
ACGGGG 24.3% 21.8%  0.84 0.57 – 1.24 P=0.377 
GCGGGG 22.6% 20.9%  0.85 0.59 – 1.23 P=0.396 
ACCGGG 15.1% 15.6%  1.09 0.70 – 1.68 P=0.703 
ACGGGA 12.2% 17.3%  1.47 1.01 – 2.13 P=0.042 
ACGAGA 9.8% 10.1%  1.08 0.68 – 1.70 P=0.750 
ACGGAG 8.8% 6.2%  0.89 0.48 – 1.67  P=0.718 
ATGGGA 7.2% 8.2% P=0.315 1.32 0.78 – 2.23 P=0.304 
*Bold nucleotides represent haplotype tagging polymorphisms. 
†Estimated copy frequency of each haplotype weighted according to the sampling fraction. 
‡Haplotype includes polymorphisms 1, 2, 4, 5, 6, and 10, respectively. 
§Chi-square P-value for the overall distribution of haplotypes by coronary heart disease case status. 
║Adjusted for age, gender, study center, current smoker, diabetes, hypertension, high density lipoprotein cholesterol, total cholesterol, and body 
mass index. 
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Figure Legends 
Figure 9.  Nucleotide positions of the 10 polymorphisms evaluated are given relative to the 
EPHX2 cDNA start site (Genbank accession number NT_022666).  Activity is reported as 
higher (↑), lower (↓), unchanged (↔), or unknown (?) relative to wild-type enzyme based on 
previous in vitro studies (68, 69).  Minor allele frequencies are presented separately by race, 
and P-values for their comparison are reported. 
 
Figure 10.  Mean (± standard error of the mean) calculated plasma EpOME:DHOME ratios 
are presented according to K55R genotype in Caucasians (A) and African-Americans (B).  
9,10-EpOME:DHOME (black bars, *P<0.05 versus A/A), and 12,13-EpOME:DHOME 
(white bars, ^P<0.05 versus A/A) ratios are presented. 
 
  
 
 
124
Figure 9.  Selected EPHX2 polymorphisms for genotyping. 
 
ATG TAG
Exon 1                          2              3          4       5              6             7   8            9      10       11        12                        13         14      15  16  17   18   19
Polymorphism         1           2            3             4   5              6                                      7              8               9                  10
dbSNP ID  rs17057255                           rs57816586   rs751141                                    rs1042032
Nucleotide            9846    12582     13928     14029      20675      25206                              45678       47539    50360            53415 
Position
Major Allele             A           C            G            G G             G                                     - T              A                   A
Minor Allele             G           T            A            C A             A                                    CGT            C              G                   G
Amino Acid          K55R    R103C    C154Y        - - R287Q                             402InsR    V422A    E470G               -
Substitution
Activity      ↑ ↔ ↑ ?          ? ↓ ↓ ↔ ↑ ?
Minor allele
frequency
Caucasian          0.098      0.003         0         0.002   0.427      0.106                                0.064        0               0                 0.261 
AA                       0.223      0.100     0.001      0.149 0.090      0.080                                0.007     0           0.009              0.670
P-value              <0.001    <0.001 N/A      <0.001    <0.001 0.442                              <0.001         N/A      N/A <0.001  
Chromosome 8p21-p12
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Figure 10.  Biomarker of soluble epoxide hydrolase activity by K55R genotype and race. 
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CHAPTER VI 
 
CYP2J2 AND CYP2C8 POLYMORPHISMS AND CORONARY HEART DISEASE 
RISK: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY 
 
 
Introduction 
    Coronary heart disease (CHD) is a major cause of morbidity and mortality, with 1.2 
million Americans estimated to experience a new or recurrent acute coronary syndrome event 
this year. (1).  Endothelial dysfunction is associated with risk of CHD events such as 
myocardial infarction (10).  Various risk factors including cigarette smoking (6) contribute to 
this process, which has been primarily ascribed to functional impairments in nitric oxide 
biosynthesis and activity.  However, dysfunction in other endothelial pathways also appears 
to be important. 
    Arachidonic acid is oxidatively metabolized to epoxyeicosatrienoic acids (EETs) in 
endothelial cells and cardiomyocytes by the cytochromes P450 epoxygenases CYP2J2 and 
CYP2C8 (20).  The EETs have potent vasodilatory (30, 31), anti-inflammatory (32), 
fibrinolytic (33) and post-ischemic cardioprotective (34, 35) effects, and are considered one 
of the primary endothelial-derived hyperpolarizing factors (30, 31).  Multiple genetic 
polymorphisms in CYP2J2 and CYP2C8 have been recently discovered (63-66).  In CYP2J2, 
the G-50T (CYP2J2*7) polymorphism in the proximal promoter disrupts a Sp1 transcription 
factor binding site and leads to reduced CYP2J2 transcription (64).  In CYP2C8, the I269F 
(CYP2C8*2), R139K/K399R (CYP2C8*3) and I264M (CYP2C8*4) nonsynonymous variants 
possess lower CYP2C8 metabolic activity in vitro (65, 66).  Case-control studies have 
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demonstrated an association between the CYP2J2*7 variant allele and higher risk of 
angiographically-documented CHD in a German population (64), and between the 
CYP2C8*3 variant allele and higher risk of prevalent myocardial infarction in a Swedish 
cohort (67).  However, associations between polymorphisms in these genes and risk of 
incident CHD clinical events remain to be evaluated. 
    The primary aim was to determine if genetic variation in CYP2J2 and CYP2C8 was 
associated with risk of incident CHD events in individuals enrolled in the biethnic 
Atherosclerosis Risk in Communities (ARIC) study.  A secondary aim was to determine if 
this risk was modified by environmental factors known to impair endothelial function such as 
cigarette smoking. 
 
Methods 
Study Population.  Participants were selected from the ARIC study, a longitudinal, 
population-based cohort study of 15,792 men and women aged 45 to 64 years from four U.S. 
communities (Forsyth County, NC; Jackson, MS; Minneapolis, MN; and Washington 
County, MD) enrolled between 1987 and 1989 (102).  Since enrollment, participants have 
been followed prospectively via annual phone interviews, clinic examinations approximately 
every three years through 1998, and ongoing abstraction of hospital and death certificate 
records.  The study protocol was approved by the Institutional Review Board of each center, 
and consent was obtained from each participant. 
 
Ascertainment of Incident CHD Cases.  All incident cases that occurred between baseline 
and December 31, 1998 were evaluated (median follow-up 9.1 years), excluding participants 
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with a history of a CHD or stroke event at baseline.  Incident CHD (n=1085) was defined as 
1) definite or probable myocardial infarction (n=520), 2) electrocardiographic evidence of 
silent myocardial infarction (n=112), 3) definite CHD death (n=110), or 4) coronary 
revascularization procedure (n=343). 
    The ascertainment of cases and criteria for classification have been previously described 
(103).  All potential events were systematically reviewed and adjudicated by the ARIC 
Morbidity and Mortality Classification Committee (102, 103).  Hospitalized myocardial 
infarction was classified as definite or probable based on chest pain symptoms, cardiac 
enzyme levels, and electrocardiographic changes.  Definite CHD death was classified based 
on chest pain symptoms, underlying cause of death, hospitalization records, and medical 
history.  Coronary revascularization procedures included coronary artery bypass grafting and 
percutaneous coronary interventions. 
 
Baseline Measurements.  Detailed demographic, clinical, and biochemical data were 
obtained from each participant at baseline, as described (139) (Chapter V).  Briefly, race was 
self-reported and detailed information on cigarette smoking was obtained through an 
interview-administered questionnaire. 
 
Cohort Random Sample.  A random sample of all ARIC participants without history of 
CHD or stroke at baseline was assembled to serve as the reference group for the case-cohort 
comparisons (n=1065, 85 of which are also incident CHD cases).  Sampling of the cohort 
was stratified on age (<55 or ≥55 years), gender, and race (Caucasian or African-American).  
Sampling proportions varied across each stratum. 
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Genotyping.  Genomic DNA from all incident CHD cases and the cohort random sample 
was genotyped for ten polymorphisms in coding and noncoding regions of CYP2J2 (Figure 
11) and the nonsynonymous I269F (CYP2C8*2), K399R (CYP2C8*3) and I264M 
(CYP2C8*4) polymorphisms in CYP2C8 using either multiplex matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (Sequenom, Inc., San 
Diego, CA) (107) (Appendix II) or BeadArray (Illumina, Inc., San Diego, CA) (108) 
(Appendix III) methods, as described.  Blind replicates were included for quality control.   
    The CYP2J2 polymorphisms were identified from a resequencing effort as part of the 
NIEHS Environmental Genome Single Nucleotide Polymorphism program (https://dir-
apps.niehs.nih.gov/egsnp/home.htm) (63) and specifically selected based on their known 
functional relevance in vitro and/or haplotype tagging properties.  Due to the very low 
frequency of nonsynonymous variants in CYP2J2, evaluation of potential associations 
between common CYP2J2 haplotypes and CHD risk were also of particular interest.  Briefly, 
pairwise linkage disequilibrium (LD) statistics were calculated and haplotypes were 
reconstructed separately in European/Caucasians (n=24) and Africans (n=24) using all 
polymorphisms in CYP2J2 identified by resequencing (Haploview 3.2) (63, 81).  
Polymorphisms tagging haplotypes with >5% frequency in either population were selected 
for genotyping.   
    Three nonsynonymous polymorphisms in CYP2C8 were selected since these represent the 
most frequent variants in Caucasian or African-American populations with known functional 
relevance (65, 66).  The CYP2C8*3 variant consists of two nonsynonymous polymorphisms 
in complete LD (R139K and K399R) (65); however, only the K399R locus was genotyped in 
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the current analysis.  Due to the frequency of these functionally relevant nonsynonymous 
variants, CYP2C8 haplotypes were not evaluated. 
 
Data Analysis.  All incident CHD cases and individuals from the cohort random sample 
were included in the current analysis (n=2065).  Inverse sampling fractions from each 
stratum were used as weights in variance estimation of adjusted covariate means and 
proportions by linear and logistic regression, respectively, in non-cases included in the cohort 
random sample.  Hazard rate ratios (HRR) and 95% confidence intervals (CI) for the 
development of incident CHD in relation to CYP2J2 or CYP2C8 genotype were calculated by 
weighted proportional hazards regression, using Barlow’s method to account for the stratified 
random sampling and case-cohort design (109).  Model 1 included baseline age, gender, and 
study center as covariates.  Model 2 also included current smoking status, diabetes, 
hypertension, high density lipoprotein cholesterol, total cholesterol, and body mass index at 
baseline.  Assuming an autosomal dominant mode of inheritance, individuals with one or two 
variant alleles were combined for comparison to wild-type individuals.  All analyses were 
completed separately in Caucasians and African-Americans.  Assuming a case-control 
design, type I error α=0.05 and 10% variant genotype frequency, there was approximately 
99% and 80% power to detect an odds ratio of 2.0 in Caucasians and African-Americans, 
respectively. 
    Cohort random sample allele frequencies were evaluated for deviation from Hardy-
Weinberg equilibrium, and pairwise LD statistics were calculated (Haploview 3.2) (81).  
CYP2J2 haplotypes and their frequencies were estimated using the phase reconstruction 
method (PHASE 2.1), which assigned the most probable haplotype pair to each individual 
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(121).  Only polymorphisms with >5% frequency and pairwise r2 values <0.80 were 
considered for haplotype reconstruction, which included polymorphisms 1 and 7 in 
Caucasians and 1, 7, 9, and 10 in African-Americans (Figure 11).  Haplotype frequencies 
were compared across case status by chi-square.  Only haplotypes with >5% frequency were 
considered.  Frequency comparisons were repeated using the expectation-maximization 
algorithm (Haploview 3.2) (81), which accounted for the uncertainty in haplotype 
reconstruction by weight-adjusting each inferred haplotype according to its estimated 
posterior haplotype probability.  Associations between haplotype (0,1) and risk of incident 
CHD were also evaluated by modeling each haplotype relative all other haplotypes using 
Barlow’s method (109).  The association analysis was repeated after excluding individuals 
with posterior haplotype probabilities <0.75. 
    Gene-environment interaction testing was completed on a multiplicative scale between 
selected CYP2J2 and CYP2C8 variants and baseline current smoking status (yes/no) using a 
Wald chi-square test for significance of the estimated β-coefficient for the interaction term 
(110).  Because interaction hypothesis testing on a multiplicative scale is underpowered, the 
critical value for statistical significance was set to α=0.15, two-sided (111).  Stratified 
weighted proportional hazards regression was also completed to further explore potential 
interactions. 
    To minimize the impact of the multiple statistical tests conducted in the current analysis, 
the false discovery rate (FDR) q-value was estimated for each comparison, separately for 
CYP2J2 and CYP2C8, which is defined as the proportion of statistical tests deemed 
significant that are actually false-positives (QVALUE) (112).  In order to calculate 
conservative q-value estimates, statistical tests from the unadjusted, model 1 and model 2 
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association analysis of each polymorphism and reconstructed haplotype were considered as 
independent, even though each model assessed the same independent variable and certain 
genotype and haplotype associations are not completely independent.  Additional q-value 
estimates were also calculated for the gene-smoking interaction analysis.  Only q-values for 
significant findings are presented. 
 
Results 
Study Population.  Significant baseline differences in various risk factors were observed 
between incident CHD cases and non-cases included in the cohort random sample (Table 6).  
Cases were significantly older and more likely to be male, cigarette smokers, diabetic, 
hypertensive and have abnormal fasting lipid panels compared to non-cases. 
 
CYP2J2/CYP2C8 Genotype.  The observed race-specific allele frequencies of the 10 
CYP2J2 polymorphisms are presented in Figure 11.  The R158C (CYP2J2*3), I192N 
(CYP2J2*4), and N404Y (CYP2J2*6) polymorphisms were monomorphic in both Caucasians 
and African-Americans.  Significant LD was observed between certain CYP2J2 
polymorphisms, particularly in Caucasians (Figure 12).  The minor allele frequencies of the 
I264M (0.041 versus 0.011), I269F (0.002 versus 0.141) and K399R (0.108 versus 0.019) 
polymorphisms in CYP2C8 were significantly different in Caucasians and African-
Americans, respectively, in the cohort random sample (P<0.001 for each comparison).  No 
evidence of LD was observed in either subpopulation (r2<0.01).  The distribution of all 
evaluated polymorphisms were in Hardy-Weinberg equilibrium in both Caucasians and 
African-Americans (P>0.05).   
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CYP2J2 Polymorphisms and CHD Risk.  In African-Americans, the variant -50T allele was 
significantly less common among CHD cases compared to cohort random sample non-cases 
(20.9% versus 29.3%, respectively, P=0.043) (Table 25).  Moreover, presence of at least one 
variant -50T allele was associated with significantly lower risk of incident CHD events 
relative to -50G homozygotes (model 2, HRR 0.58, 95% CI 0.35-0.96, P=0.036, q=0.051) 
(Table 26).  This association was not modified by gender (P for interaction=0.797).  In 
Caucasians, no significant difference in G-50T genotype frequency was observed across 
CHD case status (P=0.719) (Table 25), and no significant association between presence of 
the variant -50T allele and CHD risk was observed (model 2, HRR 1.15, 95% CI 0.78-1.70, 
P=0.472) (Table 26).   
    The rare R49S variant allele appeared to be less common in CHD cases compared to non-
cases in African-Americans (0.5% versus 2.5%, respectively) and Caucasians (0.1% versus 
0.6%, respectively) (Table 25).  However, no significant association with risk of CHD was 
observed in either ethnic group after covariate adjustment (Table 26). 
    Haplotype reconstruction identified five common haplotypes in African-Americans and 
three in Caucasians, which accounted for 94.7% and 98.1% of all haplotypes, respectively.  
In African-Americans, the overall haplotype distribution tended to be different in individuals 
with and without CHD (P=0.086); however, this did not attain statistical significance (Table 
27).  No difference in haplotype distribution was observed in Caucasians (P=0.731) (Table 
27). 
    In African-Americans, haplotype TGTA [tagged by the polymorphism 1 (G-50T), 7 and 9 
variant alleles] was less frequent (8.1% versus 12.3%, P=0.052) in CHD cases compared to 
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non-cases, respectively (Table 27).  Similar differences in haplotype TGTA frequency were 
also observed using the expectation-maximization algorithm (P=0.027).  Moreover, presence 
of at least one haplotype TGTA copy was significantly less common in CHD cases compared 
to non-cases (14.5% versus 22.9%, respectively, P=0.027), and was associated with 
significantly lower risk of incident CHD (model 2, HRR 0.51, 95% CI 0.29-0.91, P=0.023, 
q=0.041) (Table 27).  Significant associations were also observed after excluding the 1.5% of 
individuals with a posterior haplotype probability <0.75 from the analysis (P=0.020).  In 
Caucasians, presence of haplotype TG [tagged by the polymorphism 1 (G-50T) and 7 variant 
alleles] was not significantly associated with risk of incident CHD after covariate adjustment 
(model 2, HRR 1.33, 95% CI 0.87-2.02, P=0.184) (Table 27). 
 
CYP2C8 Polymorphisms and CHD Risk.  No significant differences in the genotype 
frequency of the I264M, I269F or K399R polymorphisms in CYP2C8 were observed across 
CHD case status in either African-Americans or Caucasians (Table 25).  Moreover, presence 
of the I264M, I269F or K399R variant alleles were not significantly associated with risk of 
incident CHD after covariate adjustment (Table 26). 
 
Genotype by Smoking Interaction.  In Caucasians, cigarette smoking status at baseline 
appeared to modify the association between CHD risk and both the I264M (P for 
interaction=0.104, q=0.166) and K399R (P for interaction=0.060, q=0.160) polymorphisms 
in CYP2C8 (Table 28).  A significant interaction was identified when individuals carrying at 
least one variant allele in either the I264M or K399R polymorphisms were compared to those 
wild-type for both (P for interaction=0.008, q=0.064) (Table 29).  When stratified by 
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smoking status, smokers carrying at least one variant allele were at significantly higher risk 
of CHD compared to smokers wild-type at both loci (model 2, HRR 1.89, 95% CI 1.05-3.38, 
P=0.033).  Smoking status did not modify risk associated with the CYP2C8 variant I269F 
allele in African-Americans (P for interaction=0.746), or the CYP2J2 variant -50T allele in 
either African-Americans (P for interaction=0.605) or Caucasians (P for interaction=0.690). 
 
Discussion 
    The current analysis demonstrated a statistically significant association between the variant 
-50T allele in CYP2J2 and lower risk of incident CHD events in African-Americans enrolled 
in the ARIC study.  A common CYP2J2 haplotype which carried the -50T allele was also 
associated with significantly lower CHD risk in African-Americans.  The I264M, I269F and 
K399R polymorphisms in CYP2C8 were not associated with risk of CHD in either ethnic 
group.  However, in Caucasians, cigarette smokers carrying either the variant I264M or 
K399R allele were at significantly higher risk of incident CHD, whereas no significant 
association with disease risk was observed in the absence of the smoking exposure. 
    Endothelial dysfunction is associated with increased risk of acute cardiovascular events 
(10), and is typically manifested by impairment in endothelial-dependent vasodilation (2).  
The vasodilatory and anti-inflammatory properties of CYP2J2 and CYP2C8-derived EETs 
are important mediators of this process (20, 130).  Soluble epoxide hydrolase (EPHX2) 
rapidly hydrolyzes EETs and is integrally involved in regulation of their cellular levels and 
vascular effects (28)  The K55R variant allele in EPHX2 was associated with significantly 
higher soluble epoxide hydrolase activity in vivo and higher risk of incident CHD events in 
Caucasians (139) (Chapter V).  Although regulation of EET levels by soluble epoxide 
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hydrolase in vivo is well-documented, variation in CYP2J2 and/or CYP2C8-mediated EET 
biosynthesis may also be critical.  However, the relative contribution of each P450 
epoxygenase to the regulation of cellular and systemic EET levels has not been extensively 
characterized, particularly in humans. 
    Multiple polymorphisms in CYP2J2 and CYP2C8 associated with reduced enzyme 
expression or metabolic activity have been identified (63-66).  In CYP2J2, the R158C, 
I192N, and N404Y polymorphisms possess significantly lower epoxygenase activity in vitro 
(63).  However, these variants are extremely infrequent, and were found to be monomorphic 
in the 2065 individuals genotyped in the current analysis.  The G-50T polymorphism disrupts 
a Sp1 transcription factor binding site in the proximal promoter, leads to reduced CYP2J2 
transcription in vitro and represents the only common, functionally relevant polymorphism in 
CYP2J2 identified to date (64).  Importantly, the variant -50T allele was associated with 
significantly lower plasma DHET levels and higher risk of prevalent angiographically-
documented CHD in a recently characterized German population (64).  However, in the 
current analysis the variant -50T allele was associated with significantly lower risk of 
incident CHD clinical events in African-Americans at both the polymorphism and haplotype 
levels, in contrast to these previous findings and current hypotheses related to the beneficial 
effects of EETs in the vasculature.  The rare R49S variant allele also appeared to be less 
frequent in African-American CHD cases; however, the metabolic relevance of this 
infrequent variant remains to be characterized.  In Caucasians, the -50T allele was not 
significantly associated with risk of incident CHD events after covariate adjustment, 
inconsistent with the previously described German population (64).  However, the primary 
analysis of this investigation by Spiecker et al. defined CHD angiographically, not by clinical 
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event incidence as defined in the ARIC study.  Interestingly, Spiecker et al. also reported a 
non-significant association between the -50T allele and risk of prevalent acute coronary 
syndrome events (adjusted odds ratio 1.38, 95% CI 0.85-2.25, P=0.19) (64), which was 
similar to the non-significant relationship observed in Caucasians between a common 
haplotype carrying the -50T allele and risk of incident CHD events in the ARIC study (HRR 
1.33, 95% CI 0.87-2.02, P=0.184).  Future studies validating these associations across 
ethnicities appear warranted.  
    In CYP2C8, the I264M, I269F, and R139K/K399R polymorphisms possess significantly 
lower metabolic activity in vitro; however, only the R139K/K399R variant has been 
associated with significantly reduced CYP2C8-mediated EET biosynthesis (65, 66) and 
higher risk of prevalent myocardial infarction in a Swedish cohort (67).  The I264M and 
R139K/K399R polymorphisms are more frequent in Caucasians, while the I269F 
polymorphism is more frequent in African-Americans.  Overall, these variants were not 
significantly associated with risk of incident CHD events in the ARIC population.  However, 
in Caucasians, cigarette smoking history significantly modified the association between the 
variant I264M and K399R alleles and CHD incidence, such that smokers carrying either of 
these variant alleles were at the greatest risk of developing CHD.  Smoking did not modify 
the association between the G-50T polymorphism in CYP2J2 and CHD risk, suggesting such 
an interaction may be isolated to CYP2C8-mediated epoxygenase activity.  Cigarette 
smoking is a well-characterized environmental risk factor which substantially impairs 
endothelial function (6).  Cigarette smoking modified the association between each the 
endothelial nitric oxide synthase (eNOS, NOS3) E298D and EPHX2 K55R polymorphisms 
and risk of incident CHD in Caucasians, with the highest risk observed in smokers carrying 
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these variant alleles (135, 139) (Chapters IV and V).  Perhaps presence of established 
underlying endothelial dysfunction, as observed in cigarette smokers, may be necessary for 
genetic variation in CYP2C8, NOS3, and EPHX2 to significantly influence endothelial 
function and cardiovascular disease risk in Caucasians.  Future studies will be required to 
further characterize this potential gene-environment interaction and the mechanistic influence 
of cigarette smoking on vascular CYP2C8 and CYP2J2-mediated EET biosynthesis. 
    Importantly, the relationships between genetic variation in both CYP2J2 and CYP2C8 and 
risk of incident CHD events appear to differ substantially across the Caucasian and African-
American subsets of the ARIC cohort.  In particular, the observed association between the G-
50T polymorphism in CYP2J2 and CHD risk in African-Americans existed in the opposite 
direction of both preclinical findings and previous genetic epidemiological data in Caucasian 
populations, suggesting reduced P450-mediated EET biosynthesis could have protective 
effects against the development of CHD clinical events.  Despite their well-characterized 
vasodilatory and anti-inflammatory effects, preclinical evidence has demonstrated that 
increased EET generation also significantly increases matrix metalloproteinase (MMP) 
enzyme activity in endothelial cells (140). The MMPs are potent stimulators of vascular 
remodeling and atherosclerotic plaque destabilization, and are integrally involved in the 
precipitation of plaque rupture and acute CHD events (141).  Perhaps the role of EET-
mediated regulation of MMP activity is of particular importance in African-Americans, and 
genetic determinants of reduced EET generation, such as the G-50T polymorphism in 
CYP2J2, significantly reduce the risk of experiencing an acute CHD clinical event via its 
downregulation of MMP activity.  Interestingly, a similar ethnic contrast was observed in the 
evaluation of EPHX2 polymorphisms and CHD risk (139) (Chapter V).  The variant K55R 
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allele was associated with significantly higher risk of incident CHD in Caucasians (HRR 
1.45, 95% CI 1.05-2.01, P=0.026); however, a non-significant trend toward lower CHD risk 
was observed in African-Americans (HRR 0.76, 95% CI 0.50-1.16, P=0.208).  Although the 
mechanisms underlying the observed ethnic differences remain unknown, additional genetic 
and/or environmental factors not accounted for in the current analysis could be contributing 
to population differences in the likely complex relationship between the P450 epoxygenase 
pathway, endothelial function and cardiovascular disease risk.  In fact, racial differences in 
endothelial-mediated vasodilatory responses are well-documented, with African-American 
populations typically demonstrating more pronounced endothelial dysfunction (142).  
Mechanistic investigations have implicated enhanced NADPH oxidase-mediated reactive 
oxygen species production and eNOS uncoupling in African-Americans compared to 
Caucasians (143).  However, population-specific differences in P450 epoxygenase-derived 
EET biosynthesis and its effect on endothelial function, vascular inflammation, and MMP 
activity in humans remains to be evaluated. 
    Although the current study evaluated rigorously ascertained incident events, mechanisms 
underlying the observed population-specific associations between CHD risk and genetic 
variation in CYP2J2 and CYP2C8 were not elucidated.  In addition, since haplotypes are 
inferred some uncertainty exists in the CYP2J2 haplotype assigned to each individual.  
However, similar results were observed using the expectation-maximization algorithm and 
after excluding individuals with posterior haplotype probabilities <0.75.  Although 
polymorphisms with known functional relevance and/or haplotype tagging properties were 
specifically selected, and a hypothesis-driven approach in the analysis was utilized, it may be 
difficult to gauge the statistical significance of these findings considering the number of 
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comparisons completed.  Consequently, the FDR was assessed across all completed tests in 
the genotype and haplotype association analysis.  Since all q-values related to the association 
between CHD risk and both the G-50T polymorphism and TGTA haplotype in African-
Americans were conservatively estimated to be 0.051 or less, there is a high level of 
confidence in these findings.  Similarly, the FDR analysis enhanced confidence in the 
CYP2C8-smoking interaction findings.  However, the observations of significant gene-
smoking interactions with the CYP2C8 I264M and K399R polymorphisms in the absence of 
significant main effects suggest these findings should be interpreted with caution. 
    In summary, the current analysis suggests that genetic variation in CYP2J2 and CYP2C8 
may influence the development of CHD in humans; however, these associations appear to be 
different across ethnic groups and in the presence of environmental risk factors such as 
cigarette smoking.  Future studies across multiple populations will undoubtedly be required 
to validate these findings, in addition to molecular and physiological studies evaluating the 
mechanistic relationship between the P450 epoxygenase pathway, endothelial function and 
cardiovascular disease risk. 
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Table 25.  CYP2J2 and CYP2C8 polymorphism frequency by incident CHD case status. 
 Caucasian   African-American 
Genotype* Non-cases CHD cases P-value Non-cases CHD cases P-value 
CYP2J2 
G-50T (CYP2J2*7)   
G/G   501 (88.0%) 648 (88.7%)    189 (70.7%) 167 (79.2%) 
G/T + T/T   65 (12.1%) 83 (11.4%) P=0.719  79 (29.3%) 44 (20.9%) P=0.043 
R49S  
C/C   611 (99.5%) 774 (99.9%)    280 (97.5%) 223 (99.6%) 
C/A + A/A   4 (0.6%)  1 (0.1%)  P=N/A   8 (2.5%) 1 (0.5%) P=N/A 
CYP2C8 
I264M (CYP2C8*4)  
C/C   512 (91.9%) 696 (90.0%)    299 (97.7%) 221 (97.7%) 
C/G + G/G   44 (8.1%)  77 (10.0%) P=0.261  6 (2.3%) 5 (2.2%) P=0.950 
I269F (CYP2C8*2)  
A/A   570 (99.7%) 759 (99.5%)    216 (73.8%) 163 (74.1%) 
A/T + T/T   2 (0.3%)  4 (0.5%) P=N/A  80 (26.2%) 57 (25.9%) P=0.940 
K399R (CYP2C8*3)  
A/A   461 (81.3%) 618 (80.0%)    299 (96.6%) 213 (95.1%) 
A/G + G/G  116 (18.7%) 155 (20.1%) P=0.552  10 (3.4%) 11 (4.9%) P=0.424 
*Genotype data presented as absolute (percent) genotype frequency. Frequencies are weighted according to the sampling fraction.  The R158C 
(CYP2J2*3), I192N (CYP2J2*4), and N404Y (CYP2J2*6) polymorphisms in CYP2J2 were monomorphic (minor allele frequency 0.0), and the 
V113M (rs11572242) variant allele was identified in only one Caucasian non-case. 
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Table 26.  Hazard rate ratio between CYP2J2 and CYP2C8 polymorphisms and risk of incident CHD. 
 Caucasian         African-American 
Polymorphism HRR  95% CI P-value HRR  95% CI P-value 
CYP2J2 
G-50T (CYP2J2*7) G/T + T/T versus G/G  G/T + T/T versus G/G 
Model 1* 1.08 0.75–1.54 P=0.692 0.58 0.37–0.89 P=0.014 
Model 2† 1.15 0.78–1.70 P=0.472 0.58 0.35–0.96 P=0.036 
R49S  C/A + A/A versus C/C  C/A + A/A versus C/C 
Model 1* 0.18 0.02–1.67 P=0.132 0.17 0.02–1.22 P=0.078 
Model 2†  0.23 0.02–2.39 P=0.220 0.26 0.04–1.84 P=0.176 
CYP2C8 
I264M (CYP2C8*4) C/G + G/G versus C/C  C/G + G/G versus C/C 
Model 1* 1.29 0.86–1.92 P=0.222 1.11 0.36–3.42 P=0.858 
Model 2† 0.98 0.58–1.65 P=0.926 1.14 0.36–3.67 P=0.823 
I269F (CYP2C8*2) A/T + T/T versus A/A  A/T + T/T versus A/A 
Model 1* 4.40 0.77–25.1 P=0.095 0.90 0.60–1.37 P=0.634 
Model 2† 5.35 0.93–30.7 P=0.060 0.99 0.62–1.56 P=0.951 
K399R (CYP2C8*3) A/G + G/G versus A/A  A/G + G/G versus A/A 
Model 1* 0.97 0.73–1.28 P=0.816 1.22 0.55–2.73 P=0.627 
Model 2†  0.97 0.70–1.34 P=0.848 1.20 0.51–2.83 P=0.669 
HRR=hazard rate ratio, CI=confidence interval.   
*Adjusted for age, gender, and study center. 
†Adjusted for age, gender, study center, current smoker, diabetes, hypertension, high density lipoprotein cholesterol, total cholesterol, and body 
mass index. 
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Table 27.  CYP2J2 haplotypes and risk of incident CHD. 
 
 Distribution Analysis  Association Analysis 
Haplotype*,† Non-cases CHD cases P-value‡ HRR§ 95% CI P-value 
African-American║ n=260 n=200 
GTCA 56.3% 56.9%  1.14 0.65–2.00 P=0.653 
GGCA 16.1% 13.6%  0.82 0.51–1.31 P=0.402 
GGCG 10.5% 14.9%  1.42 0.83–2.42 P=0.201 
TGTA 12.3% 8.1%  0.51 0.29–0.91 P=0.023 
GGTA 4.8% 6.5% P=0.086 0.93 0.41–2.10 P=0.858 
Caucasian# n=493 n=692 
GT 85.7% 86.2%  1.15 0.53 – 2.47 P=0.728 
GG 8.5% 7.6%  0.96 0.66 – 1.40 P=0.831 
TG 5.8% 6.2% P=0.731 1.33 0.87 – 2.02 P=0.184 
*Bold nucleotides represent haplotype tagging polymorphisms. 
†Estimated copy frequency weighted according to the sampling fraction. 
‡Chi-square P-value for the overall distribution of haplotypes by CHD case status. 
§Adjusted for age, gender, study center, current smoker, diabetes, hypertension, high density lipoprotein cholesterol, total cholesterol, and body 
mass index. 
║Haplotype includes polymorphisms 1, 7, 9, and 10 (Figure 11). 
#Haplotype includes polymorphisms 1 and 7 (Figure 11). 
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Table 28.  CYP2C8 polymorphisms, cigarette smoking and risk of incident CHD in Caucasians. 
Smoking Exposure  CYP2C8 Genotype    Interaction  P-value 
  Wild-type Variant 
I264M  C/C C/G + G/G 
Non-current smokers 
Model 1*  1 (referent) 1.13 (0.70 – 1.83) 
Model 2†  1 (referent) 0.72 (0.36 – 1.45) 
Current Smokers 
Model 1*  1.74 (1.32 – 2.31) 3.18 (1.47 – 6.90)  1.61 (0.64 – 4.09) P=0.314 
Model 2†  1.62 (1.18 – 2.21) 2.76 (1.28 – 5.95)  2.38 (0.84 – 6.78) P=0.104 
K399R  A/A A/G + G/G 
Non-current smokers 
Model 1*  1 (referent) 0.87 (0.62 – 1.20) 
Model 2†  1 (referent) 0.79 (0.53 – 1.16) 
Current Smokers 
Model 1*  1.75 (1.30 – 2.36) 2.73 (1.58 – 4.75)  1.80 (0.91 – 3.54) P=0.089 
Model 2†  1.64 (1.18 – 2.29) 2.63 (1.46 – 4.74)  2.03 (0.97 – 4.25) P=0.060 
Data presented as Hazard Rate Ratio (95% confidence interval). 
*Adjusted for age, gender, and study center 
†Adjusted for age, gender, study center, diabetes, hypertension, high density lipoprotein cholesterol, total cholesterol, and body mass index. 
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Table 29.  CYP2C8 polymorphisms, cigarette smoking and risk of incident CHD in 
Caucasians (2). 
 
Smoking Exposure  CYP2C8 Genotype (I264M or K399R)* 
  Wild-type Variant 
Non-current smokers 
Model 1†  1 (referent) 0.90 (0.67–1.21) 
Model 2‡  1 (referent) 0.73 (0.51–1.05) 
Current Smokers 
Model 1†  1.63 (1.19–2.24) 2.88 (1.80–4.62) 
Model 2‡  1.48 (1.04–2.11) 2.65 (1.61–4.39) 
Data presented as Hazard Rate Ratio (95% confidence interval). 
*Individuals carrying at least one variant allele for either the I264M (C/G+G/G) or K399R (A/G+G/G) 
polymorphism were compared to those wild-type for both (C/C and A/A, respectively). 
†Adjusted for age, gender, and study center (interaction term: HRR 1.97, 95% CI 1.08-3.61, 
P=0.028). 
‡Adjusted for age, gender, study center, diabetes, hypertension, high density lipoprotein cholesterol, 
total cholesterol, and body mass index (interaction term: HRR 2.45, 95% CI 1.26-4.75, P=0.008). 
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Figure Legends 
Figure 11.  Nucleotide positions of the 10 CYP2J2 polymorphisms evaluated are given 
relative to the CYP2J2 transcriptional start site (Genbank accession number AF272142).  
Activity is reported as lower (↓) or unknown (?) relative to wild-type enzyme based on 
previous studies (63, 64).  Cohort random sample minor allele frequencies are presented 
separately by race, and P-values for their comparison are reported. 
 
Figure 12.  Pairwise estimates of linkage disequilibrium (LD) between each CYP2J2 
polymorphism are plotted for (A) Caucasians and (B) African-Americans in the cohort 
random sample using Haploview 3.2.  Each polymorphism is numbered according to its 
position in the CYP2J2 gene as presented in Figure 11.  Black squares indicate complete LD 
(r2=1.0), white squares indicate zero LD (r2=0.0), and increasing intensity of gray indicates 
increasing degrees of LD. 
 
 
  
 
 
147
Figure 11.  Selected CYP2J2 polymorphisms for genotyping. 
 
ATG (start) TAA (stop)
Polymorphism     1           2           3             4        5                6                   7                    8              9            10
dbSNP ID rs890293 rs11572190 rs11572242   rs3738474                      rs2271800             rs4388726    rs11572327 
Nucleotide         -50       170     10798     10860       14558        15054       18778              25687      33291     33497
Position
Major Allele         G          C          G            G       C               T                   T                    A             C             A
Minor Allele         T           A          A A              T               A                   G   T             T             G
Amino Acid          - R49S   V113M         - R158C       I192N                - N404Y         - -
Substitution
Activity ↓ ?           ?             ?              ↓ ↓ ? ↓ ?             ?
Minor allele
frequency
Caucasian       0.064    0.003    0.001      0.066           0  0                0.159                  0           0.069       0.014 
AA                   0.155    0.014       0          0.014     0              0                0.445                  0  0.170       0.106
P-value          <0.001    0.058     N/A      <0.001         N/A  N/A <0.001               N/A        <0.001     <0.001
CYP2J2 Chromosome 1p31.3 – p31.2
Exon 1                                       2                  3       4             5              6                 7       8                              9
 
  
 
 
148
Figure 12.  CYP2J2 linkage disequilibrium plots by race. 
 
Caucasians African-Americans
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CHAPTER VII 
 
DEVELOPMENT AND BASELINE CHARACTERIZATION OF TIE2-CYP2J2 AND 
TIE2-CYP2C8 TRANSGENIC MICE 
 
 
Introduction 
    Arachidonic acid is oxidatively metabolized to epoxyeicosatrienoic acids (EETs) by 
cytochrome P450 epoxygenases from the CYP2J and CYP2C subfamilies (20).  In humans, 
CYP2J2 and CYP2C8 are the primary isoforms responsible for the formation of EETs in 
endothelial cells and cardiomyocytes, where they possess potent biological effects (20, 31, 
144).  Once formed, EETs are rapidly hydrolyzed to their corresponding 
dihydroxyeicosatrienoic acid (DHET) metabolites by soluble epoxide hydrolase (sEH, 
EPHX2) (27-29).  In general, DHETs are much less active than EETs in the cardiovascular 
system (20).  Previous work has demonstrated that EETs have substantial vasodilatory (30, 
31), anti-inflammatory (32), fibrinolytic (33), post-ischemic cardioprotective (34, 35), pro-
angiogenic (36), and vascular smooth muscle cell anti-migratory (37) effects.  Although both 
CYP2J and CYP2C isoforms catalyze EET biosynthesis in endothelial cells, the source of 
EETs may also be a critical factor related to their biological properties. 
    To date, the majority of the research characterizing the cardiovascular effects of CYP2J 
and CYP2C-mediated EET biosynthesis and sEH-mediated EET hydrolysis has been 
conducted in vitro and ex vivo; however, the biological effects of this pathway have not been 
extensively characterized in whole animal models in vivo.  Moreover, evaluation of the 
potential biological differences between CYP2J2 and CYP2C8-mediated EET biosynthesis 
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under controlled conditions remains to be characterized.  Recent work in genetically altered 
mouse models has further demonstrated the important role of this pathway in cardiovascular 
function.  Specifically, transgenic mice with cardiomyocyte-specific overexpression of 
CYP2J2 and enhanced cardiac EET biosynthesis exhibit significant cardioprotection and 
improvement in post-ischemic recovery of left ventricular function (35).  Ephx2-/- mice have 
also demonstrated significantly greater post-ischemic recovery of heart contractile function 
(46) and lower systemic blood pressure (45) compared to wild-type mice.  However, the role 
of P450-mediated EET biosynthesis in the regulation of endothelial function, vascular 
inflammation, atherosclerotic lesion development and other vascular processes has not been 
extensively evaluated in vivo.   
    Importantly, at least 8 CYP2J and 15 CYP2C isoforms in mice have been identified to 
date, which each possess distinct tissue expression and substrate specificity profiles (145-
148).  Moreover, specific pharmacological inducers and inhibitors of each isoform have not 
been developed.  Thus, characterization of the vascular effects of the P450 epoxygenase 
pathway in mice via either 1) pharmacological manipulation of wild-type mice, or 2) 
development of isoform-specific knock-out mice carries substantial limitations.  
Development of transgenic mice overexpressing human CYP2J2 or CYP2C8 in the 
vasculature offers a mechanism to further characterize the in vivo role of both CYP2J2 and 
CYP2C8-derived EETs in vascular function.  The primary aim was to develop transgenic 
mice that exhibit constitutive, vascular endothelial cell-specific expression of either human 
CYP2J2 or CYP2C8 using the Tie2 promoter and Tie2 full enhancer (149), resulting in 
increased vascular and systemic EET concentrations, for use in future phenotying studies. 
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Methods 
Chemicals.  All chemicals were purchased from Sigma (St. Louis, MO), unless otherwise 
noted. 
 
Generation of Tie2-CYP2J2 and Tie2-CYP2C8 Transgenic Mice.  Two separate 
transgenic mouse lines were developed on a C57BL/6 background to specifically overexpress 
either human CYP2J2 (Tie2-CYP2J2) or human CYP2C8 (Tie2-CYP2C8) in vascular 
endothelial cells under control of the Tie2 promoter and Tie2 full enhancer (intron 1) (Figure 
13A) (149).  The human CYP2J2 (Genbank accession number NM_000775) and CYP2C8 
(Genbank accession number NM_000770) cDNA sequences were subcloned downstream of 
the murine Tie2 promoter (2.1-kb) and upstream of the Tie2 full enhancer (10-kb) sequences 
(generously provided by Dr. Tom Sato, University of Texas Southwestern Medical Center, 
Dallas, TX) to drive endothelial cell-specific expression of CYP2J2 and CYP2C8 in mice. 
    The full-length human CYP2J2 (1.8-kb) (144) and CYP2C8 (1.8-kb) (150) cDNA 
sequences were previously subcloned into the pBluescript® SK (+) vector (Stratagene, La 
Jolla, CA) by reverse transcriptase (RT)-PCR, as described.  The CYP2J2 and CYP2C8 
cDNA sequences were PCR amplified with specific forward (CYP2J2: 5’-
CGCTCTAGAACTAGTGGATC-3’; CYP2C8: 5’-AAGAAGAGAAGGCTTCAATGG-3’) 
and reverse (CYP2J2: 5’-TCTTCTTGCTTTCCTTGCCC-3’; CYP2C8: 5’-
AGGTGATAGCAGATCAGCAG-3’) primers, and then subcloned into the intermediate 
pCR®2.1-TOPO vector using the TOPO TA Cloning® system (Invitrogen, Carlsbad, CA) per 
the manufacturer instructions.  Escherichia coli TOP10 One Shot® Competent Cells 
(Invitrogen) were heat transformed with the subcloning reaction, plated out on Luria-Bertani 
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(LB)-agar plates containing kanamycin (50 μg/mL), and incubated at 37°C overnight.  
Kanamycin-resistant colonies were selected and grown in 10 mL of LB-media containing 
kanamycin (50 μg/mL) at 37°C overnight, and plasmid DNA was isolated using the QIAprep 
Spin Miniprep Kit (QIAGEN, Valencia, CA).  The presence and orientation of each cDNA 
was confirmed by direct sequencing using the BigDye Terminator Reaction Ready Mix 
(Applied Biosystems, Foster City, CA) and an ABI Prism 377 DNA sequencer (Applied 
Biosystems). 
    The CYP2J2 and CYP2C8 cDNA sequences were then PCR amplified with specific 
forward primers to add a 5’-HindIII site (CYP2J2: 5’-
GTTACTAAGCTTGGAGCCATGCTCGCGGCG-3; CYP2C8: 5’-
GTCAGCAAGCTTAGAGGCTTCAATGGAACC-3’), and a common reverse primer 
specific for the pCR®2.1-TOPO vector (5’-GAATTGTAATACGACTCACTATAGGGCCA-
3’).  The pCR®2.1-TOPO vector contains a NotI site immediately downstream of the 3’ end 
of each cDNA sequence.  Each cDNA (~1.6-kb) was restriction enzyme digested with 
HindIII and NotI, and subcloned into the HindIII/NotI sites of the pSPTg.T2FpAXK (#52) 
vector (generously provided by Dr. Tom Sato) downstream of the Tie2 promoter (2.1-kb) and 
upstream of the SV40 polyadenylation (polyA) (0.3-kb) and Tie2 core enhancer (1.7-kb) 
sequences (149).  Escherichia coli TOP10 One Shot® Competent Cells (Invitrogen) were 
heat transformed with the subcloning reaction, plated out on LB-agar plates containing 
ampicillin (50 μg/mL), and incubated at 37°C overnight.  Ampicillin-resistant colonies were 
selected and grown in 10 mL of LB-media containing ampicillin (50 μg/mL) at 37°C 
overnight, and plasmid DNA was isolated using the QIAprep Spin Miniprep Kit (QIAGEN).  
The presence and orientation of each cDNA was confirmed by direct sequencing.   
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    However, since the Tie2 core enhancer fragment has been found to drive “patchy” 
endothelial cell transgene expression (data not shown), the Tie2 promoter-CYP2J2/2C8 
cDNA fragment was subcloned upstream of the SV40 polyA (0.3-kb) and Tie2 full enhancer 
(10-kb) sequences in order to obtain constitutive and uniform endothelial expression 
(personal communication with Dr. Tom Sato).  First, the polyA and Tie2 full enhancer were 
excised from the pT2HLacZp1I.7 (#59) vector (generously provided by Dr. Tom Sato) via a 
complete SalI digestion and subsequent partial XbaI digestion, in order to obtain the linear 
polyA-Tie2 full enhancer sequence (10.3-kb) with 5’-XbaI and 3’-SalI restriction enzyme 
sites.  This fragment was then subcloned into the XbaI/SalI sites of the pBluescript® SK (+) 
vector (Stratagene), transformed into Escherichia coli, and ampicillin-resistant colonies were 
selected and grown as described above.  Plasmid DNA was isolated, and the presence and 
orientation of the polyA-Tie2 full enhancer was confirmed by direct sequencing.  Second, the 
Tie2 promoter-CYP2J2/2C8 cDNA (3.7-kb) fragments were PCR amplified with a common 
forward primer to add a 5’-NotI site to the Tie2 promoter (5’-
GTTACTCAGCGGCCGCGTCGACACTAGCTTACTAAGA-3’) and a common reverse 
primer specific for the Tie2 core enhancer (5’-
CTCTATCCCTGCCCTCCTGCCTTGTTTCCC-3’).  The amplified products were then 
restriction enzyme digested with NotI, treated with calf intestinal alkaline phosphatase to 
prevent self-ligation, and subcloned into the NotI sites of the pBluescript® SK (+) vector 
immediately upstream of the polyA-Tie2 full enhancer.  After transformation into 
Escherichia coli, ampicillin-resistant colonies were selected and grown in 250 mL of LB-
media containing ampicillin (50 μg/mL) at 37°C overnight, and plasmid DNA was isolated 
using the QIAGEN plasmid Maxi kit (QIAGEN).  The presence and orientation of the Tie2 
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promoter-CYP2J2/2C8 cDNA-polyA-Tie2 full enhancer (14-kb) constructs were confirmed 
by direct sequencing and restriction enzyme digestion with NotI and SalI. 
    The 14-kb Tie2-CYP2J2 and Tie2-CYP2C8 transgenic constructs were linearized by SalI 
restriction enzyme digestion and agarose gel-purified.  The constructs were then 
microinjected in pronuclei of single cell C57BL6/J mouse embryos and implanted into 
pseudopregnant mice (Dr. Carl Pinkert, University of Rochester Medical Center, Rochester, 
NY).  Hemizygous “founder” pups were identified via PCR genotyping of genomic DNA, as 
described below. 
 
PCR Genotyping.  Genomic DNA isolated from the tails of hemizygous founder mice, and 
their progeny were genotyped by PCR in order to screen for presence of the transgenic 
construct in the mouse genome.  Two primer pair sets were designed for each construct 
(Figure 13A).  The first amplified a fragment extending from the 3’ end of the Tie2 promoter 
into the 5’ end of each cDNA, using a common forward primer (Tie2 promoter: 5’-
GTCCTCATCGCATACCATAC-3’) and a reverse primer specific for each cDNA (CYP2J2: 
5’-CGACAGTGCCCAGTAGGAGA-3’; CYP2C8: 5’-AATAGGAAGAGGAGTGGGGC-
3’), yielding 526 and 567 base pair products for the Tie2-CYP2J2 and Tie2-CYP2C8 
constructs, respectively.  The second amplified a fragment extending from the 3’ end of each 
cDNA into the 5’ end of the Tie2 enhancer, using a forward primer specific for each cDNA 
(CYP2J2: 5’-CATGCCCTACACCAATGCTG-3’; CYP2C8: 5’-
AACTTGGTTGGCACTGTAGC-3’) and a common reverse primer (Tie2 enhancer: 5’-
GGTGCCGCTGGAATCTGAACT-3’), yielding 967 and 1158 base pair products, 
respectively.  Each amplification reaction was carried out in a 50 μL reaction volume with 
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200 ng genomic DNA, 0.4 M each primer, 0.2 mM dNTPs, 10X Taq polymerase reaction 
buffer (5 μL), and 2.5 units of AmpliTaq GoldTM DNA polymerase (Applied Biosystems), 
and was completed as follows: 15 minutes at 94°C (x 1 cycle); 30 seconds at 94°C, 60 
seconds at 66°C (Tie2 promoter primer pair) or 68°C (Tie2 enhancer primer pair), and 90 
seconds at 72°C (x 30 cycles); and 15 minutes at 72°C (x 1 cycle). 
 
Breeding.  Upon identification of hemizygous founder mice, the breeding scheme involved 
crossing Tie2-CYP2J2 and Tie2-CYP2C8 transgenic (Tg) founder mice with C57BL/6 wild 
type mice in order to obtain Tie2-CYP2J2 and Tie2-CYP2C8 heterozygous Tg mice and 
wild-type littermates at an approximate ratio of 1:1.  The progeny generated from this 
breeding scheme were genotyped to identify the founder lines in which the transgene 
demonstrated germline incorporation into the mouse genome.  This breeding scheme was 
subsequently applied to each germline founder line, and the Tie2-CYP2J2 and Tie2-CYP2C8 
Tg and wild-type littermates were evaluated for endothelial expression and function of 
CYP2J2 and CYP2C8, respectively. 
 
Real Time RT-PCR.  Total RNA was isolated from snap frozen lung, aorta, heart, liver and 
kidney using the QIAgen RNeasy Miniprep Kit and RNase-free DNase (QIAGEN) per the 
manufacturer instructions.  Total RNA was reverse transcribed to cDNA using the ABI High 
Capacity cDNA Archive Kit (Applied Biosystems) for 10 minutes at 25°C, and then 120 
minutes at 37°C.  Expression of human CYP2J2 (Hs00356031_m1), human CYP2C8 
(Hs00426387_m1), and murine GAPDH (Mm99999915_g1) were quantified by real time 
quantitative RT-PCR using Taqman® Assays on Demand (Applied Biosystems).  Each 
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amplification reaction was carried out in a 25 μL reaction volume with 100 ng cDNA, 20X 
Assay on Demand Gene Expression kit (1.25 μL), and 2X Taqman Universal PCR Master 
Mix (12.5 μL), and was completed as follows: 2 minutes at 50°C (x 1 cycle); 10 minutes at 
95°C (x 1 cycle); 15 seconds at 95°C, and 60 seconds at 60°C (x 40 cycles).  All reactions 
were performed in triplicate using the ABI Prism 7900HT Sequence Detection System 
(Applied Biosystems).   
    The human CYP2J2 and CYP2C8 assays demonstrated minimal cross-reactivity with 
murine CYP2Js and CYP2Cs, respectively, in various tissues from wild-type animals (data 
not shown).  Thus, these assays provided a sensitive means to detect presence of the human 
CYP2J2 and CYP2C8 transgenes at the transcript level in Tie2-CYP2J2 and Tie2-CYP2C8 
Tg mice, respectively, relative to wild-type littermates.  Murine GAPDH expression was 
used as an endogenous reference to account for potential differences in the amount of total 
RNA and/or differences in amplification efficiency across each reaction.  Expression data 
were calculated using the 2-ΔΔCt method (151), and presented as the relative fold-difference of 
CYP2J2 and CYP2C8 expression in Tie2-CYP2J2 and Tie2-CYP2C8 Tg mice, respectively, 
normalized to GAPDH and compared to wild-type littermates (defined as 1.0 for each 
comparison). 
 
Immunoblotting.  Microsomal fractions from whole lung, heart, liver and kidney, and 12 
pooled aortas for each genotype were also prepared.  Briefly, snap frozen tissue was 
homogenized on ice in a 0.25 M sucrose, 10 mM Tris-Cl buffer (pH=7.5) containing protease 
inhibitors.  Tissue homogenates were centrifuged at 5000 rpm at 4°C for 20 minutes, 12000 
rpm at 4°C for 20 minutes, and 12000 rpm at 4°C for 20 minutes consecutively to remove 
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cellular debris.  Supernatants were then ultracentrifuged at 40,000 rpm (Beckman 70Ti) at 
4°C for 90 minutes.  The microsomal pellets were resuspended in 50-100 μL of a 50 mM 
Tris, 1 mM DTT, 1 mM EDTA buffer (pH=7.5) containing 20% glycerol.  Protein 
concentrations of the microsomal fractions were quantified using the Bio-Rad protein assay 
(Bio-Rad, Hercules, CA), and then stored in aliquots at -80°C.   
    Microsomes (70 μg) were thawed on ice, added to 4X sample buffer containing β-
mercaptoethanol, and boiled for 5 minutes.  Proteins were separated by 10% Novex Tris-
glycine polyacrylamide gels (Invitrogen) and transferred to nitrocellulose membranes 
(Invitrogen) in transfer buffer containing 20% methanol.  The membranes were blocked in 
5% nonfat milk in Tris-buffered saline (TBS) for 2 hours.  For Tie2-CYP2J2 mice, 
membranes were then incubated in a 1:1000 dilution of anti-CYP2J2pep1 antibody in 5% 
nonfat milk at 4°C overnight.  Anti-CYP2J2pep1 is a purified rabbit polyclonal antibody 
raised against a CYP2J2-specific peptide (amino acids 103-117) immunospecific for human 
CYP2J2 (63).  For Tie2-CYP2C8 mice, membranes were incubated in a 1:1000 dilution of 
anti-CYP2C8 antibody (kindly provided by Dr. Joyce Goldstein, NIEHS, Research Triangle 
Park, NC) in 3% nonfat milk at 4°C overnight.  Anti-CYP2C8 is a purified rabbit polyclonal 
antibody raised against recombinant human CYP2C8; although, some cross-reactivity with 
mouse CYP2Cs exists.  Subsequently, the membranes were washed in 0.05% TBS-Tween 20 
four times, and then incubated with a 1:2000 (CYP2J2) or 1:1000 (CYP2C8) dilution of 
horseradish peroxidase conjugated bovine anti-rabbit secondary antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) in 5% nonfat milk at room temperature for 1 hour.  After 
additional washing in 0.05% TBS-Tween 20 and TBS, CYP2J2 and CYP2C8 
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immunoreactive bands were detected by chemiluminescence using the SuperSignal West 
Pico chemiluminescent substrate (Pierce, Rockford, IL). 
 
Immunohistochemistry.  Lung and aorta tissue were also fixed in 10% neutral buffered 
formalin, and embedded in paraffin.  Serial sections (6 μm) were stained 
immunohistochemically for evaluation endothelial cell-specific transgene expression.  
Briefly, sections were deparaffinized in xylene, hydrated through a graded series of ethanols 
to 1X Automation Buffer (Biomeda, Foster City, CA), and then blocked for endogenous 
peroxidase activity with 3% (v/v) hydrogen peroxide.  Enzyme-based antigen retrieval was 
completed using 0.05% pronase (Dako Corporation, Carpinterina, CA) for 5 minutes at room 
temperature prior to 15 minutes of blocking with 10% normal donkey serum in 1.25% 
normal mouse serum (Jackson Immunoresearch Labs, West Grove, PA).  Following blocking 
for endogenous biotin using the Avidin-Biotin blocking kit (Vector Laboratories, 
Burlingame, CA), sections were incubated with primary antibody.  For Tie2-CYP2J2 mice, 
sections were incubated with anti-CYP2J2pep1 or normal rabbit serum (1:50 dilution) for 30 
minutes at room temperature.  For Tie2-CYP2C8 mice, sections were incubated with anti-
CYP2C8 (kindly provided by Dr. Joyce Goldstein) or normal rabbit serum (1:100 dilution) 
for 30 minutes at room temperature.  Sections were rinsed in 1X Automation Buffer, and 
then incubated with a donkey anti-rabbit secondary antibody (Vector Laboratories) (1:500 
dilution) for 30 minutes at room temperature.  Sections were subsequently rinsed in 1X 
Automation Buffer, followed by a 30 minute incubation with a pre-diluted streptavidin 
complex (BioGenex, San Ramon, CA).  Visualization of the antibody complex was 
completed using liquid 3,3’-diaminobenzidine solution (Dako Corporation) for 6 minutes in 
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the dark.  Slides were counterstained with Harris hematoxylin (Harelco, Gibbston, NJ), 
rinsed in 1X Automation Buffer, dehydrated through a graded series of ethanol to xylene 
washes, and coverslipped with Permount (Surgipath, Richmond, IL).  Stained sections were 
observed under a light microscope. 
 
Quantification of Systemic EETs.  Plasma samples were analyzed for epoxy and dihydroxy 
fatty acid metabolites of arachidonic acid and linoleic acid using established HPLC/MS/MS 
methods (128).  In particular, plasma concentrations of each EET regioisomer (5,6-EET, 8,9-
EET, 11,12-EET, 14-15-EET) were quantified.   
    Plasma samples were extracted by solid phase extraction using 60 mg Oasis-HLB SPE 
cartridges (Waters, Milford, MA) (46).  Briefly, the cartridges were preconditioned with 2 
mL of a 0.1% acetic acid-10% methanol solution, and then 10 μL of a 0.17 mg/mL solution 
of EDTA and butylated hydroxytoluene (BHT) in 50% methanol.  Plasma samples (250 μL) 
were added to the column, diluted 1:1 (v/v) with 0.1% acetic acid-10% methanol, and then 
spiked with 30 ng of the following analytical surrogates for the epoxide [10,11-
epoxyheptadecanoic acid (10,11-EpHep)] and diol [10,11-dihydroxynonadecanoic acid 
(10,11-DHN)] metabolites of the P450 epoxygenase pathway.  After sample loading, the 
cartridges were washed with 2 mL of 0.1% acetic acid-10% methanol.  Analytes were then 
eluted in 2 mL of ethyl acetate, and dried under nitrogen.  Oxylipids were separated by 
reverse phase HPLC on a 2x150 mm, 5 μm Luna C18(2) column, (Phenomenex, Torrance, 
CA) and quantified using a MDS Sciex API 3000 triple quadrupole mass spectrometer 
(Applied Biosystems) with negative mode electrospray ionization and multiple reaction 
monitoring, as previously described (128).  The relative response ratios of each analyte were 
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used to calculate concentrations, while correcting for surrogate losses via quantification 
relative to the internal standard. 
 
Data analysis.  All data are expressed as mean ± standard error of the mean (SEM).  Data 
were analyzed by analysis of variance (ANOVA) or Student’s t test, where applicable.  A P-
value <0.05 was considered statistically significant. 
 
Results 
Generation of Tie2-CYP2J2 and Tie2-CYP2C8 Transgenic Mice.  The Tie2-CYP2J2 and 
Tie2-CYP2C8 transgenic constructs were successfully synthesized (Figures 13A and 13B).  
Microinjection of the linearized 14-kb constructs produced three Tie2-CYP2J2 and six Tie2-
CYP2C8 hemizygous founder mice.  Two Tie2-CYP2J2 and four Tie2-CYP2C8 founder 
mice successfully produced progeny for screening for germline transmission of the transgene.  
Genotyping of the progeny from the Tie2-CYP2J2 founder mice demonstrated that both 
founder lines (designated as Lines 1-2) exhibited germline incorporation of the transgene into 
the mouse genome (Figure 14).  Genotyping of the progeny from the Tie2-CYP2C8 founder 
mice demonstrated that three founder lines (designated as Lines 1-3) exhibited germline 
incorporation into the mouse genome (Figure 14).  Subsequent breeding of Tg mice from 
each germline founder line with wild-type C57BL/6 mice demonstrated Mendelian 
inheritance of the transgene, producing Tg (heterozygous) and wild-type pups at an 
approximate ratio of 1:1.  Moreover, male and female Tg and wild-type mice were fertile 
with no impaired reproductive capacity, and expression of the transgene was not lethal and 
did not result in developmental defects. 
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Real Time RT-PCR.  Quantitative real-time RT-PCR demonstrated that Tie2-CYP2J2 and 
Tie2-CYP2C8 Tg mice exhibit significantly higher expression of the human CYP2J2 and 
CYP2C8 transgenes, respectively, at the RNA level in lung and aorta relative to wild-type 
littermates (Figure 15A and 15B).  The Tie2-CYP2J2 and Tie2-CYP2C8 Tg mice also had 
higher RNA expression of their respective transgene in heart, kidney and liver compared to 
wild-type littermates (n=2-3 per genotype, data not shown).   
    The apparent lower degree of transgene expression in lung (Figure 15A, ~100-150-fold) 
compared to aorta (Figure 15B, ~10,000-15,000-fold) in Tg mice relative to wild-type 
littermates was driven by the substantially greater degree of cross-reactivity of the human 
CYP2J2 and CYP2C8 real time RT-PCR assays with murine CYP2Js and CYP2Cs, 
respectively, in wild-type lung compared to wild-type aorta.  These apparent differences were 
not due to lower RNA expression of the human CYP2J2 or CYP2C8 transgenes in Tg lung 
compared to Tg aorta. 
 
Immunoblotting.  Immunoblotting demonstrated that Tie2-CYP2J2 and Tie2-CYP2C8 Tg 
mice exhibit significantly higher expression of the human CYP2J2 and CYP2C8 transgenes, 
respectively, at the protein level in lung microsomes relative to wild-type littermates (Figure 
16A and 16B).  In Tie2-CYP2J2 mice, immunoreactivity with the anti-CYP2J2pep1 antibody 
was observed in Tg mice of germline founder lines 1 and 2, whereas no immunoreactivity 
was observed in wild-type littermates (Figure 16A).  In Tie2-CYP2C8 mice, a substantially 
greater degree of immunoreactivity with the anti-CYP2C8 antibody was observed in Tg mice 
of germline founder lines 1, 2 and 3 compared to wild-type littermates (Figure 16B).  
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Interestingly, no differences in immunoreactivity to either antibody were observed in Tg 
mice compared to wild-type littermates in aorta, heart, liver or kidney microsomes (data not 
shown). 
 
Immunohistochemistry.  Immunohistochemical staining demonstrated that Tie2-CYP2J2 
and Tie2-CYP2C8 Tg mice exhibit endothelial cell-specific expression of the human 
CYP2J2 and CYP2C8 transgenes, respectively (Figures 17-20).  In Tie2-CYP2J2 mice, 
CYP2J2 expression was observed in pulmonary endothelial cells in Tg mice, whereas no 
detectable expression was observed in wild-type littermates or with normal rabbit serum 
(Figure 17A-17D).  This expression profile was observed across multiple vessels located 
throughout the lung, and was consistent with the immunoblotting results observed in lung 
microsomes.  Endothelial cell expression of CYP2J2 was also observed in the aorta of Tg 
mice, with minimal to no detectable expression observed in wild-type littermates (Figure 
18A-18D). 
    In Tie2-CYP2C8 mice, CYP2C8 expression was observed in pulmonary endothelial cells 
in Tg mice, whereas minimal to no detectable expression was observed in wild-type 
littermates (Figure 19A-19B).  No expression was observed with normal rabbit serum (Figure 
19C-19D).  This expression profile was observed across multiple vessels located throughout 
the lung, and was consistent with the immunoblotting results observed in lung microsomes.  
Endothelial cell expression of CYP2C8 was also observed in the aorta of Tg mice, with 
minimal to no detectable expression observed in wild-type littermates (Figure 20A-20D). 
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Quantification of Systemic EETs.  Tie2-CYP2J2 and Tie2-CYP2C8 Tg mice have 
significantly higher plasma concentrations of EETs compared to wild-type littermates 
(Figures 21A and 21B), demonstrating enhanced CYP2J2 and CYP2C8-mediated EET 
biosynthesis, respectively, in mice expressing the transgene.  Tie2-CYP2J2 Tg mice had a 
mean 1.5-fold higher concentration of total EETs in plasma compared to WT littermates 
(P=0.019) (Figure 21A).  Tie2-CYP2C8 Tg mice had a mean 1.6-fold higher concentration of 
total EETs in plasma compared to WT littermates (P=0.039) (Figure 21B). 
 
Discussion 
    Preclinical studies have demonstrated that CYP2J2 and CYP2C8-derived EETs play an 
important role in the regulation of cardiovascular function.  However, the vascular effects of 
this pathway have not been extensively characterized in whole animal models in vivo, 
including the potential biological differences related to CYP2J2 versus CYP2C8-mediated 
EET generation.  In order to further characterize the in vivo role of both CYP2J2 and 
CYP2C8-mediated EET biosynthesis in the regulation of endothelial function, vascular 
inflammation and atherosclerotic lesion development, in vivo models enabling alteration of 
the P450 epoxygenase pathway must be developed.  Due to the complexity of the murine 
CYP2J and CYP2C subfamilies and their relative tissue distribution in mice (145), both 
pharmacological manipulation of wild-type mice and the development of isoform-specific 
knock-out mice carry substantial limitations.  Consequently, transgenic mice which 
overexpress either human CYP2J2 or CYP2C8 in vascular endothelial cells were developed.   
    Transgenic constructs were synthesized via subcloning human CYP2J2 or CYP2C8 cDNA 
downstream of the Tie2 promoter and upstream of the Tie2 full enhancer (intron 1) sequences 
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(149).  Utilizing this approach, Tie2-CYP2J2 and Tie2-CYP2C8 Tg mice which exhibit 
constitutive, vascular endothelial cell-specific expression of CYP2J2 and CYP2C8, 
respectively, were successfully generated.  Transgene expression was observed at the RNA 
level by real time quantitative RT-PCR in various tissues, including lung and aorta.  
Moreover, transgene expression at the protein level was observed by immunoblotting in lung 
microsomal fractions.  Endothelial-specific expression was confirmed by 
immunohistochemical staining of lung and aorta sections.  Overall, Tie2-CYP2J2 and Tie2-
CYP2C8 Tg mice demonstrated significantly enhanced expression of CYP2J2 and CYP2C8, 
respectively, compared to wild-type littermates.  Importantly, Tie2-CYP2J2 and Tie2-
CYP2C8 Tg mice also had significantly higher plasma EET concentrations compared to their 
wild-type littermates, demonstrating enhanced CYP2J2 and CYP2C8-mediated EET 
biosynthesis in mice expressing the transgene. 
    In order to confirm transgene expression at the RNA level, real time quantitative RT-PCR 
and assays which quantified expression of human CYP2J2 and CYP2C8 in mice were 
utilized.  Due to the high degree of homology between human and murine CYP2J and 
CYP2C isoforms, assays with primers that exhibited minimal homology to murine CYP2Js 
and CYP2Cs, respectively, via sequence alignment were specifically selected.  However, 
some cross-reactivity between these “human” assays and murine CYP2J and CYP2C 
isoforms was present, particularly in lung.  Consequently, the relative differences in 
transgene expression observed between Tg mice and wild-type littermates should not be 
compared across tissues.  This is apparent by comparing the substantial differences in relative 
expression (Tg versus wild-type) observed across lung and aorta (Figure 15), which was 
driven by differences in CYP2J2 and CYP2C8 cross-reactivity in the lung and aorta of wild-
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type mice.  Importantly, the data presented in Figure 15 demonstrate that Tie2-CYP2J2 and 
Tie2-CYP2C8 Tg mice have significantly higher RNA expression of CYP2J2 and CYP2C8, 
respectively, compared to wild-type littermates within both lung and aorta. 
    CYP2J2 protein expression was clearly observed in lung microsomes by immunoblotting 
in Tie2-CYP2J2 Tg mice, whereas no detectable expression was observed in wild-type 
littermates.  The anti-CYP2J2pep1 antibody utilized in these analyses is specific for human 
CYP2J2, and does not cross-react with murine CYP2Js (63).  Immunohistochemistry 
demonstrated that CYP2J2 expression in Tg mice was specifically present in endothelial cells 
in both lung and aorta sections.  In Tie2-CYP2C8 Tg mice, CYP2C8 protein expression was 
also observed in lung microsomes by immunoblotting and specifically in endothelial cells in 
both lung and aorta by immunohistochemistry.  Although some CYP2C8 expression was 
observed in wild-type littermates, this was due to cross-reactivity of the anti-CYP2C8 
antibody with certain murine CYP2C isoforms such as CYP2C29 and CYP2C40 (data not 
shown).  Importantly, the level of expression in Tg mice was substantially greater than that 
observed in wild-type mice.  However, overexpression of the CYP2J2 and CYP2C8 
transgenes was not detectable by immunoblotting in aorta, heart, liver or kidney microsomes.  
This was likely due to the greater degree of vascularization in lung tissue, which has been 
reported to have a greater proportion of endothelial cells per given amount of tissue 
compared to other organs in mice (152).  The substantial degree of vascularization in lung 
was evident in the immunohistochemistry analysis, in which multiple vessels throughout the 
lung exhibited clear endothelial cell expression of each transgene.  Moreover, development 
of other endothelial transgenic mice using the Tie2 promoter and Tie2 full enhancer has 
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demonstrated that transgene expression is most readily detectable in lung, particularly when 
expression was evaluated by immunoblotting (152).  
    Since microinjected transgenic constructs are randomly inserted into the mouse genome 
when generating transgenic mice, the goal was to obtain at least two germline founder lines 
which express the transgene for each the Tie2-CYP2J2 and Tie2-CYP2C8 mice.  Evaluation 
of more than one founder line in future phenotyping studies will enhance confidence that any 
observed phenotype is due to the expression and function of the transgene, and not due to 
disruption of the genome region in which the transgene was randomly inserted.  The results 
of the reported baseline studies have confirmed that two Tie2-CYP2J2 and three Tie2-
CYP2C8 distinct founder lines exhibit expression of the transgene in vascular endothelial 
cells. 
    Development of these novel Tie2-CYP2J2 and Tie2-CYP2C8 transgenic mice (in addition 
to existing Ephx2-/- mice) will enable investigators to characterize the effects of altered 
CYP2J2 and CYP2C8-mediated EET biosynthesis (or decreased EET hydrolysis) on 
endothelial function, vascular inflammation and atherosclerotic lesion development in vivo.  
Collectively, phenotypic studies in these genetically altered mouse models will improve the 
mechanistic understanding of the role of CYP2J2, CYP2C8 and sEH in these processes in 
vivo, which have proven vital to the development and progression of cardiovascular disease.  
Moreover, future phenotypic studies in these mouse models will help to provide a 
mechanistic rationale for the observed associations at the population level between genetic 
variation in CYP2J2, CYP2C8 and EPHX2 and cardiovascular disease susceptibility in 
humans. 
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Figure Legends 
Figure 13.  (A) Diagram of the linear 14-kb Tie2-CYP2J2 and Tie2-CYP2C8 transgenic 
constructs.  (B) Restriction enzyme digested Tie2-CYP2J2 and Tie2-CYP2C8 transgenic 
constructs run on an ethidium bromide-stained, 0.8% agarose gel and visualized under 
ultraviolet light.  NotI digestion produced the linearized Tie2 promoter-CYP2J2/2C8 cDNA 
(~3.7-kb) and pBS vector-polyA-Tie2 full enhancer (~13.3-kb) fragments.  SalI digestion 
produced the linearized Tie2 promoter-CYP2J2/2C8 cDNA-Tie2 full enhancer (~14-kb) and 
pBS vector (~3-kb) fragments.  NotI and SalI digestion produced the linearized Tie2 
promoter-CYP2J2/2C8 cDNA (~3.7-kb), polyA-Tie2 full enhancer (~10.3-kb), and pBS 
vector (~3-kb) fragments. 
 
Figure 14.  PCR genotyping of transgenic (Tg) and wild-type (WT) littermate mice from the 
(A) two Tie2-CYP2J2 and (B) three Tie2-CYP2C8 germline founder lines, and 0.1 pg (0.5 
gene copies per cell) of each transgenic construct as a positive control.  Both PCR reactions 
were run on an ethidium bromide-stained, 1% agarose gel and visualized under ultraviolet 
light.  The Tg mice demonstrate bands at approximately 600 and 1000 base pairs for PCR 
reaction #1 and #2, respectively, while WT mice demonstrate no detectable bands. 
 
Figure 15.  Mean±SEM expression of human CYP2J2 and CYP2C8 RNA in Tie2-CYP2J2 
and Tie2-CYP2C8 transgenic (Tg) mice and wild-type (WT) littermates in (A) lung and (B) 
aorta (n=4-7 per genotype group).  CYP2J2 and CYP2C8 RNA expression was quantified by 
real-time quantitative RT-PCR, and normalized to murine GAPDH expression.  Data are 
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presented as relative expression compared to WT littermates (reference 1.0) using the 2-ΔΔCt 
method (151).  *P<0.05 versus wild-type. 
 
Figure 16.  Representative immunoblot of lung microsomal fractions (70 μg per lane) in (A) 
Tie2-CYP2J2 and (B) Tie2-CYP2C8 transgenic (Tg) mice and wild-type (WT) littermates, 
using the anti-CYP2J2pep1 and anti-CYP2C8 antibodies, respectively.  Lane 1 includes 
recombinant CYP2J2 or CYP2C8 (0.5 pg), respectively, as a positive control.  Subsequent 
lanes include Tg and WT littermate pairs from each germline founder line. 
 
Figure 17.  Immunohistochemical staining of a representative lung section in (A, B) Tie2-
CYP2J2 transgenic (Tg) mice and (C, D) wild-type (WT) littermates.  Staining was 
completed using the anti-CYP2J2pep1 antibody (A, C) or normal rabbit serum negative 
control (B, D).  Arrows indicate the presence and absence of endothelial cell staining in Tg 
and WT mice. 
 
Figure 18.  Immunohistochemical staining of a representative aorta section in (A, B) Tie2-
CYP2J2 transgenic (Tg) mice and (C, D) wild-type (WT) littermates.  Staining was 
completed using the anti-CYP2J2pep1 antibody (A, C) or normal rabbit serum negative 
control (B, D).  Arrows indicate the presence and absence of endothelial cell staining in Tg 
and WT mice.  
 
Figure 19.  Immunohistochemical staining of a representative lung section in (A, B) Tie2-
CYP2C8 transgenic (Tg) mice and (C, D) wild-type (WT) littermates.  Staining was 
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completed using the anti-CYP2C8 antibody (A, C) or normal rabbit serum negative control 
(B, D).  Arrows indicate the presence and absence of endothelial cell staining in Tg and WT 
mice. 
 
Figure 20.  Immunohistochemical staining of a representative aorta section in (A, B) Tie2-
CYP2C8 transgenic (Tg) mice and (C, D) wild-type (WT) littermates.  Staining was 
completed using the anti-CYP2C8 antibody (A, C) or normal rabbit serum negative control 
(B, D).  Arrows indicate the presence and absence of endothelial cell staining in Tg and WT 
mice.  
 
Figure 21.  Mean±SEM plasma EET concentrations in (A) Tie2-CYP2J2 and (B) Tie2-
CYP2C8 transgenic (Tg) mice and wild-type (WT) littermates (n=5-6 per genotype group), 
quantified by HPLC/MS/MS.  Concentrations of the four individual EET regioisomers (5,6-
EET, 8,9-EET, 11,12-EET, 14,15-EET) and their sum total (Sum EETs) are presented in 
ng/mL.  *P<0.05 and ^P<0.10 versus WT. 
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Figure 13.  Tie2-CYP2J2 and Tie2-CYP2C8 transgenic constructs. 
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Figure 14.  Genotyping Tie2-CYP2J2 and Tie2-CYP2C8 mice. 
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Figure 15.  CYP2J2 and CYP2C8 RNA expression by real time quantitative RT-PCR. 
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Figure 16.  CYP2J2 and CYP2C8 protein expression in lung microsomes by 
immunoblotting. 
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Figure 17.  Endothelial cell expression of CYP2J2 in lung by immunohistochemical 
staining in Tie2-CYP2J2 mice. 
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Figure 18.  Endothelial cell expression of CYP2J2 in aorta by immunohistochemical 
staining in Tie2-CYP2J2 mice. 
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Figure 19.  Endothelial cell expression of CYP2C8 in lung by immunohistochemical 
staining in Tie2-CYP2C8 mice. 
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Figure 20.  Endothelial cell expression of CYP2C8 in aorta by immunohistochemical 
staining in Tie2-CYP2C8 mice. 
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Figure 21.  Plasma EETs in Tie2-CYP2J2 and Tie2-CYP2C8 mice. 
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CHAPTER VIII 
DISCUSSION AND PERSPECTIVE 
 
    Endothelial dysfunction plays an integral role in the pathogenesis and progression of 
ischemic cardiovascular disease in humans (2).  Risk factors including cigarette smoking 
significantly contribute to endothelial dysfunction (6), which is independently associated 
with an increased risk of myocardial infarction and ischemic stroke events in patients (10, 
11).  The development of endothelial dysfunction has been primarily ascribed to functional 
impairments in nitric oxide biosynthesis and activity; however, arachidonic acid metabolism 
by the cyclooxygenase (COX) and P450 epoxygenase pathways also appear to be important 
regulators of endothelial function (Figures 1 and 2).  Consequently, genetic variation in these 
pathways may be important modifiers of cardiovascular disease risk in humans.  Numerous 
polymorphisms in the genes encoding endothelial nitric oxide synthase (NOS3), COX-1 
(PTGS1), COX-2 (PTGS2), CYP2J2 (CYP2J2), CYP2C8 (CYP2C8) and soluble epoxide 
hydrolase (EPHX2) have been recently discovered.  However, their contribution to 
cardiovascular disease susceptibility remains poorly understood.  The collective objective of 
the studies outlined in this doctoral dissertation was to determine if genetic variation in these 
established (NOS3, PTGS1 and PTGS2) and recently characterized (CYP2J2, CYP2C8 and 
EPHX2) pathways are significantly associated with cardiovascular disease risk. 
    The identification and functional characterization of genetic polymorphisms in PTGS2 and 
NOS3 have been reported (53, 54, 58, 59); however, characterization of PTGS1 
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polymorphisms and their influence on COX-1-mediated arachidonic acid metabolism has not 
been extensively investigated.  Consequently, the first aim was to determine if 
nonsynonymous polymorphisms in PTGS1 significantly alter COX-1 metabolic activity in 
vitro, in order to guide the design and interpretation of epidemiological studies evaluating 
associations between PTGS1 variants and cardiovascular disease risk.  The relatively 
infrequent R53H, R78W, K185T, G230S and L237M variants demonstrated significantly 
lower metabolic activity (35-60%) relative to wild-type COX-1, suggesting individuals 
carrying these variant alleles may have significantly altered prostaglandin biosynthesis in 
vivo (Chapter II).  No significant differences in enzymatic activity were detected with the 
R8W and P17L variants, which are prevalent at higher frequencies in European/Caucasian 
and African populations. 
    Subsequently, the second aim was to determine if genetic variation in PTGS1, PTGS2 
and/or NOS3 is significantly associated with the development of incident coronary heart 
disease (CHD) or ischemic stroke clinical events in individuals enrolled in the 
Atherosclerosis Risk in Communities (ARIC) study.  Genetic variation in PTGS1 and PTGS2 
was associated with risk of incident ischemic cardiovascular disease events (Chapter III).  
Interestingly, these associations appeared most prominent for risk of ischemic stroke events, 
consistent with various preclinical studies implicating both COX-1 and COX-2-mediated 
arachidonic acid metabolism in ischemic brain injury (113-118).  Specifically, the variant -
1006A allele in PTGS1 was associated with higher risk of ischemic stroke events in 
Caucasians.  Although the functional relevance of this polymorphism has not been 
characterized, evaluation of linkage disequilibrium in PTGS1 demonstrated that seven 
polymorphisms in the 5’UTR (T-1749C, G-1598A, A-1202G, A-1201G, G-1006A, A-918G 
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and A-707G) were present on the same haplotype in individuals of either 
European/Caucasian or African descent (Chapter II).  Consequently, the G-1006A 
polymorphism may not be the functionally relevant locus driving the observed association 
with ischemic stroke risk in the ARIC study.  Future studies evaluating the functional 
relevance of these variants appear necessary.  Moreover, the rare G230S variant allele in 
PTGS1 was associated with significantly higher risk of both ischemic stroke and CHD events 
in African-Americans.  This variant was associated with reduced COX-1 metabolic activity 
in vitro (Chapter II).  Moreover, protein modeling suggested that this variant may disrupt the 
active conformation of COX-1, leading to the observed reductions in metabolic activity.  
Future studies validating this association and confirming the functional relevance of the 
G230S variant allele in vivo are necessary. 
    Previous studies have demonstrated that the G-765C polymorphism in the proximal 
promoter of PTGS2 disrupts a Sp1 binding site and is associated with significantly lower 
PTGS2 transcription (59).  Due to its anti-inflammatory effects, the variant -765C allele was 
associated with significantly lower risk of prevalent myocardial infarction or ischemic stroke 
events in a high-risk Italian population (60).  In contrast, the variant -765C allele was 
associated with higher risk of incident ischemic stroke events in African-Americans, but not 
Caucasians, in the ARIC study (Chapter III).  Moreover, although the G-765C polymorphism 
in PTGS2 was not significantly associated with CHD incidence, aspirin utilization appeared 
to modify this relationship in Caucasians.  The variant -765C allele appeared to be associated 
with higher risk of CHD in aspirin non-users and lower risk in those receiving aspirin 
therapy, suggesting presence of a potential gene-drug interaction.  This observation is 
consistent with the hypothesis that concomitant aspirin utilization may mitigate the 
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cardiovascular hazard associated with selective COX-2 inhibition via restoration of 
prostacyclin-thromboxane A2 balance (24), and could explain the contrasting results 
observed by Cipollone et al. (60).  However, due to the power limitations and lack of data 
elucidating the underlying mechanism, this interaction must be interpreted with caution and 
confirmed in an independent population. 
    Numerous studies evaluating potential associations between NOS3 polymorphisms and 
cardiovascular disease risk have reported inconsistent results (55).  However, few have 
considered the potential influence of cigarette smoking despite their potential synergistic 
contribution to worsening endothelial function in vivo (56, 57).  No statistically significant 
associations between the T-786C or E298D polymorphisms and risk of either incident CHD 
or ischemic stroke events in Caucasians and African-Americans enrolled in the ARIC study  
were observed (Chapter IV).  Importantly, a potential interaction between genetic variation in 
NOS3, cigarette smoking history, and risk of incident CHD and ischemic stroke events was 
identified in these individuals.  Specifically, the T-786C or E298D polymorphism variant 
alleles appeared to be associated with significantly higher risk of developing CHD or 
ischemic stroke in cigarette smokers, whereas no associations were observed in the absence 
of the smoking exposure.  This interaction was particularly evident with the E298D 
polymorphism and CHD risk in Caucasians, and the T-786C polymorphism and ischemic 
stroke risk in African-Americans.  These data 1) suggest that presence of established 
underlying endothelial dysfunction, as observed in cigarette smokers, may be necessary for 
these variant alleles to significantly attenuate endothelial function and predispose patients to 
increased risk of cardiovascular events, and 2) demonstrate the potential existence of a 
complex interplay between NOS3 polymorphisms, cigarette smoking and cardiovascular 
  
 
 
183
disease risk (i.e., a gene-environment interaction).  Similar interactions with cigarette 
smoking were not observed with polymorphisms in PTGS1 and PTGS2.  Collectively, the 
observed associations between genetic variation in PTGS1, PTGS2 and NOS3 and risk of 
incident cardiovascular disease events in the ARIC study further implicate these established 
pathways in the development of ischemic cardiovascular disease in humans.   
    Since the identification and functional characterization of genetic polymorphisms in 
EPHX2, CYP2J2 and CYP2C8 have been previously reported (63-66, 68, 69), the third aim 
was to determine if genetic variation in EPHX2, CYP2J2 and/or CYP2C8 is significantly 
associated with the development of incident CHD clinical events in individuals enrolled in 
the ARIC study.  Although potential associations between genetic variants in these pathways 
and ischemic stroke risk are also of interest (133), the results of those analyses were not 
included in this doctoral dissertation.  First, a significant association between genetic 
variation in EPHX2 and risk of incident CHD events in Caucasians was observed, 
implicating EPHX2 as a potential cardiovascular disease-susceptibility gene (Chapter V).  
Specifically, presence of the K55R polymorphism variant allele was associated with 
significantly higher risk of CHD incidence in Caucasians.  Consistent with previous in vitro 
findings (69), higher soluble epoxide hydrolase activity in Caucasians carrying the K55R 
variant allele was also observed in vivo.  Based on the role of EPHX2 in endothelial function, 
it was hypothesized that higher epoxide hydrolase activity would be associated with higher 
risk of acute coronary events.  A significant association between the K55R variant allele and 
higher risk of incident CHD in Caucasians are consistent with this hypothesis.  Variation in 
EPHX2 at the haplotype level was also associated with risk of CHD in Caucasians, 
suggesting multiple variants within or near EPHX2 may contribute to CHD risk.  Genetic 
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variation in EPHX2 was not associated with risk of incident CHD in African-Americans.  
Interestingly, no apparent influence of K55R genotype on soluble epoxide hydrolase activity 
was observed in African-Americans in vivo. 
    Second, a significant association between the variant -50T allele in CYP2J2 and lower risk 
of incident CHD events was observed in African-Americans, whereas no significant 
association was observed in Caucasians (Chapter VI).  The G-50T polymorphism disrupts a 
Sp1 transcription factor binding site in the proximal promoter and leads to reduced CYP2J2 
transcription in vitro (64).  Importantly, the variant -50T allele was associated with higher 
risk of prevalent angiographically-documented CHD in a recently characterized German 
population (64).  However, the findings in African-Americans exist in contrast to these 
previous findings and current hypotheses related to the beneficial effects of EETs in the 
vasculature.  Interestingly, a similar ethnic contrast was observed in the evaluation of both 
NOS3 and EPHX2 polymorphisms and CHD risk (135, 139) (Chapters IV and V).  
Specifically, the E298D variant allele in NOS3 and the K55R variant allele in EPHX2, which 
were hypothesized to be associated with higher CHD risk, were each associated with a non-
significant trend toward lower CHD risk in African-Americans.  Additional genetic and/or 
environmental factors not accounted for in this analysis could be contributing to population 
differences in the likely complex relationship between these pathways, endothelial function 
and cardiovascular disease risk, particularly since ethnic differences in endothelial function 
are well-documented (142).  Future studies further characterizing the mechanisms underlying 
these contrasting observations at the population level appear necessary. 
    Third, the I264M, I269F and K399R polymorphisms in CYP2C8, which have been 
associated with reduced CYP2C8 metabolic activity in vitro (65, 66), were not associated 
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with risk of CHD in either ethnic group (Chapter VI).  However, in Caucasians, cigarette 
smokers carrying either the variant I264M or K399R allele were at significantly higher risk of 
incident CHD, whereas no significant association with disease risk was observed in the 
absence of the smoking exposure.  Similar interactions were observed with each the E298D 
polymorphism in NOS3 and K55R polymorphism in EPHX2 and risk of incident CHD in 
Caucasians, with the highest risk observed in smokers carrying these variant alleles (135, 
139) (Chapters IV and V).  However, a similar interaction was not observed with the G-50T 
polymorphism in CYP2J2 (Chapter VI), demonstrating potential biological differences 
related to CYP2J2 versus CYP2C8-mediated epoxyeicosatrienoic acid (EET) biosynthesis in 
humans.  Perhaps presence of established underlying endothelial dysfunction, as observed in 
cigarette smokers, may be necessary for genetic variation in CYP2C8, NOS3 and EPHX2 to 
significantly influence endothelial function and cardiovascular disease risk in Caucasians.  
Interestingly, similar interactions with CHD risk were not observed in African-Americans in 
the ARIC study, further demonstrating potential differences in the contribution of these 
endothelial pathways to cardiovascular disease risk across populations.  Future mechanistic 
studies will be required to further characterize this potential gene-environment interaction.  
Collectively, the observed associations between genetic variation in EPHX2, CYP2J2 and 
CYP2C8 and risk of incident CHD events in the ARIC study demonstrate the potential 
importance of the P450 epoxygenase pathway in the pathogenesis of ischemic cardiovascular 
disease in humans.   
    Importantly, the mechanisms underlying the role of P450-mediated EET biosynthesis in 
the regulation of endothelial function, vascular inflammation and atherosclerotic lesion 
development in vivo remain poorly understood.  Moreover, evaluation of the potential 
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biological differences between CYP2J2 and CYP2C8-mediated EET biosynthesis under 
controlled conditions has not been extensively characterized.  Due to the complexity of the 
murine CYP2J and CYP2C subfamilies and their relative tissue distribution in mice (145), 
both pharmacological manipulation of wild-type mice and the development of isoform-
specific knock-out mice carry substantial limitations.  Thus, the fourth aim was to develop 
transgenic mice that exhibit vascular endothelial cell-specific overexpression of either human 
CYP2J2 or CYP2C8 for use in future phenotyping studies.  Using the murine Tie2 promoter 
and Tie2 full enhancer fragments (149), Tie2-CYP2J2 and Tie2-CYP2C8 transgenic mice 
which exhibit constitutive, vascular endothelial cell-specific expression of CYP2J2 and 
CYP2C8, respectively, were successfully generated (Chapter VII).  Transgene expression 
was observed at the RNA level by real time quantitative RT-PCR and the protein level by 
both immunoblotting and immunohistochemistry.  Importantly, Tie2-CYP2J2 and Tie2-
CYP2C8 transgenic mice also had significantly higher plasma EET concentrations compared 
to their wild-type littermates, demonstrating enhanced CYP2J2 and CYP2C8-mediated EET 
biosynthesis in mice expressing the transgene.   
    Development of these Tie2-CYP2J2 and Tie2-CYP2C8 transgenic mice (in addition to 
existing Ephx2-/- mice) will enable further characterization of the effects of altered CYP2J2 
and CYP2C8-mediated EET biosynthesis (or decreased EET hydrolysis) on endothelial 
function, vascular inflammation and atherosclerotic lesion development in vivo in order to 
improve the mechanistic understanding of the role of CYP2J2, CYP2C8 and soluble epoxide 
hydrolase in these processes, which have proven vital to the development and progression of 
cardiovascular disease in humans.  Moreover, future phenotypic studies in these mouse 
models will help to provide a mechanistic rationale for the observed associations at the 
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population level between genetic variation in CYP2J2, CYP2C8 and EPHX2 and 
cardiovascular disease susceptibility in the ARIC study.  Collectively, the results of these 
current and future translational investigations will enable investigators to more extensively 
determine if modulation of the P450 epoxygenase pathway using genetic and/or 
pharmacological approaches represents a useful therapeutic strategy for the prevention and/or 
treatment of cardiovascular disease in patients. 
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APPENDIX I 
 
The reality of pharmacogenomics: optimizing therapeutic decision making (editorial) 
 
Lee CR and Zeldin DC. The reality of pharmacogenomics: optimizing therapeutic decision  
making. Environ Health Perpesct. 2003;111:A566-67. 
 
 
    It is now well established that significant interindividual variability exists in the 
disposition and pharmacological effects of certain medications.  Influences such as 
environmental exposures, nutritional status, comorbidities, severity of disease, and 
concomitant medications have all been associated with heterogeneity in drug responses.  In 
addition, the profound contribution of genetics has been appreciated for some time and is 
receiving greater emphasis in recent years. 
    Approximately 1.8 million single nucleotide polymorphisms (SNPs) in the human genome 
have been identified by the SNP Consortium (http://snp.cshl.org), a collaboration of several 
companies and institutions.  Numerous SNPs in genes encoding various drug metabolizing 
enzymes, drug transporters, and drug targets (e.g., receptors, enzymes involved in 
metabolism of endogenous substrates, etc.) have been shown to be associated with 
interindividual differences in the pharmacokinetics and pharmacodynamics of certain 
medications (153).  Many in vitro and in vivo “pharmacogenetic” studies performed to date 
have evaluated the association between SNPs in a single gene and a specific drug’s 
pharmacological properties.  Preclinical and clinical investigations have evaluated genetic 
determinants of drug metabolism, and demonstrated that polymorphisms in genes encoding 
drug metabolizing enzymes can markedly influence a drug’s pharmacokinetics, change its 
efficacy and/or toxicity profile, and necessitate dosing changes in certain individuals.  More 
recent studies have begun to evaluate the association between drug target polymorphisms and 
pharmacodynamic effects.   
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    Due to the complex interplay between the pharmacological effects of drugs and disease 
pathophysiology, inherited differences in drug responses are most likely polygenic, rather 
than monogenic, in nature (153).  Hence, “pharmacogenomics” has emerged as a new field of 
study which attempts to identify and elucidate the contribution of multiple, interrelated genes 
to the efficacy and toxicity of certain medications.  Ultimately, the goal of 
pharmacogenomics is to account for and minimize interindividual variability in drug 
response, thus allowing clinicians to enhance the efficacy and minimize the toxicities 
associated with drug therapy.  By considering the role of multiple genes, pharmacogenomics 
seeks to divide a given patient population into smaller, less variable, more predictable 
subgroups, which enables clinicians to individualize drug therapy (i.e., to administer the right 
drug, at the right dose, to the right patient) (154).   
    For example, it has been increasingly recognized that SNPs can impact the activity of drug 
transporters and drug metabolizing enzymes, and substantially influence an individual’s 
systemic exposure to certain agents.  Genetic variation in a given drug’s target can also 
contribute to its pharmacological effect.  Moreover, variation in a disease-modifying gene 
can impact the rate and/or extent of disease progression, ultimately influencing the 
therapeutic effect of a drug.  Therefore, simultaneously characterizing genetic determinants 
of drug exposure, drug effect, and disease progression will likely improve the ability to 
predict a drug’s overall effect in an individual patient.  In other words, genomic data will 
divide a given patient population into subpopulations of “responders” and “nonresponders,” 
allowing prescribers to better predict the potential therapeutic effect of a drug.  
Pharmacogenomic testing may also lead to more predictable toxicity profiling for individual 
patients, thus prospectively identifying and eventually minimizing idiosyncratic or 
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unexpected drug reactions.  Such testing might also offer new insight into the mechanisms of 
such toxicities.  Overall, this approach has the potential to account for variability in drug 
response, maximize beneficial and minimize untoward drug effects, optimize therapeutic 
decision making, and ultimately improve clinical outcomes. 
    In order to facilitate utilization of pharmacogenomic-guided therapy, genomic diagnostics 
are also being developed at a rapid rate.  Microarray and “chip” technologies have enabled 
the simultaneous evaluation of multiple SNPs in multiple genes.  We envision that a variety 
of diagnostic pharmacogenomic “packages” will be developed for certain patient populations 
at risk for or recently diagnosed with specific diseases (e.g. breast cancer, cardiovascular 
disease, asthma).  These packages will provide critical genomic information that will help 
predict disease susceptibility, the likelihood of disease progression, drug efficacy, and drug 
toxicity.  Together with other clinical information (e.g. breast cancer stage, lipid profile, lung 
function studies), the genomic data will substantially improve a clinician’s ability to identify 
subpopulations of patients most likely to respond to specific preventive or therapeutic 
strategies, as well as identify specific drugs and dosing regimens that can be used in 
individual patients to optimize outcomes.  In addition, pharmacogenomic concepts will be 
applied to the development of novel therapeutic agents by the pharmaceutical industry, which 
has already reported substantial increases in the use of pharmacogenomic testing in clinical 
trials (154).  This approach will eventually yield medicines which directly modify genetically 
validated targets. 
    The future of pharmacogenomics is quickly becoming a reality.  Indeed, preclinical and 
clinical investigations are already evaluating the contribution of multiple genes to the 
observed variability in drug response.  However, unraveling the full potential of 
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pharmacogenomics will require the translation of discoveries from basic to clinical science, 
and eventually the application of these findings to patient care (i.e. from bench to bedside).  
Current approaches to pharmacogenomic research involve 1) SNP discovery, 2) in vitro 
studies which characterize the functional and mechanistic significance of known SNPs, and 
3) in vivo studies in healthy volunteers or patients which investigate the clinical relevance of 
known SNPs.  Clinical evaluations have included prospective clinical pharmacology studies 
with pharmacokinetic and pharmacodynamic endpoints, and retrospective outcome analyses 
of genetic subgroups from randomized, controlled clinical trials.  Future prospective clinical 
trials that evaluate the safety and efficacy of pharmacogenomic-guided drug therapy will be 
necessary to determine if these strategies can actually improve patient outcomes.  
Furthermore, detailed economic analyses, which evaluate the cost-effectiveness of such 
approaches, will be crucial before widespread implementation into clinical practice can 
occur. 
    Understanding the relevance of genomic information will be crucial to close the gap 
between basic science and patient care.  Moreover, open dialogue regarding the numerous 
ethical issues surrounding genomic testing, such as the protection of privacy as it relates to 
insurance and employment, will need to occur as this field moves towards clinical 
application.  Ultimately, the factors essential to the appropriate utilization of 
pharmacogenomic data include collaboration between basic researchers and clinicians, 
development of a multidisciplinary approach to patient care, and education of clinician-
scientists in pharmacogenomic medicine.  Perhaps the biggest challenge to effective 
utilization of pharmacogenomic strategies in clinical practice will involve educating the 
public on its availability, uses, and limitations.   
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    The recent sequencing of the human genome has facilitated identification of polymorphic 
variants in genes involved in the disposition and pharmacological action of numerous drugs.  
The rapidly growing field of pharmacogenomics offers enormous potential to improve the 
way clinicians utilize medications.  Pharmacogenomics will ultimately serve to minimize 
variability in the way patients respond to medications, enabling clinicians to individualize 
therapy and improve overall clinical outcome. 
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APPENDIX II 
 
Methods used for genotyping PTGS1, PTGS2, NOS3, EPHX2, CYP2J2 and CYP2C8 polymorphisms by MALDI-TOF 
 
 
Polymorphism Amplification Primers Extension Primer Alleles 
PTGS1 
G-1006A F: 5’-ACGTTGGATGCCAGGAGCCAGCACAAGAAC-3’ F: 5’-AGCACAAGAACCTCTGA-3’ G 
 R: 5’-ACGTTGGATGATCTCCCTCAGTTTCCCCAG-3’  A 
R8W (rs1236913) F: 5’-ACGTTGGATGCTGGGTCCGCGAGCAGGA-3’ R: 5’-GAGCAGGAACAGCAAGAACC-3’ C 
 R: 5’-ACGTTGGATGTCATCTCTCTCCTCTGCAGG-3’  T 
P17L (rs3842787) F: 5’-ACGTTGGATGTCATCTCTCTCCTCTGCAGG-3’ F: 5’-GTTCCTGCTCCTGCTCC-3’ C 
 R: 5’-ACGTTGGATGCTGGGTCCGCGAGCAGGA-3’  T 
R53H (rs3842789) F: 5’-ACGTTGGATGAGGGCATCTGTGTCCGCTTC-3’ F: 5’-CCGCTTCGGCCTTGACC-3’ G 
 R: 5’-ACGTTGGATGAGCTCACGGATGGTGCAGTT-3’  A 
G230S F: 5’-ACGTTGGATGGTATGTCATCGACAGTGGGC-3’ F: 5’-CTCTGTCCACAGGTAGACCTC-3’ G 
 R: 5’-ACGTTGGATGCGCTCCAGATTGTCTCCATA-3’  A 
L237M (rs5789) F: 5’-ACGTTGGATGTCTGTCCACAGGTAGACCTC-3’ F: 5’-CCACATTTATGGAGACAAT-3’ C 
 R: 5’-ACGTTGGATGTTCCCATCCTTAAAGAGCCG-3’  A 
PTGS2 
V511A (rs5273) F: 5’-ACGTTGGATGCTTCTGGTAGAAAAGCCTCG-3’ F: 5’-GTGAAACCATGGTAGAAG-3’ T 
 R: 5’-ACGTTGGATGCCATAAGTCCTTTCAAGGAG-3’  C 
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Polymorphism Amplification Primers Extension Primer Alleles 
NOS3 
T-786C (rs2070744) F: 5’-ACGTTGGATGACTGTAGTTTCCCTAGTCCC-3’ F: 5’-CATCAAGCTCTTCCCTGGC-3’ T 
 R: 5’-ACGTTGGATGAGGTCAGCAGAGAGACTAGG-3’   C 
E298D (rs1799983) F: 5'-ACGTTGGATGACCTCAAGGACCAGCTCGG-3' F: 5’-GCTGCAGGCCCCAGATGA-3’ G 
 R: 5'-ACGTTGGATGAAACGGTCGCTTCGACGTGC-3’   T 
EPHX2 
K55R F: 5’-ACGTTGGATGATGATGCTTTCCAGAAAGGG-3’ F: 5’-CACTACCCGGCTTATGA-3’ A 
 R: 5’- ACGTTGGATGTCACCTGGGAAAGTGTGATC-3’   G 
R103C (rs17057255) F: 5’-ACGTTGGATGAGGCGATTTCAGCCAGAAAG-3’ F: 5’-CAGCCAGAAAGATCAAC-3’ C 
 R: 5’-ACGTTGGATGGCCAGTATCAGATCCTTACC-3’    T 
C154Y F: 5’-ACGTTGGATGAGCTGATGTGTGAGCTGAAG-3’ F: 5’-TGACTTCCTGATAGAGTCGT-3’ G 
 R: 5’-ACGTTGGATGGTTCAGGTTTGACCATTCCC-3’    A 
G14029C F: 5’-ACGTTGGATGCCCTGGTTGCAATATCTCTG-3’  R: 5’-CAATATCTCTGAACATCCTTCT-3’ G 
 R: 5’-ACGTTGGATGACAAGTTTCTGCTGGACACC-3’    C 
G20675A (rs57816586) F: 5’-ACGTTGGATGGGGTATTGAGAAGCTGTAAG-3’ R: 5’-CTGTAAGCAGGAAAGGTA-3’ G 
 R: 5’-ACGTTGGATGTATTCAGGAGAGCCTCTCAC-3’    A 
402InsR F: 5’-ACGTTGGATGTGTTTTAGGGAGTGGCTGAG-3’  F: 5’-GGAACAGAACCTGAGTCG-3’ CGT 
 R: 5’-ACGTTGGATGTTGCTCTGAAGAGGCTTTTG-3’    - 
V422A F: 5’-ACGTTGGATGTGGTTCCAGATATGGCTCTC-3’  R: 5’-CTCTTACCCGCTTCACAG-3’ T 
 R: 5’-ACGTTGGATGTCCTTCAGAGTGTTTTATCC-3’    C 
E470G F: 5’-ACGTTGGATGAGCTTTTGCAAGCCCACTTC-3’  R: 5’-CCCACTTCCAGTTCCTT-3’ A 
 R: 5’-ACGTTGGATGACTTTCTGATCTCTCCCCAG-3’   G 
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Polymorphism Amplification Primers Extension Primer Alleles 
CYP2J2 
G10860A (rs3738474) F: 5’-ACGTTGGATGGGTAAGTTTCTTGGCCAACG-3’ F: 5’-CTTGGCCAACGAAAGGT-3’ G 
 R: 5’-ACGTTGGATGGTCACCAAGGTGCCTTTAAC-3’  A 
R158C (*3) F: 5’-ACGTTGGATGCTCTGACAGCACTAAGGAAC-3’ F: 5’-AGGAAAGAAGAGCTTAGAGGAA-3’ C 
 R: 5’-ACGTTGGATGTTGCTTCAGTGAGGTGTTGG-3’  T 
T18778G (rs2271800) F: 5’-ACGTTGGATGGGGACCTTTTCTTCCAAATG-3’ F: 5’-CCTCCTAGGATGAAGCCCCT-3’ T 
 R: 5’-ACGTTGGATGTCAGAGGATTCCTGATTGCC-3’  G 
N404Y (*6) F: 5’-ACGTTGGATGGTCCGGATTGAATGTGTCAG-3’ R: 5’-CCTGTGCAGCGCCGTCAAAT-3’ A 
 R: 5’-ACGTTGGATGGCTTTCTCTAGGGTACCATG-3’  T 
CYP2C8 
I264M (*4, rs1058930) F: 5’-ACGTTGGATGAGAACACCAAGCATCACTGG-3’ F: 5’-TAACAATCCTCGGGACTTTAT-3’ C 
 R: 5’-ACGTTGGATGGCTAATATCTTACCTGCTCC-3’  G 
I269F (*2, rs11572103) F: 5’-ACGTTGGATGGCTAATATCTTACCTGCTCC-3’ F: 5’-CTTACCTGCTCCATTTTGA-3’ A 
 R: 5’-ACGTTGGATGAGAACACCAAGCATCACTGG-3’  T 
K399R (*3, rs10509681) F: 5’-ACGTTGGATGACTGACTTCCGTGCTACATG-3’ F: 5’-TTCCGTGCTACATGATGACA-3’ A 
 R: 5’-ACGTTGGATGTATCTAGAAAGTGGCCAGGG-3’  G 
*Targeted sequences were amplified via polymerase chain reaction using the designated forward (F) and reverse (R) primers, followed by 
extension reactions utilizing specific oligonucleotide primers that annealed immediately upstream of each polymorphic site and extended the 
amplification product by a single base pair in either the forward (F) or reverse (R) direction, as indicated.  The mass of the extension reaction 
products was determined and translated into genotype using the MassARRAY RT software (Sequenom Inc., San Diego, CA) (107). 
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APPENDIX III 
 
Methods used for genotyping PTGS2 and CYP2J2 polymorphisms by BeadArray 
 
Polymorphism 
 
PTGS2   
G-765C (rs20417) 
CYP2J2:    
G-50T (CYP2J2*7, rs890293) 
R49S (rs11572190) 
V113M (rs11572242) 
I192N (CYP2J2*4) 
C33291T (rs4388726) 
A33497G (rs11572327) 
*Genotyping was performed using the BeadStation system (Illumina, Inc., San Diego, CA) and a 
custom oligonucleotide pool comprised of 384 single nucleotide polymorphism variants in multiple 
genes (108).  Briefly, double-stranded genomic DNA was labeled with biotin to facilitate the capture 
of single stranded DNA onto streptavidin-coated sepharose beads for purification of PCR template.  
The PCR template was created using a highly specific polymerase and ligase that extend and ligate 
allele-specific primers that bind to complementary sequences surrounding the variant sites and 
include universal primer sequences and an “address” sequence that is ultimately hybridized to the 
genotyping array.  The PCR template was amplified via the use of universal primers labeled with 
either Cy3 or Cy5 fluorescent tags, and the amplified products were hybridized to a fiber optic bundle 
array and imaged with the BeadArray Reader (Illumina).  Allele detection and genotype calling were 
performed using the GenCall and GTS Reports software (Illumina).  Primer sequences are available 
upon request. 
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APPENDIX IV 
 
Methods used for genotyping EPHX2 polymorphisms by Taqman® 
 
 
Polymorphism Amplification Primers Probe Primers Alleles 
EPHX2 
R287Q (rs751141) F: 5'-ATCCCTGCTCTGGCCCA-3' 5’-ATGTCCATAGCTAGGACCCGGTAACCT-3’ G 
 R: 5'-GGAGGAGCAGATGACTCTCCATA-3' 5’-ATGTCCATAGCTAGGACCTGGTAACCT-3’ A 
A53415G (rs1042032) F: 5'-GTGCCCACGCTCAGCAG-3' 5’-TGTGCCATCCTTCCA-3’ A 
 R: 5'-TAAGAATGGTGCCCCAGCAG-3' 5’-TGCCGTCCTTCCA-3’ G 
*Targeted sequences were amplified via polymerase chain reaction using the designated forward (F) and reverse (R) primers, and hybridized with 
two allele-specific probes that differed at the polymorphic site (bold) and were labeled with the distinct fluorescent reporter dyes VIC and TAM. 
The fluorescent intensity of each reported dye was quantified and translated into genotype (Applied Biosystems, Foster City, CA) (126). 
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